



THE *A Big Welcome*
to the *Liver Festival* in Gyeongju, Korea!

LIVER WEEK

2025 May 29 - 31, 2025
HICO, Gyeongju, Korea



The Korean Association
for the Study of the Liver



THE KOREAN ASSOCIATION
OF HBP SURGERY



THE KOREAN LIVER
CANCER ASSOCIATION



The Korean Liver
Transplantation Society



ABOUT THE LIVER WEEK

The Liver Week is a multidisciplinary international conference at which the liver-related societies in Korea - the Korean Association for the Study of the Liver, the Korean Association of HBP Surgery, the Korean Liver Cancer Association, and the Korean Liver Transplantation Society gathered together for the first time in 2014 as hosting organizations. It is being held as an annual meeting with more than 1,300 participants each year.

The Liver Week is held not only for the study of recent research trends and views on liver disorders from the perspectives of eminent professors and researchers around the world, but also for exchanges of information between participants, which contributes to the revitalization of our study and researches. The Liver Week imbues delegates with authoritative lectures and discussions from both domestic and foreign speakers on the major issues on liver diseases, such as viral hepatitis, liver fibrosis, liver cirrhosis, liver cancer, and more.



**Program Book
Abstract Book
and View More**

www.theliverweek.org



WELCOME MESSAGE	03
ORGANIZING COMMITTEE	04
INVITED FACULTY	05
VENUE	10
SHUTTLE BUS SCHEDULE	13
FLOOR PLAN & SESSION	16
INDUSTRY LUNCHEON SYMPOSIA	22
SCIENTIFIC PROGRAM	26
FREE PAPER PRESENTATION	61
ORAL POSTER PRESENTATION	74
POSTER EXHIBITION	90
GENERAL INFORMATION	120
INDUSTRIAL EXHIBITION FLOOR PLAN	124
BOOTH TOUR	

THE LIVER WEEK 2025

WELCOME MESSAGE

Dear Colleagues and Friends,

Welcome to THE LIVER WEEK 2025 in the beautiful city of Gyeongju, Korea!

On behalf of the organizing committee, we are delighted to have you join us from May 29 to May 31, 2025, for this special gathering of esteemed experts, clinicians, researchers, and industry leaders from around the world.

This year's program features distinguished keynote lectures, interactive workshops, and cutting-edge research presentations, all designed to foster meaningful exchange and collaboration. We are especially excited to highlight an enhanced academic program that underscores the importance of multidisciplinary cooperation between internal medicine and surgical fields, offering a truly holistic approach to liver disease care.

Set against the rich historical and cultural backdrop of Gyeongju, we hope this meeting offers not only deep academic engagement but also moments of inspiration and rejuvenation. We encourage you to take some time to explore the city's ancient landmarks, serene temples, and scenic landscapes during your stay.

Whether this is your first time attending or you are a returning participant, we hope THE LIVER WEEK 2025 proves to be a rewarding and memorable experience.

We look forward to seeing you throughout the conference!

Warm regards,



Sook-Hyang Jeong
Chairman



Yoon Jun Kim
President



Jin-Young Jang
Vice President



Kyung Sik Kim
Vice President



Kwang-Woong Lee
Vice President





ORGANIZING COMMITTEE

Congress Chairman

Sook-Hyang Jeong (Seoul National Univ.)

Congress President

Yoon Jun Kim (Seoul National Univ.)

Congress Vice President

Jin-Young Jang (Seoul National Univ.)

Kyung Sik Kim (Yonsei Univ.)

Kwang-Woong Lee (Seoul National Univ.)

Secretary General

Hyung Joon Kim (Chung-Ang Univ.)

Do Young Kim (Yonsei Univ.)

YoungRok Choi (Seoul National Univ.)

Scientific Committee Chair

Ju Hyun Shim (Univ. of Ulsan)

Scientific Committee Vice Chair

Jongman Kim (Sungkyunkwan Univ.)

Su Jong Yu (Seoul National Univ.)

Hae Won Lee (Seoul National Univ.)

Treasurer

Bo Hyun Kim (National Cancer Center)

Do Young Kim (Yonsei Univ.)

Publication

Won Kim (Seoul National Univ.)

Public Relations

Sung-Eun Kim (Hallym Univ.)

Scientific Committee Members

** Executive Scientific Members for The Liver Week 2025*

Do Seon Song (The Catholic Univ. of Korea) *

Jihyun An (Hanyang Univ.) *

Young-Sun Lee (Korea Univ.) *

Eun Sun Jang (Seoul National Univ.) *

Young Eun Chon (CHA Univ.) *

Soon Sun Kim (Ajou Univ.)

Seong Kyun Na (Inje Univ.)

Byeong Geun Song (Sungkyunkwan Univ.)

In Hye Song (Univ. of Ulsan)

Seung Kak Shin (Gachon Univ.)

Hyuk Soo Eun (Chungnam National Univ.)

Jae Seung Lee (Yonsei Univ.)

Yu Rim Lee (Kyungpook National Univ.)

Young Chang (Soonchunhyang Univ.)

Ju-Yeon Cho (Chosun Univ.)

Sang Hyun Choi (Univ. of Ulsan)

Won-Mook Choi (Univ. of Ulsan)

Yong-Hyun Han (Kangwon National Univ.)

Moon Haeng Hur (Seoul National Univ.)

Sang Youn Hwang (Dongnam Institute of

Radiological & Medical Sciences)

INVITED FACULTY

Argentina

Silvia Sookoian *Maimonides Univ.*

Australia

Jacob George *The Univ. of Sydney*

France

Dominique Damais-Thabut *Sorbonne Univ.*

Germany

Markus Cornberg *Hannover Medical School*

Hong Kong, China

Loey Lung-Yi Mak *The Univ. of Hong Kong*

India

Shiv Kumar Sarin *Institute of Liver and Biliary Sciences*

Shashwat Sarin *Max Hospital*

Barjesh Chander Sharma *Govind Ballabh Pant Hospital*

Manoj Kumar Sharma *Institute of Liver and Biliary Sciences*

Japan

Etsuro Hatano *Kyoto Univ.*

Hideki Iwamoto *Kurume Univ.*

Tatsuya Kanto *Japan Institute for Health Security*

Masao Omata *The Univ. of Tokyo*

Masahito Shimizu *Gifu Univ.*

Atsushi Tanaka *Teikyo Univ.*

Shuji Terai *Niigata Univ.*

Takehisa Watanabe *Kumamoto Univ.*

Tomoharu Yamada *The Univ. of Tokyo*

Tomoharu Yoshizumi *Kyushu Univ.*

Mongolia

Unenbat Gurbadam *National Cancer Center*

Chinburen Jigjidsuren *Parliament of Mongolia*

Singapore

Valerie Chew *Duke-NUS Medical School*

Taiwan

Chien-Hung Chen *National Taiwan Univ.*

Shang-Chin Huang *National Taiwan Univ.*

Yi-Hsiang Huang *National Yang Ming Chiao Tung Univ.*

Chun-Jen Liu *National Taiwan Univ.*

Ming-Chin Yu *Chang Gung Medical Foundation*

Thailand

Poowanai Sarkhampee *Sunpasitthiprasong Hospital*

USA

Sumeet Asrani *Baylor Univ.*

Renumathy Dhanasekaran *Stanford Univ.*

W. Ray Kim *Mayo Clinic*

Kris V. Kowdley *Washington State Univ.*

Amit Singal *UT Southwestern Medical Center*

Augusto Villanueva *NYU Langone*



INVITED FACULTY

Korea

Chul Soo Ahn	<i>Univ. of Ulsan</i>
Sang Bong Ahn	<i>Eulji Univ.</i>
Sang Hoon Ahn	<i>Yonsei Univ.</i>
Sangzin Ahn	<i>Inje Univ.</i>
Sangho Bae	<i>Soonchunhyang Univ.</i>
Si Hyun Bae	<i>The Catholic Univ. of Korea</i>
Soon Koo Baik	<i>Yonsei Univ. Wonju</i>
Hee Bok Chae	<i>Chungbuk National Univ.</i>
Jong-In Chang	<i>Chung-Ang Univ.</i>
Young Chang	<i>Soonchunhyang Univ.</i>
Gab Jin Cheon	<i>Univ. of Ulsan</i>
Jaeyoun Cheong	<i>Ajou Univ.</i>
Chan Woo Cho	<i>Yeungnam Univ.</i>
Dong-Charm Cho	<i>Korea Science Journalists Association</i>
Eun Ju Cho	<i>Seoul National Univ.</i>
Eun Young Cho	<i>Wonkwang Univ.</i>
Jai Young Cho	<i>Seoul National Univ.</i>
Sung Bum Cho	<i>Chonnam National Univ.</i>
Yuri Cho	<i>National Cancer Center</i>
Won Hyeok Choe	<i>Konkuk Univ.</i>
Gi Hong Choi	<i>Yonsei Univ.</i>
Gyu-seong Choi	<i>Sungkyunkwan Univ.</i>
In Seok Choi	<i>Konyang Univ.</i>
Jin-Young Choi	<i>Yonsei Univ.</i>
Jong Young Choi	<i>Chung-Ang Univ.</i>
Jungmin Choi	<i>Korea Univ.</i>
Moon Seok Choi	<i>Sungkyunkwan Univ.</i>
Murim Choi	<i>Seoul National Univ.</i>
Nam Kyu Choi	<i>Chosun Univ.</i>
Sae Byeol Choi	<i>Korea Univ.</i>
Sung Kyu Choi	<i>Chonnam National Univ.</i>
Won-Choong Choi	<i>Eulji Univ.</i>
Won-Mook Choi	<i>Univ. of Ulsan</i>
YoungRok Choi	<i>Seoul National Univ.</i>

Young Eun Chon	<i>CHA Univ.</i>
Jin Wook Chung	<i>Seoul National Univ.</i>
Sung Won Chung	<i>Univ. of Ulsan</i>
Woo Jin Chung	<i>Keimyung Univ.</i>
Hyuk Soo Eun	<i>Chungnam National Univ.</i>
Geum-Youn Gwak	<i>Sungkyunkwan Univ.</i>
Yeonjung Ha	<i>CHA Univ.</i>
Chang Yeob Han	<i>Jeonbuk National Univ.</i>
Chul Ju Han	<i>Korea Cancer Center Hospital</i>
Dai Hoon Han	<i>Yonsei Univ.</i>
Ji Won Han	<i>The Catholic Univ. of Korea</i>
Seul Ki Han	<i>Yonsei Univ. Wonju</i>
Yong-Hyun Han	<i>Kangwon National Univ.</i>
Young Seok Han	<i>Dague Catholic Univ.</i>
Jeong Heo	<i>Pusan National Univ.</i>
Nae-Yun Heo	<i>Inje Univ.</i>
Seunghui Hong	<i>Samsung Medical Center</i>
Su Young Hong	<i>Seoul National Univ.</i>
Moon Haeng Hur	<i>Seoul National Univ.</i>
Jaeseok Hwang	<i>Keimyung Univ.</i>
Sang Youn Hwang	<i>Dongnam Institute of Radiological & Medical Sciences</i>
Dongho Hyun	<i>Sungkyunkwan Univ.</i>
Byoung Kuk Jang	<i>Keimyung Univ.</i>
Eun Sun Jang	<i>Seoul National Univ.</i>
Heejoon Jang	<i>Seoul National Univ.</i>
Hyeon Ji Jang	<i>Univ. of Ulsan</i>
Jae Young Jang	<i>Soonchunhyang Univ.</i>
Jeong Won Jang	<i>The Catholic Univ. of Korea</i>
Jin-Young Jang	<i>Seoul National Univ.</i>
Se Young Jang	<i>Kyungpook National Univ.</i>
Jae Yoon Jeong	<i>Ewha Womans Univ.</i>
Sook-Hyang Jeong	<i>Seoul National Univ.</i>
Soung Won Jeong	<i>Soonchunhyang Univ.</i>
Won-II Jeong	<i>KAIST</i>

INVITED FACULTY

Seungwon Jeung	<i>Korea Health Information Service</i>	Jongman Kim	<i>Sungkyunkwan Univ.</i>
Dae Won Jun	<i>Hanyang Univ.</i>	Ju Youn Kim	<i>Hanyang Univ.</i>
Bo-Hyun Jung	<i>Inje Univ.</i>	Jung Hee Kim	<i>Hallym Univ.</i>
Dong-Hwan Jung	<i>Univ. of Ulsan</i>	Junil Kim	<i>Soongsil Univ.</i>
Haeil Jung	<i>Soonchunhayng Univ.</i>	Kang Mo Kim	<i>Univ. of Ulsan</i>
Inkyung Jung	<i>Yonsei Univ.</i>	Kwan Woo Kim	<i>Dong-A Univ.</i>
Yong Jin Jung	<i>Seoul National Univ.</i>	Kyeong Deok Kim	<i>Inha Univ.</i>
Young Kul Jung	<i>Korea Univ.</i>	Kyung Sik Kim	<i>Yonsei Univ.</i>
Youngmi Jung	<i>Pusan National Univ.</i>	Kyung-Ah Kim	<i>Inje Univ.</i>
Keon Wook Kang	<i>Seoul National Univ.</i>	Kyun-Hwan Kim	<i>Sungkyunkwan Univ.</i>
Mi Young Kang	<i>Health Insurance Review & Assessment Service</i>	Mi Na Kim	<i>Yonsei Univ.</i>
Seong Hee Kang	<i>Korea Univ.</i>	Mi-Sook Kim	<i>Korea Cancer Center Hospital</i>
Wonseok Kang	<i>Sungkyunkwan Univ.</i>	Moon Young Kim	<i>Yonsei Univ. Wonju</i>
Yeowoal Kang	<i>Dong-A Univ.</i>	Myoung Soo Kim	<i>Yonsei Univ.</i>
Beom Kyung Kim	<i>Yonsei Univ.</i>	Sang Gyune Kim	<i>Soonchunhyang Univ.</i>
Bo Hyun Kim	<i>National Cancer Center</i>	Sang Jin Kim	<i>Korea Univ.</i>
Byung Ik Kim	<i>Sungkyunkwan Univ.</i>	Sehee Kim	<i>Univ. of Ulsan</i>
Byung Seok Kim	<i>Daegu Catholic Univ.</i>	Seok-Hwan Kim	<i>Chungnam National Univ.</i>
Chang Wook Kim	<i>The Catholic Univ. of Korea</i>	Seung Up Kim	<i>Yonsei Univ.</i>
Do Young Kim	<i>Yonsei Univ.</i>	So Yeon Kim	<i>Univ. of Ulsan</i>
Dong-Sik Kim	<i>Korea Univ.</i>	Soon Sun Kim	<i>Ajou Univ.</i>
Doojin Kim	<i>Gachon Univ.</i>	Suk Bae Kim	<i>Dankook Univ.</i>
Elisabet Kim	<i>Asan Medical Center</i>	Sung-Eun Kim	<i>Hallym Univ.</i>
Ha Il Kim	<i>Hanyang Univ.</i>	Tae Hun Kim	<i>Ewha Womans Univ.</i>
Haeryoung Kim	<i>Seoul National Univ.</i>	Tae Hyung Kim	<i>Korea Univ.</i>
Hong Soo Kim	<i>Soonchunhyang Univ.</i>	Tae-Seok Kim	<i>Keimyung Univ.</i>
Hyeyoung Kim	<i>Soonchunhyang Univ.</i>	Tae-Suk Kim	<i>Kangwon National Univ.</i>
Hyo-Cheol Kim	<i>Seoul National Univ.</i>	Won Kim	<i>Seoul National Univ.</i>
Hyung Joon Kim	<i>Chung-Ang Univ.</i>	Won-Ho Kim	<i>Korea National Institute of Health</i>
In Hee Kim	<i>Jeonbuk National Univ.</i>	Yoon Jun Kim	<i>Seoul National Univ.</i>
Ja Kyung Kim	<i>Yonsei Univ.</i>	Yunsuk Kim	<i>Korea Disease Control and Prevention Agency</i>
Jeong Han Kim	<i>Konkuk Univ.</i>	Young Seok Kim	<i>Soonchunhyang Univ.</i>
Ji Hoon Kim	<i>Korea Univ.</i>	Yun Soo Kim	<i>Gachon Univ.</i>
Jin-Wook Kim	<i>Seoul National Univ.</i>	Yang-Seok Koh	<i>Chonnam National Univ.</i>



INVITED FACULTY

Ja Hyun Koo	<i>Seoul National Univ.</i>
Jung Hyun Kwon	<i>The Catholic Univ. of Korea</i>
Oh Sang Kwon	<i>Gachon Univ.</i>
So Young Kwon	<i>Konkuk Univ.</i>
Yong Hwan Kwon	<i>Kyungpook National Univ.</i>
Byung Seok Lee	<i>Chungnam National Univ.</i>
Chang Hun Lee	<i>Jeonbuk National Univ.</i>
Chang Hyeong Lee	<i>Daegu Catholic Univ.</i>
Danbi Lee	<i>Univ. of Ulsan</i>
Danielle Lee	<i>Asan Medical Center</i>
Hae Lim Lee	<i>The Catholic Univ. of Korea</i>
Hae Won Lee	<i>Seoul National Univ.</i>
Han Ah Lee	<i>Chung-Ang Univ.</i>
Han Chu Lee	<i>Univ. of Ulsan</i>
Hye Won Lee	<i>Yonsei Univ.</i>
Hyun Woong Lee	<i>Yonsei Univ.</i>
Jae Seung Lee	<i>Yonsei Univ.</i>
Jeong-Hoon Lee	<i>Seoul National Univ.</i>
Jin-Woo Lee	<i>Inha Univ.</i>
Jooho Lee	<i>CHA Univ.</i>
Joon Hyeok Lee	<i>Sungkyunkwan Univ.</i>
Joonyub Lee	<i>The Catholic Univ. of Korea</i>
June Sung Lee	<i>Inje Univ.</i>
Jung Il Lee	<i>Yonsei Univ.</i>
Kwang-Woong Lee	<i>Seoul National Univ.</i>
Kye-Seong Lee	<i>Incheon Chamsarang Hospital</i>
Minjong Lee	<i>Ewha Womans Univ.</i>
Moon Hyung Lee	<i>Kyung Hee Univ.</i>
Sae Hwan Lee	<i>Soonchunhyang Univ.</i>
Sejoon Lee	<i>Seoul National Univ.</i>
Seung Soo Lee	<i>Univ. of Ulsan</i>
Soon Kyu Lee	<i>The Catholic Univ. of Korea</i>
Sung Hak Lee	<i>The Catholic Univ. of Korea</i>
Sung Won Lee	<i>The Catholic Univ. of Korea</i>
Tae-Hee Lee	<i>Konyang Univ.</i>

Woojoo Lee	<i>Seoul National Univ.</i>
Young-Sun Lee	<i>Korea Univ.</i>
Yu Rim Lee	<i>Kyungpook National Univ.</i>
Yun Bin Lee	<i>Seoul National Univ.</i>
Joon Seo Lim	<i>Asan Medical Center</i>
Tae Seop Lim	<i>Yonsei Univ.</i>
Young-Suk Lim	<i>Univ. of Ulsan</i>
Seong Kyun Na	<i>Inje Univ.</i>
Yang Won Nah	<i>Univ. of Ulsan</i>
Heechul Nam	<i>The Catholic Univ. of Korea</i>
Soon Woo Nam	<i>The Catholic Univ. of Korea</i>
Hyunwoo Oh	<i>Sungkyunkwan Univ.</i>
Junghwan Oh	<i>The Catholic Univ. of Korea</i>
Se-Woong Oh	<i>Yuhan Corp.</i>
Yong-Han Paik	<i>Sungkyunkwan Univ.</i>
Cheon Soo Park	<i>The Catholic Univ. of Korea</i>
Hyo Jung Park	<i>Univ. of Ulsan</i>
Jeong-Ik Park	<i>Univ. of Ulsan</i>
Ji-Won Park	<i>Hallym Univ.</i>
Jong Hoon Park	<i>Daegu Fatima Hospital</i>
Jong-Eun Park	<i>KAIST</i>
Joong-Won Park	<i>Myoungji Hospital, Hanyang Univ.</i>
Jung Gil Park	<i>Yeungnam Univ.</i>
Junsung Park	<i>Samsung Medison</i>
Min Kyung Park	<i>Seoul National Univ.</i>
Min-Su Park	<i>Kyung Hee Univ.</i>
Pyoung Jae Park	<i>Korea Univ.</i>
Sang Hoon Park	<i>Hallym Univ.</i>
Seung Ha Park	<i>Inje Univ</i>
Soo Young Park	<i>Kyungpook National Univ.</i>
Su Cheol Park	<i>Korea Cancer Center Hospital</i>
Sung Jae Park	<i>Inje Univ.</i>
Yewan Park	<i>Kyung Hee Univ.</i>
Young Joon Park	<i>Korea Disease Control and Prevention Agency</i>

INVITED FACULTY

Hyunsoo Rho	<i>Ewha Womans Univ.</i>
Woo Sun Rou	<i>Chungnam National Univ.</i>
Soo Hyung Ryu	<i>SSOK Internal Medicine Clinic</i>
Tom Ryu	<i>Soonchunhyang Univ.</i>
Wonhyo Seo	<i>Ewha Womans Univ.</i>
Ju Hyun Shim	<i>Univ. of Ulsan</i>
Hyun Phil Shin	<i>Kyung Hee Univ.</i>
Seung Kak Shin	<i>Gachon Univ.</i>
Dong Hyun Sinn	<i>Sungkyunkwan Univ.</i>
Joo Hyun Sohn	<i>Hanyang Univ.</i>
Won Sohn	<i>Sungkyunkwan Univ.</i>
Sunyoung Son	<i>Gangnam Severance Hospital</i>
Byeong Geun Song	<i>Sungkyunkwan Univ.</i>
Byung-Cheol Song	<i>Jeju National Univ.</i>
Do Seon Song	<i>The Catholic Univ. of Korea</i>
Il Han Song	<i>Dankook Univ.</i>
In Hye Song	<i>Univ. of Ulsan</i>
Jeong Eun Song	<i>Daegu Catholic Univ.</i>
Myeong Jun Song	<i>The Catholic Univ. of Korea</i>
Sang Hwa Song	<i>Chonnam National Univ.</i>
Eunseon Suh	<i>Hwaseong Community Addiction Management Center</i>
Ki Tae Suk	<i>Hallym Univ.</i>
Pil Soo Sung	<i>The Catholic Univ. of Korea</i>
Won Young Tak	<i>Kyungpook National Univ.</i>
Hyun Young Woo	<i>Pusan National Univ.</i>
Hyun Yang	<i>The Catholic Univ. of Korea</i>
Kwangho Yang	<i>Pusan National Univ.</i>
Yoon Mee Yang	<i>Kangwon National Univ.</i>
Jong Chul Ye	<i>KAIST</i>
Jong Eun Yeon	<i>Korea Univ.</i>
Hyung Joon Yim	<i>Korea Univ.</i>
Jeong-Ju Yoo	<i>Soonchunhyang Univ.</i>
Sung Hwan Yoo	<i>Yonsei Univ.</i>
Eileen L. Yoon	<i>Hanyang Univ.</i>

Jae Hyun Yoon	<i>Chonnam National Univ.</i>
Jun Sik Yoon	<i>Inje Univ.</i>
Jung-Hwan Yoon	<i>Seoul National Univ.</i>
Ki Tae Yoon	<i>Pusan National Univ.</i>
Sang Min Yoon	<i>Univ. of Ulsan</i>
Seung Kew Yoon	<i>The Catholic Univ. of Korea</i>
Young Chul Yoon	<i>The Catholic Univ. of Korea</i>
Young-In Yoon	<i>Univ. of Ulsan</i>
Young Kyoung You	<i>The Catholic Univ. of Korea</i>
Hee Chul Yu	<i>Jeonbuk National Univ.</i>
Su Jong Yu	<i>Seoul National Univ.</i>
Min Kyu Yum	<i>KAIST</i>
Sung Su Yun	<i>Yeungnam Univ.</i>



HICO

Gyeongju Hwabaek International Convention Center


507 Bomun-ro, Gyeongju, Gyeongsangbuk-do Province, Korea, 38116

HICO (Hwabaek International Convention Center) is located within Bomun Lake Resort, a key tourist district in Gyeongju offering accommodations, golf courses, theme parks, and entertainment around scenic Bomun Lake.


It is conveniently accessible:

- 21 km from Gyeongju Station (KTX)
- 11 km from Gyeongju Bus Terminals (with airport limousine service)
- 90 km from Gimhae International Airport

making it well-connected for both domestic and international travelers.



GYEONGJU, the ancient capital of the Silla Kingdom, is often called an “open-air museum” for its rich historical and cultural heritage. It features UNESCO World Heritage Sites like Bulguksa Temple, Seokguram Grotto, and Daereungwon Tomb Complex, making it a must-visit for those interested in Korean history.



10 Must-Visit Historical Sites in Gyeongju for Foreign Visitors



Bulguksa Temple
a UNESCO World Heritage Site, is celebrated for its beautiful architecture and peaceful setting.



Gyeongju National Museum
offers a rich collection of artifacts and is essential for understanding the history of Gyeongju and the Silla Kingdom.



Seokguram Grotto
set on Mount Tohamsan, features a majestic Buddha statue and scenic mountain views.



Bunhwangsa Temple
One of the oldest temples in Gyeongju, known for its distinctive stone pagoda from the Silla period.



Daereungwon Tomb Complex
Also known as "Tumuli Park," this site features large Silla royal tombs, with some open for visitors to enter.




Woljeonggyo Bridge
A beautifully restored wooden bridge over Namcheon Stream, combining historical charm with scenic views.



Donggung Palace & Wolji Pond (Anapji)
A scenic artificial pond from the Silla royal palace, known for its stunning reflections and night views.




Yangdong Folk Village
A UNESCO World Heritage Site that showcases traditional Korean houses and preserves centuries-old customs.



Cheomseongdae Observatory
The oldest existing astronomical observatory in East Asia, built during the Silla period.



Wolseong Fortress (Banwolsong)
The former royal palace site of the Silla Kingdom, offering a glimpse into the grandeur of ancient Korean royal life.



In 1L unresectable Hepatocellular Carcinoma

**TECENTRIQ® +
Bevacizumab
(AVASTIN®)
combination
therapy is
the first
immunotherapy¹
that demonstrated survival
benefit vs. existing therapy**

- Median OS :
19.2 months with TECENTRIQ® + Bevacizumab
(AVASTIN®) vs 13.4 months with sorafenib
(HR=0.66; 95% CI, 0.52,0.85; P<0.001)²

IMBrave150 : 501patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib. The coprimary endpoints were OS and IRF assessed PFS. **HR** : Hazard ratio **CI** : Confidence interval **OS** : Overall survival **IRF** : Independent review facility **PFS** : Progression free survival **References** 1. Finn et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med* 2020;382:1894-905. May 14, 2020. 2. Ai. Cheng, et al. Updated efficacy and safety data from IMBrave150 : atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. *J Hepatol*. 2021 Dec; 105(5):689-697. DOI:10.1053/j.jhep.2021.09.018. *descriptive purpose only

*보다 자세한 제품정보 문의 및 제품 관련 부차음 보고는 (주)한글리수 (02-3451-3600)로 연락 주시기 바랍니다. *티벳트릭과 아바스틴의 최신 제품정보는 QR code를 스캔하여 확인하실 수 있습니다.

(주)한글리수 서울특별시 서초구 서호대로 411, GT Tower(East) 17층 (06615)Tel:02-3451-3600 / www.roche.com



SHUTTLE BUS SCHEDULE

from/to Gyeongju Station

The Liver Week 2025 Committee provides a complimentary shuttle service to enhance convenience for all conference participants. You are welcome to use it freely during your stay. Please note that Singyeongju Station was officially renamed “Gyeongju Station” in 2024. This is the only station in Gyeongju served by KTX (Korea Train Express), and the complimentary shuttle will operate from this station. Kindly be advised not to confuse it with the former Gyeongju Station, which no longer accommodates KTX trains.

Wednesday, May 28, 2025

Gyeongju Station	Lahan	Hilton
14:30	15:05	15:10
15:30	16:05	16:10
16:30	17:05	17:10
17:30	18:05	18:10

Thursday, May 29, 2025

Gyeongju Station	HICO
08:00	08:40
09:00	09:40
10:00	10:40

Friday, May 30, 2025

Gyeongju Station	HICO
08:00	08:40
09:00	09:40
10:00	10:40

Friday, May 30, 2025

HICO	Gyeongju Station
13:30	14:10
15:00	15:40
16:40	17:20


Saturday, May 31, 2025

HICO	Gyeongju Station
13:10	13:50
15:00	15:40
16:30	17:10



SHUTTLE BUS SCHEDULE

around Bomun Lake



LAHAN
BUS STOP 1

in front of the flagpole

COMMODORE
BUS STOP 2

in front of the main gate

HICO
BUS STOP 3

in front of the Gate 5

Thursday, May 29, 2025

Lahan	→ Commodore →	HICO	HICO	→ Commodore →	Lahan
07:30	07:35	07:40	15:40	15:45	15:50
07:40	07:45	07:50	17:30	17:35	17:40
07:50	07:55	08:00			
08:00	08:05	08:10			
09:30	09:35	09:40			
09:40	09:45	09:50			
09:50	09:55	10:00			
10:00	10:05	10:10			

SHUTTLE BUS SCHEDULE

around Bomun Lake

Friday, May 30, 2025

Lahan	→ Commodore →	HICO
06:30	06:35	06:40
06:40	06:45	06:50
06:50	06:55	07:00
07:00	07:05	07:10
08:10	08:15	08:20
08:20	08:25	08:30
08:30	08:35	08:40
08:40	08:45	08:50
09:20	09:25	09:30
09:30	09:35	09:40
09:40	09:45	09:50
09:50	09:55	10:00

HICO	→ Commodore →	Lahan
15:10	15:15	15:20
16:50	16:55	17:00
17:50	17:55	18:00

 WELCOME RECEPTION
HICO → Hwangnyongwon

17:40

Hwangnyongwon	→ Commodore →	Lahan
20:00	20:05	20:10

Saturday, May 31, 2025

Lahan	→ Commodore →	HICO
06:30	06:35	06:40
06:40	06:45	06:50
06:50	06:55	07:00
07:00	07:05	07:10
08:10	08:15	08:20
08:20	08:25	08:30
08:30	08:35	08:40
08:40	08:45	08:50
09:40	09:45	09:50
09:50	09:55	10:00

For More Information



KTX




From Incheon Int'l Airport
or Gimpo Int'l Airport

FLOOR PLAN & SESSION

3F

★ QR Scanner




DAY 1 Thursday, May 29, 2025

ROOM 1 (3F)

- 08:40-10:25 PG Course 1 **K**
- 10:40-12:00 PG Course 2 **K**
- 12:00-12:50 Luncheon Symposium 1 **K** **L** **YUHAN**
- 12:50-13:40 Special Lecture **K**
- 13:40-15:20 PG Course 3 **K**
- 15:40-17:20 PG Course 4 **K**

4F






B Breakfast **L** Lunch Box **K** Session in Korean

FLOOR PLAN & SESSION

DAY 2 Friday, May 30, 2025

ROOM 1 (3F)





- 07:30-08:50 KASL SIG 1 
- 09:10-10:30 KASL-AASLD Joint Symposium 1
- 10:30-11:10 **Opening Ceremony**
- 11:10-11:40 State-of-the-Art Lecture
- 11:40-12:40 Plenary Presentation 1
- 12:40-13:30 Luncheon Symposium 5  
- 13:30-14:50 KASL Symposium 2
- 15:10-16:30 KASL-KAHBPS- KLCA-KLTS Joint Symposium

ROOM 2 (3F)




- 07:30-08:50 KLCA Symposium 1 
- 08:50-09:10 Liver Biopsy in HCC 
- 09:10-10:30 KLCA Symposium 2
- 12:40-13:30 KLCA General Meeting  
- 13:30-14:50 KLCA-JLCA Joint Symposium

DAY 3 Saturday, May 31, 2025

ROOM 1 (3F)

- 07:30-08:50 KASL SIG 4 
- 09:10-10:30 KASL-AASLD Joint Symposium 2
- 10:50-11:20 President's Choice Lecture
- 11:20-12:20 Plenary Presentation 2
- 12:20-13:10 Luncheon Symposium 10  
- 13:10-14:30 KASL Symposium 3
- 14:30-14:50 KASL Leading Research Achievement Award 
- 14:50-15:50 The Liver Week 2025 Debrief
- 15:50-16:10 **Closing & Award**

ROOM 2 (3F)

- 07:30-08:50 KLCA Symposium 3 
- 09:10-10:30 KLCA-TLCA Joint Symposium
- 12:20-13:10 Luncheon Symposium 11  

FLOOR PLAN & SESSION

2F

★ QR Scanner



DAY 1 Thursday, May 29, 2025

ROOM 3 (2F)





- 08:40-10:20 Basic Research 1 **K**
- 10:40-12:00 Basic Research 2 **K**
- 12:00-12:50 Luncheon Symposium 2 **L** BORYUNG
- 13:40-15:20 Young Investigator Meeting
- 15:40-17:10 Research Assistant Program

B Breakfast **L** Lunch Box **K** Session in Korean





FLOOR PLAN & SESSION

DAY 2 Friday, May 30, 2025






ROOM 3 (2F)

- 07:30-08:50 KAHBPS Symposium 1 
- 09:10-10:30 KAHBPS Symposium 2
- 11:20-12:40 KLTS Coordinator Session 
- 12:40-13:30 Luncheon Symposium 6  
- 13:30-14:50 KAHBPS Symposium 3
- 15:10-16:30 Free Paper 1

ROOM 5 (2F)




- 07:20-08:30 Industry Forum 1  
- 08:30-09:10 Industry Forum 3  
- 15:10-16:30 Free Paper 2

ROOM 4 (2F)

- 07:30-08:50 KASL SIG 2 
- 09:10-10:30 Hepatology Associates 1 
- 12:40-13:30 Luncheon Symposium 7  
- 13:30-14:50 Data Science Camp 1
- 15:10-16:30 Hepatology Associates 2 

DAY 3 Saturday, May 31, 2025




ROOM 3 (2F)

- 07:30-08:50 KLTS Symposium 1 
- 09:10-10:30 KLTS Symposium 2
- 12:20-13:10 Luncheon Symposium 12  
- 13:10-14:30 KLTS Symposium 3

ROOM 5 (2F)


- 13:10-14:30 Free Paper 8

ROOM 4 (2F)

- 07:30-08:50 KASL SIG 5 
- 09:10-10:30 Data Science Camp 2
- 12:20-13:10 Luncheon Symposium 13  
- 13:10-14:50 KASL Symposium 4

FLOOR PLAN & SESSION

1F



DAY 1

Thursday, May 29, 2025

ROOM 6, ROOM 6-1 (1F)

12:00-12:50 Luncheon Symposium 3 **L** **abbvie**

14:00-15:30 Ultrasound Trainee Session **K**

ROOM 8 (1F)

15:40-17:10 Ultrasound Hands-On Course **K**

ROOM 7 (1F)

12:00-12:50 Luncheon Symposium 4 **K** **L** **6C Cell**

14:00-15:30 Ultrasound Trainer Session 1 **K**

15:40-17:10 Ultrasound Trainer Session 2 **K**






B Breakfast **L** Lunch Box **K** Session in Korean

FLOOR PLAN & SESSION




DAY 2

Friday, May 30, 2025




ROOM 6, ROOM 6-1 (1F)

- 07:30-08:50 Translational Hepatology 
- 12:40-13:30 Luncheon Symposium 8  
- 13:30-14:50 Health Insurance & Policy Forum 
- 15:10-16:30 Free Paper 3
- 15:10-16:30 Free Paper 4 

ROOM 8 (1F)

- 07:30-08:10 Industry Forum 2  
- 08:30-09:10 Industry Forum 4  
- 15:10-16:30 Free Paper 6

ROOM 7 (1F)

- 07:30-08:50 KASL SIG 3 
- 09:10-10:30 KASL Symposium 1
- 12:40-13:30 Luncheon Symposium 9  
- 13:30-14:50 TLW SIG
- 15:10-16:30 Free Paper 5





ROOM 9 (1F)

- 08:30-09:10 Industry Forum 5  
- 15:10-16:30 Free Paper 7

DAY 3

Saturday, May 31, 2025

ROOM 6, ROOM 6-1 (1F)

- 07:30-08:50 KASL SIG 6 
- 12:20-13:10 Luncheon Symposium 14  
- 13:10-14:30 Free Paper 9
- 13:10-14:30 Free Paper 10 

ROOM 8 (1F)

- 13:10-14:30 Free Paper 12

ROOM 7 (1F)

- 13:10-14:30 Free Paper 11

ROOM 9 (1F)

- 13:10-14:30 Free Paper 13

INDUSTRY LUNCHEON SYMPOSIA



DAY 1 Thursday, May 29, 2025

 Lunch box will be served.

ROOM 1 (3F)	12:00-12:40 Luncheon Symposium 1 	 YUHAN
	<i>Jae Young Jang (Soonchunhyang Univ.)</i>	
	Curable Chronic Hepatitis C: Evolving Treatment Strategies to Eliminate HCV <i>Jae Young Jang (Soonchunhyang Univ.)</i>	
Simplified HCV Treatment Strategies for Accelerated Elimination <i>Jung Hyun Kwon (The Catholic Univ. of Korea)</i>		

ROOM 3 (2F)	12:00-12:40 Luncheon Symposium 2	BORYUNG
	<i>Do Young Kim (Yonsei Univ.)</i>	
	Optimizing Outcomes in HCC: From First-Line IO based Therapies to Real World Second-Line Management <i>Won-Mook Choi (Univ. of Ulsan)</i>	

ROOM 6 (1F)	12:00-12:40 Luncheon Symposium 3	abbvie
	<i>Sang Hoon Ahn (Yonsei Univ.)</i>	
	KOREA HCV Elimination Status & Benefit of G/P 8 Weeks Treatment <i>Su Jong Yu (Seoul National Univ.)</i>	
Korean Long-Term Treatment Experience with G/P 8 Weeks Treatment and Recent Update <i>Sung Won Lee (The Catholic Univ. of Korea)</i>		

ROOM 7 (1F)	12:00-12:40 Luncheon Symposium 4 	 GC Cell
	<i>Joon Hyeok Lee (Sungkyunkwan Univ.)</i>	
	The First & Only Adjuvant Therapy for Hepatocellular Carcinoma: Immuncell-LC <i>Jeong-Hoon Lee (Seoul National Univ.)</i>	


 Session in Korean

INDUSTRY LUNCHEON SYMPOSIA

L Lunch box will be served.

Friday, May 30, 2025 **DAY 2**

ROOM 1 (3F)	12:40-13:20 Luncheon Symposium 5 
	<i>Moon Seok Choi (Sungkyunkwan Univ.)</i>
	The Power of a Fast Start: Early Survival Benefit with Atezolizumab + Bevacizumab <i>Jacob George (The Univ. of Sydney, Australia)</i>
	Managing What Matters: Navigating Adverse Event with Atezolizumab + Bevacizumab <i>Bo Hyun Kim (National Cancer Center)</i>

ROOM 3 (2F)	12:40-13:20 Luncheon Symposium 6 
	<i>Young-Suk Lim (Univ. of Ulsan)</i>
	Advancing HBV Management: ATTENTION, the Role of Early Treatment <i>Young-Suk Lim (Univ. of Ulsan)</i>
	8 Years of TAF: Real-World Evidence and Clinical Insights <i>Wonseok Kang (Sungkyunkwan Univ.)</i>
	EASL Guideline Updates and the Importance of Early Treatment <i>Markus Cornberg (Hannover Medical School, Germany)</i>

ROOM 4 (2F)	12:40-13:20 Luncheon Symposium 7 
	<i>Jae Young Jang (Soonchunhyang Univ.)</i>
	Fexuclue: Leading Beyond GERD-Clinical Update <i>Yong Hwan Kwon (Kyungpook National Univ.)</i>

ROOM 6 (1F)	12:40-13:20 Luncheon Symposium 8 
	<i>Sang Hoon Ahn (Yonsei Univ.)</i>
	Beyond Albumin: BCAA Effects <i>Dong Hyun Shin (Sungkyunkwan Univ.)</i>

ROOM 7 (1F)	12:40-13:20 Luncheon Symposium 9 
	<i>Ji Hoon Kim (Korea Univ.)</i>
	Current uHCC Treatment in Japan: Why LENVIMA Is Still an Optimal Choice? <i>Hideki Iwamoto (Kurume Univ., Japan)</i>

INDUSTRY LUNCHEON SYMPOSIA

DAY 3 Saturday, May 31, 2025


 Lunch box will be served.

<p>ROOM 1 (3F)</p>	<p>12:20-13:00 Luncheon Symposium 10 <i>Byoung Kuk Jang (Keimyung Univ.)</i></p> <p>Recent Advances in the Treatment of MASLD and the Therapeutic Potential of Carnitine Complex <i>Sung Won Lee (The Catholic Univ. of Korea)</i></p>	
<p>ROOM 2 (3F)</p>	<p>12:20-13:00 Luncheon Symposium 11 <i>Yong-Han Paik (Sungkyunkwan Univ.)</i></p> <p>The Optimal Sequencing of Unresectable Hepatocellular Carcinoma Treatment: Exploring Real-World Practice <i>Yuri Cho (National Cancer Center)</i></p>	
<p>ROOM 3 (2F)</p>	<p>12:20-13:00 Luncheon Symposium 12 <i>Kyung-Ah Kim (Inje Univ.)</i></p> <p>Evolution of PBC Care: What Comes Next? <i>Kris V. Kowdley (Washington State Univ., USA)</i></p>	
<p>ROOM 4 (2F)</p>	<p>12:20-13:00 Luncheon Symposium 13  <i>Junghwan Oh (The Catholic Univ. of Korea)</i></p> <p>Zastaprazan: A New Paradigm in GERD Management</p>	
<p>ROOM 6 (1F)</p>	<p>12:20-13:00 Luncheon Symposium 14 <i>Jae Young Jang (Soonchunhyang Univ.)</i></p> <p>Improving Treatment Outcomes and Adherence in CHB: The Role of Entecavir ODT <i>Jae Hyun Yoon (Chonnam National Univ.)</i></p>	

 Session in Korean


Cheomseongdae Observatory

Cheomseongdae, built in the 7th century during the Silla Dynasty, is Asia's oldest astronomical observatory, reflecting advanced scientific knowledge.




Bulguksa Temple

It is a masterpiece of architecture and Buddhist art from the Unified Silla period, and a significant cultural heritage that reflects the era's remarkable cultural and religious accomplishments.



Seokguram Grotto

Seokguram stands as the world's only artificially constructed granite grotto, showcasing the remarkable architectural sophistication of its time.





DAY 1

Thursday, May 29, 2025

PROGRAM AT A GLANCE

	ROOM 1 3F	ROOM 3 2F	ROOM 6 1F	ROOM 7 1F	Exhibition 1F	
09:00	PG Course 1 <i>Viral Hepatitis</i> 08:40-10:25	Basic Research 1 08:40-10:20			Booth & Poster Exhibition — Allday Coffee & Tea Station	
10:00			Coffee Break 10:25-10:40			
11:00	PG Course 2 <i>Steatotic Liver Disease and Liver Fibrosis</i> 10:40-12:00	Basic Research 2 10:40-12:00				
12:00			Luncheon Symposium 1 [Yuhan] 12:00-12:50	Luncheon Symposium 2 [Boryung] 12:00-12:50		Luncheon Symposium 3 [Abbvie] 12:00-12:50
13:00	Special Lecture 12:50-13:40					
14:00	PG Course 3 <i>Alcohol-Associated Liver Disease and Liver Cirrhosis</i> 13:40-15:20	Young Investigator Meeting 13:40-15:20	Ultrasound Trainee Session 14:00-15:30	Ultrasound Trainer Session 1 14:00-15:30		
15:00						Coffee Break 15:20-15:40
16:00	PG Course 4 <i>Hepatic Tumors</i> 15:40-17:20	Research Assistant Program 15:40-17:10	ROOM 8 (1F)	Ultrasound Trainer Session 2 15:40-17:10		
17:00			Ultrasound Hands-On Course 15:40-17:10			
18:00	Faculty Dinner 18:00-20:00 * Invitation Only					
19:00						
20:00						

ROOM 1 (3F)**PG Course 1** **08:40-10:25** *Viral Hepatitis**So Young Kwon (Konkuk Univ.), Sang Hoon Park (Hallym Univ.)*

08:40-09:05 Optimal Timing Antiviral Therapy for Hepatitis B Virus:
When to Start and When to Stop?

Jeong Eun Song (Daegu Catholic Univ.)

09:05-09:30 Challenges and Future Directions for Hepatitis B Virus Cure

Jung Hyun Kwon (The Catholic Univ. of Korea)

09:30-09:55 Emerging Viral Hepatitis: New Insights into Hepatitis D and E Infections

*Seong Kyun Na (Inje Univ.)***09:55-10:25** **New KASL Guideline 2025**

09:55-10:25 Updated KASL Guidelines on Chronic Hepatitis C

*Young Kul Jung (Korea Univ.)***ROOM 3 (2F)****Basic Research 1** **08:40-10:20** *Beginners' Guide for Basic Research**Jung-Hwan Yoon (Seoul National Univ.), Won-Il Jeong (KAIST)*

08:40-09:10 Why Hepatologists Should Engage in Basic and Translational Research

Jeong Won Jang (The Catholic Univ. of Korea)

09:10-09:40 Essential Steps to Setting up a Hepatology Research Lab

Young-Sun Lee (Korea Univ.)

09:40-10:20 How to Interpret Basic Research Data in Hepatology

Sejoon Lee (Seoul National Univ.)

ROOM 1 (3F)

PG Course 2 

10:40-12:00 *Steatotic Liver Disease and Liver Fibrosis*

Joo Hyun Sohn (Hanyang Univ.), Gab Jin Cheon (Univ. of Ulsan)

10:40-11:05 From Chronic Inflammation to Fibrogenesis
Won Sohn (Sungkyunkwan Univ.)

11:05-11:30 Impact of Genetic and Environmental Risk Factors on Liver Fibrosis
Ji-Won Park (Hallym Univ.)

11:30-12:00 **New KASL Guideline 2024**

11:30-12:00 Updated KASL Guidelines on Metabolic Dysfunction-Associated Steatotic Liver Disease
Byoung Kuk Jang (Keimyung Univ.)

ROOM 3 (2F)

Basic Research 2 

10:40-12:00 *New Approaches in Translational Science*

Kyun-Hwan Kim (Sungkyunkwan Univ.)

10:40-11:10 Advances in Spatial Omics and Data Analysis
Jong-Eun Park (KAIST)

11:10-11:35 Heterogeneity in Hepatocellular Carcinoma Diagnosis and Treatment via Spatial Gene Profiling
Junil Kim (Soongsil Univ.)

11:35-12:00 Digital Spatial Protein Profiling in Liver Diseases
Ji Won Han (The Catholic Univ. of Korea)

ROOM 1 (3F)

Special Lecture 

12:50-13:40 *Han Chu Lee (Univ. of Ulsan)*

12:50-13:40 How Do Medical Policies and Media Work in an Aging Era?
Dong-Charm Cho (Korea Science Journalists Association)

ROOM 1 (3F)**PG Course 3 ****13:40-15:20 Alcohol-Associated Liver Disease and Cirrhosis***Hong Soo Kim (Soonchunhyang Univ.), Oh Sang Kwon (Gachon Univ.)*

- 13:40-14:05 Identification of High-Risk Groups in Alcohol-Associated Liver Disease
Ha Il Kim (Hanyang Univ.)
- 14:05-14:30 Therapeutic Strategies for Alcohol-Use Disorder and Alcoholic Hepatitis
Jeong-Ju Yoo (Soonchunhyang Univ.)
- 14:30-14:55 Medical and Interventional Treatments in Portal Hypertension
Ki Tae Yoon (Pusan National Univ.)
- 14:55-15:20 Recent Advances in the Management of Acute-on-Chronic Liver Failure
Jong-In Chang (Chung-Ang Univ.)

ROOM 3 (2F)**13:40-15:20 Young Investigator Meeting***Joon Hyeok Lee (Sungkyunkwan Univ.), Won Young Tak (Kyungpook National Univ.)*

- 13:40-14:05 Distinguished Papers by Korean Hepatologists Aged 40 Years or Younger in 2024-2025
Su Jong Yu (Seoul National Univ.)

Introduction of Representative Studies

- 14:05-14:20 [Clinical Study 1] Effectiveness of US Surveillance of Hepatocellular Carcinoma in Chronic Hepatitis B: US LI-RADS Visualization Score
Min Kyung Park (Seoul National Univ.)
- 14:20-14:35 [Clinical Study 2] Inhibition of Sodium-Glucose Cotransporter-2 and Liver-Related Complications in Individuals with Diabetes: A Mendelian Randomization and Population-Based Cohort Study
Sung Won Chung (Univ. of Ulsan)
- 14:35-14:50 [Basic/Translational Study 1] Dynamic Peripheral T-Cell Analysis Identifies On-Treatment Prognostic Biomarkers of Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma
Ji Won Han (The Catholic Univ. of Korea)
- 14:50-15:05 [Basic/Translational Study 2] Co-Administration of Polyethylene Glycol with Binge Ethanol Reduces Markers of Intestinal and Hepatic Inflammation in C57BL/6J Mice by Diminishing Ethanol Absorption through the Intestinal Wall
Tom Ryu (Soonchunhyang Univ.)
- 15:05-15:20 Discussion

ROOM 6 (1F)

14:00-15:30 **Ultrasound Trainee Session** **K**

Sung Kyu Choi (Chonnam National Univ.), Moon Young Kim (Yonsei Univ. Wonju)

- 14:00-14:20 What Is an Abdominal Ultrasound?
Seung Kak Shin (Gachon Univ.)
- 14:20-14:40 Ultrasound Scanning Techniques: Liver
Woo Sun Rou (Chungnam National Univ.)
- 14:40-15:00 Ultrasound Scanning Techniques: Pancreato-Biliary
Chang Hun Lee (Jeonbuk National Univ.)
- 15:00-15:20 Ultrasound Findings of Common Liver Diseases
Jun Sik Yoon (Inje Univ.)
- 15:20-15:30 Q&A

ROOM 8 (1F)

15:40-17:10 **Ultrasound Hands-On Course** **K**

Group 1: *Jung Hee Kim (Hallym Univ.)*

Group 2: *Seul Ki Han (Yonsei Univ. Wonju)*

Group 3: *Hyun Yang (The Catholic Univ. of Korea)*

Group 4: *Tae Seop Lim (Yonsei Univ.)*

* 대한내과학회 전공의 초음파교육은 5월 29일(목), Ultrasound Trainee Session과
Ultrasound Hands-On Course 수강 시 인정됩니다.

* 위 평점이 필요하신 경우, 꼭 해당 강의실 앞에서 **입실 및 퇴실시 QR을 스캔**하여 주시기 바랍니다.

ROOM 7 (1F)

14:00-15:30 Ultrasound Trainer Session 1 

Soon Koo Baik (Yonsei Univ. Wonju)

- 14:00-14:20 Current Condition of Ultrasound Education in Training Hospitals
Tae-Suk Kim (Kangwon National Univ.)
- 14:20-14:40 Point-of-Care Ultrasound (POCUS): An Invaluable Tool in the Field of Medical Procedure Services
Nae-Yun Heo (Inje Univ.)
- 14:40-15:00 Role of Ultrasound Methods for the Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease
Se Young Jang (Kyungpook National Univ.)
- 15:00-15:20 Liver Fibrosis Stages Using Ultrasound Technology
Jung Gil Park (Yeungnam Univ.)
- 15:20-15:30 Q&A

ROOM 7 (1F)

15:40-17:10 Ultrasound Trainer Session 2 

Jae Young Jang (Soonchunhyang Univ.)

- 15:40-16:00 Follow-Up of Benign Neoplasm of Liver: Role of Abdominal Ultrasound
Moon Hyung Lee (Kyung Hee Univ.)
- 16:00-16:20 SAMSUNG's Liver Solution
Jiyeon Kim (Samsung Medison)
- 16:20-16:40 Comparative Clinical Utility of Sonovue and Sonazoid in Contrast-Enhanced Ultrasound for Liver Imaging
Soo Young Park (Kyungpook National Univ.)
- 16:40-17:00 Advanced Abdominal Ultrasound Considerations
Sae Hwan Lee (Soonchunhyang Univ.)
- 17:00-17:10 Q&A

* 대한간학회 복부초음파 세부전문의, 대한임상초음파학회 평점은 5월 29일(목), Ultrasound Trainer Session 또는 Ultrasound Trainee Session & Abdominal Ultrasound Hands-On Course 수강 시 인정됩니다.

* 대한내과학회 초음파 지도전문의 교육 평점은 5월 29일(목), Ultrasound Trainer Session 수강 시 인정됩니다.

* 위 평점이 필요하신 경우, 꼭 해당 강의실 앞에서 **입실 및 퇴실시 QR을 스캔**하여 주시기 바랍니다.

ROOM 1 (3F)

PG Course 4 

15:40-17:20 *Hepatic Tumors*

Chang Hyeong Lee (Daegu Catholic Univ.), Byung Seok Lee (Chungnam National Univ.)

15:40-16:05 Surveillance Programs for Hepatocellular Carcinoma according to Risk Factors

Tae Hyung Kim (Korea Univ.)

16:05-16:30 Neoadjuvant and Adjuvant Therapies for Hepatocellular Carcinoma

Wonseok Kang (Sungkyunkwan Univ.)

16:30-16:55 Rising Tide: Hepatocellular Adenomas in Korea

So Yeon Kim (Univ. of Ulsan)

16:55-17:20 Diagnosis and Treatment of Combined Hepatocellular Carcinoma-Cholangiocarcinoma

Pil Soo Sung (The Catholic Univ. of Korea)

ROOM 3 (2F)

15:40-17:10 **Research Assistant Program**

Moon Seok Choi (Sungkyunkwan Univ.), Jong Eun Yeon (Korea Univ.)

15:40-16:10 Artificial Intelligence Tools to Power Academic Research and Publication

Joon Seo Lim (Asan Medical Center)

16:10-16:40 Effective English Presentation and Communication in a Medical Conference

Danielle Lee (Asan Medical Center)

16:40-17:10 Management of Literature and References for Scientific Writing

Sangzin Ahn (Inje Univ.)

Laying the Foundation for the Korean Association for the Study of the Liver (KASL)



- **1943**
Dr. Jang, Gi-ryeo successfully performed the first hepatic resection in Korea.



- **1956**
Dr. Han, Sim-seok participated in the "Minnesota Project," initiating modern medical education in Korea.



- **1956**
Captain Jung, Hwan-guk contributed early liver-related procedures at the Nonsan Army Hospital.



- **1977**
Dr. Kim, Jeong-ryong developed the world's first hepatitis B vaccine.



- **1988**
Dr. Kim, Soo-tae achieved Korea's first living donor liver transplantation and Asia's first partial liver transplantation in the same year.



- **1992**
Dr. Lee, Hyuk-sang performed Korea's first adult liver transplantation.

DAY 2

Friday, May 30, 2025

PROGRAM AT A GLANCE

	ROOM 1 3F	ROOM 2 3F	ROOM 3 2F	ROOM 4 2F	ROOM 5 2F
07:30					
08:00	KASL SIG 1 <i>The KASL Steatotic Liver Disease Study Group</i> 07:30-08:50 (B)	KLCA Symposium 1 <i>Epidemiology & Surveillance of HCC</i> 07:30-08:50 (B)	KAHBPS Symposium 1 <i>Considerations in Liver Surgery</i> 07:30-08:50 (B)	KASL SIG 2 <i>The KASL Abdominal Ultrasound Study Group</i> 07:30-08:50 (B)	Industry Forum 1 [Roche] 07:20-08:30 (B)
09:00		Liver Biopsy in HCC (K)			Industry Forum 3 [Yuhan] 08:30-09:10 (B)
10:00	KASL-AASLD Joint Symposium 1 <i>RCT in Hepatology</i> 09:10-10:30	KLCA Symposium 2 <i>Biomarkers of Liver Cancer</i> 09:10-10:30	KAHBPS Symposium 2 <i>Minimally Invasive Surgery</i> 09:10-10:30	Hepatology Associates 1 <i>Clinical Hepatology</i> 09:10-10:30 (K)	
11:00	Opening Ceremony 10:30-11:10				
12:00	State-of-the-Art Lecture 11:10-11:40		KLTS Coordinator Session <i>Liver Transplantation for ALD</i> 11:20-12:40 (K)		
13:00	Plenary Presentation 1 11:40-12:40				
13:30	Luncheon Symposium 5 (L) [Roche] 12:40-13:30	KLCA General Meeting (K, L) 12:40-13:30	Luncheon Symposium 6 (L) [Gilead] 12:40-13:30	Luncheon Symposium 7 (L) [Daewoong] 12:40-13:30	
14:00	KASL Symposium 2 <i>Chronic Viral Hepatitis</i> 13:30-14:50	KLCA-JLCA Joint Symposium <i>Pre- & Post-LT Management for HCC</i> 13:30-14:50	KAHBPS Symposium 3 <i>Updates on Cholangiocarcinoma</i> 13:30-14:50	Data Science Camp 1 <i>Statistics in Hepatology</i> 13:30-14:50	
15:00	Coffee Break 14:50-15:10				
16:00	KASL-KAHBPS-KLCA-KLTS Joint Symposium <i>Multidisciplinary Practice</i> 15:10-16:30		Free Paper 1 <i>Hepato-Biliary and Pancreas Surgery</i> 15:10-16:30	Hepatology Associates 2 <i>Elements for Clinical Trials</i> 15:10-16:30 (K)	Free Paper 2 <i>Liver Cancer, Clinical 1</i> 15:10-16:30
17:00					
18:00					
19:00					

Program at a Glance

DAY 2

Friday, May 30, 2025

ROOM 6 1F	ROOM 6-1 1F	ROOM 7 1F	ROOM 8 1F	ROOM 9 1F	Exhibition 1F	
Translational Hepatology 07:30-08:50		KASL SIG 3 <i>The KASL Autoimmune and Rare Liver Disease Study Group</i> 07:30-08:50	Industry Forum 2 [AstraZeneca] 07:30-08:10		07:30 08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00	
			Industry Forum 4 [Daewoong] 08:30-09:10	Industry Forum 5 [Gilead] 08:30-09:10		
	KASL Symposium 1 <i>LC and Portal HTN</i> 09:10-10:30			Booth & Poster Exhibition —		
						Allday Coffee & Tea Station
Luncheon Symposium 8 [Samil] 12:40-13:30	Luncheon Symposium 9 [Eisai] 12:40-13:30					
Health Insurance & Policy Forum 13:30-14:50	TLW SIG <i>Precision Oncology</i> 13:30-14:50					
Coffee Break 14:50-15:10						
Free Paper 3 <i>MASLD, Clinical</i> 15:10-16:30	Free Paper 4 <i>HBV Basic & ALD</i> 15:10-16:30	Free Paper 5 <i>Acute Liver Failure & DILI</i> 15:10-16:30	Free Paper 6 <i>HBV 1</i> 15:10-16:30	Free Paper 7 <i>Liver Cancer, Basic</i> 15:10-16:30		
						Oral Poster Presentation 16:40-17:40
						Welcome Reception 18:00- *All Participants*

ROOM 5 (2F)

07:20-08:30	Industry Forum 1 with   <i>Yi-Hsiang Huang (National Yang Ming Chiao Tung Univ., Taiwan)</i>
07:20-07:30	Tune-In Session
07:30-07:35	Opening Remark
07:35-07:50	Case 1. Enhancing Survival with IO + Anti-VEGF The Role of Combination Therapy in Achieving an Earlier Impact on Patient Outcomes <i>Hideki Iwamoto (Kurume Univ., Japan)</i>
07:50-08:00	Polling and Discussion
08:00-08:15	Case 2. Preserving Liver Function with Early-Stage Treatment The Importance of Timely Intervention and MDT Collaboration, with Insights from TACE-R and TACE-U Cases <i>Jacob George (The Univ. of Sydney, Australia)</i>
08:15-08:25	Polling and Discussion
08:25-08:30	Closing Remark

ROOM 1 (3F)

07:30-08:50	KASL Special Interest Group 1  The KASL Steatotic Liver Disease Study Group <i>Challenges to Overcome in the Era of MASLD</i> <i>Byoung Kuk Jang (Keimyung Univ.), Su Jong Yu (Seoul National Univ.)</i>
07:30-07:50	Best Strategies to Assess Advanced Fibrosis in MASLD <i>Mi Na Kim (Yonsei Univ.)</i>
07:50-08:10	Use of Anti-Diabetic Drugs in MASLD: Can We Kill Two Birds with One Stone? <i>Joonyub Lee (The Catholic Univ. of Korea)</i>
08:10-08:35	Relationship between MASLD and Chronic Hepatitis B: Friends or Foes <i>Shang-Chin Huang (National Taiwan Univ., Taiwan)</i>
08:35-08:50	Discussion <i>Mi Na Kim (Yonsei Univ.), Joonyub Lee (The Catholic Univ. of Korea), Shang-Chin Huang (National Taiwan Univ., Taiwan)</i>

ROOM 2 (3F)

KLCA Symposium 1 

07:30-08:50 *Evolving Epidemiology and Advancing Surveillance of Hepatocellular Carcinoma*

*Joong-Won Park (Myoungji Hospital, Hanyang Univ.),
Jin Wook Chung (Seoul National Univ.)*

07:30-07:50 Trends from the Nationwide Cancer Registry
Han Ah Lee (Chung-Ang Univ.)

07:50-08:10 Future Trends in Hepatocellular Carcinoma in Korea
Young Eun Chon (CHA Univ.)

08:10-08:30 Imaging and Beyond: Expanding Hepatocellular Carcinoma Surveillance Modalities
Hyuk Soo Eun (Chungnam National Univ.)

08:30-08:50 The Future of Imaging-Based Hepatocellular Carcinoma Surveillance: Personalized Approaches and Artificial Intelligence
Hyo Jung Park (Univ. of Ulsan)

ROOM 3 (2F)

KAHBPS Symposium 1 

07:30-08:50 *Assessment and Management of Uncommon Considerations in Liver Surgery*

*Chinburen Jigjidsuren (Parliament of Mongolia, Mongolia),
Young Chul Yoon (The Catholic Univ. of Korea)*

07:30-07:50 High-Grade Morbid Obesity in Liver Surgery
Unenbat Gurbadam (National Cancer Center, Mongolia)

07:50-08:10 Assessment and Management of Severe Cardiovascular Disease in Liver Surgery
Haeil Jung (Soonchunhyang Univ.)

08:10-08:30 Elderly Patients over 75 Years
Etsuro Hatano (Kyoto Univ., Japan)

08:30-08:50 End-Stage Renal Disease
Chan Woo Cho (Yeungnam Univ.)

ROOM 4 (2F)

07:30-08:50 **KASL Special Interest Group 2 **
The KASL Abdominal Ultrasound Study Group
Recent Progress in Clinical Application of Ultrasound
Soon Koo Baik (Yonsei Univ. Wonju), Sang Gyune Kim (Soonchunhyang Univ.)

07:30-07:50 Comparison of Liver Fibrosis Assessment Using VCTE versus SWE
Moon Hyung Lee (Kyung Hee Univ.)

07:50-08:10 The Role of Ultrasound in the Diagnosis and Assessment of MASLD
Heejoon Jang (Seoul National Univ.)

08:10-08:30 Outcome Prediction Using Ultrasound in Chronic Liver Diseases
Jun Sik Yoon (Inje Univ.)

08:30-08:50 Discussion

ROOM 6 (1F)

07:30-08:50 **Translational Hepatology **
Promising Cutting-Edge Translational Liver Study
Youngmi Jung (Pusan National Univ.), Ja Hyun Koo (Seoul National Univ.)

07:30-07:50 Tracing Cellular Dynamics during Intestinal Tumorigenesis and Metastasis
Min Kyu Yum (KAIST)

07:50-08:10 Histone Lactylation: A Novel Epigenetic Mark in Liver Fibrosis
Hyunsoo Rho (Ewha Womans Univ.)

08:10-08:30 Casp2: The New Hepatic Lipid Regulator
Ju Youn Kim (Hanyang Univ.)

08:30-08:50 Identification of Novel Targets for the Treatment of MASLD
Keon Wook Kang (Seoul National Univ.)

ROOM 7 (1F)

07:30-08:50 **KASL Special Interest Group 3** 
The KASL Autoimmune and Rare Liver Disease Study Group
Exploring Autoimmune and Rare Liver Diseases
Kyung-Ah Kim (Inje Univ.), Atsushi Tanaka (Teikyo Univ., Japan)

07:30-07:55 Challenges in the Diagnosis and Treatment of Autoimmune Hepatitis
Soon Kyu Lee (The Catholic Univ. of Korea)

07:55-08:25 Current Status and Research Trends of Autoimmune Liver Diseases in Japan
Atsushi Tanaka (Teikyo Univ., Japan)

08:25-08:50 Updates in Diagnosis and Management of Rare Vascular Liver Diseases
Yu Rim Lee (Kyungpook National Univ.)

ROOM 8 (1F)

07:30-08:10 **Industry Forum 2 with** AstraZeneca  
Yoon Jun Kim (Seoul National Univ.)

07:30-07:50 IO-Based Combinations in Advanced Hepatocellular Carcinoma: Real-World STRIDE Experience and Clinical Impact on Unmet Needs
Amit Singal (UT Southwestern Medical Center, USA)

07:50-08:10 Discussion

ROOM 5 (2F)

08:30-09:10 **Industry Forum 3 with**  **YUHAN** 
Young-Sun Lee (Korea Univ.)

08:30-09:10 Development Progress of Oral GLP-1 Receptor Agonists for Obesity Treatment
Se-Woong Oh (Yuhan Corp.)

ROOM 8 (1F)

08:30-09:10 **Industry Forum 4 with**  **DAEWOONG** 
Seung Kak Shin (Gachon Univ.)

08:30-09:10 Top-Line Results of Phase 4 Clinical Trial for Vemliver (Tenofovir Alafenamide Hemitartrate) Announced
Yeewool Kang (Dong-A Univ.)

ROOM 9 (1F)

08:30-09:10 Industry Forum 5 with  GILEAD 
Eun Sun Jang (Seoul National Univ.)

08:30-09:10 Tenofovir: Early Treatment Marks the Beginning of a Cure for Chronic Hepatitis B
Jeong Heo (Pusan National Univ.)

ROOM 2 (3F)

08:50-09:10 Liver Biopsy in Hepatocellular Carcinoma 
Kyung Sik Kim (Yonsei Univ.)

08:50-09:10 The Role of Liver Biopsy in Hepatocellular Carcinoma Management: A KLCA Perspective
Hae Lim Lee (The Catholic Univ. of Korea)

ROOM 1 (3F)

KASL-AASLD Joint Symposium 1

09:10-10:30 Randomized Controlled Trials in Hepatology
W. Ray Kim (Mayo Clinic, USA), Yoon Jun Kim (Seoul National Univ.)

09:10-09:30 Practical Tips for Designing and Conducting Successful RCT
Sumeet Asrani (Baylor Univ., USA)

09:30-09:50 Biases, Challenges, and Innovations in RCT Statistics
Inkyung Jung (Yonsei Univ.)

09:50-10:10 Successes and Failures in RCT: Insights from AASLD Experiences
Kris V. Kowdley (Washington State Univ., USA)

10:10-10:30 Successes and Failures in RCT: Insights from KASL Experiences
Young-Suk Lim (Univ. of Ulsan)

ROOM 2 (3F)**KLCA Symposium 2****09:10-10:30***Advancing Biomarker Discovery and Translational Insights in Liver Cancer**Seung Kew Yoon (The Catholic Univ. of Korea), Hee Chul Yu (Jeonbuk National Univ.)*

- 09:10-09:30 Liquid vs. Tissue Biopsy to Support Treatment Decisions in Hepatocellular Carcinoma
Soung Won Jeong (Soonchunhyang Univ.)
- 09:30-09:50 Artificial Intelligence-Based Pathology as a Biomarker of Sensitivity to Immunotherapy
Sung Hak Lee (The Catholic Univ. of Korea)
- 09:50-10:10 Strategies to Effectively Drive the Cancer-Immunity Cycle: Roles of Each Therapeutic Modality in Hepatocellular Carcinoma
Hideki Iwamoto (Kurume Univ., Japan)
- 10:10-10:30 Mechanisms of Metastasis Revealed through Single-Cell Spatial Transcriptome Analysis in Patients with Liver Metastatic Colorectal Cancer
Jungmin Choi (Korea Univ.)

ROOM 3 (2F)**KAHBPS Symposium 2****09:10-10:30***Laparoscopic Liver Resection vs. Robotic Liver Resection**Poowanai Sarkhampee (Sunpasitthiprasong Hospital, Thailand), Sang Jin Kim (Korea Univ.)*

- 09:10-09:30 Technical Differences in Surgical Approaches
Dai Hoon Han (Yonsei Univ.)
- 09:30-09:50 Challenges and Learning Curve for Beginners
Su Young Hong (Seoul National Univ.)
- 09:50-10:10 Clinical Outcomes and Complications: Laparoscopic vs. Robotic Liver Resection
Kwan Woo Kim (Dong-A Univ.)
- 10:10-10:30 Open Liver Resection as a Good Surgical Approach: Indications and Outcomes
Kwangho Yang (Pusan National Univ.)

ROOM 4 (2F)

Hepatology Associates 1 

09:10-10:30 *Updates in Clinical Hepatology*

Jaeseok Hwang (Keimyung Univ.), Hee Bok Chae (Chungbuk National Univ.)

09:10-09:30 Percutaneous Liver Biopsy: When to Decide to Perform and How to Minimize Risk
Hyeon Ji Jang (Univ. of Ulsan)

09:30-09:50 Management of Hospitalized Patients with Alcohol Withdrawal Syndrome
Jae Hyun Yoon (Chonnam National Univ.)

09:50-10:10 Inpatient Care for Gastrointestinal Bleeding in Patients with Liver Cirrhosis
Heechul Nam (The Catholic Univ. of Korea)

10:10-10:30 Precipitating Factors and Management of Hepatic Encephalopathy
Jae Seung Lee (Yonsei Univ.)

ROOM 7 (1F)

KASL Symposium 1

09:10-10:30 *Innovative Strategies in Cirrhosis Care*

*Barjesh Chander Sharma (Govind Ballabh Pant Hospital, India),
Jae Young Jang (Soonchunhyang Univ.)*

09:10-09:30 Primary Hemostasis in Cirrhosis: A Modern Perspective on Coagulopathy
Manoj Kumar Sharma (Institute of Liver and Biliary Sciences, India)

09:30-09:50 Metabolomic Biomarkers for Risk Stratification and Prognosis Prediction in Cirrhotic Patients
Eun Ju Cho (Seoul National Univ.)

09:50-10:10 Recompensation in Cirrhosis: Mechanisms, Predictors, and Therapeutic Strategies
Byeong Geun Song (Sungkyunkwan Univ.)

10:10-10:30 Treatment of Portal Hypertension in Patients with Hepatocellular Carcinoma in the Era of Baveno VII
Dominique Damais-Thabut (Sorbonne Univ., France)

ROOM 1 (3F) **ROOM 2 (3F)**  **Live****10:30-11:10 Opening Ceremony****ROOM 1 (3F)****11:10-11:40 State-of-the-Art Lecture***Masao Omata (The Univ. of Tokyo, Japan)*

- 11:10-11:40 Hepatitis B Virus with Co-Existing Liver Diseases: The Interactions between Viral Hepatitis C, MAFLD, and Hepatitis B Virus
Chun-Jen Liu (National Taiwan Univ., Taiwan)

ROOM 3 (2F)**KLTS Coordinator Session **

- 11:20-12:40** *Multidisciplinary Approach to Liver Transplantation for Alcohol-Associated Liver Disease*
Seung Heui Hong (Samsung Medical Center), Hae Won Lee (Seoul National Univ.)

- 11:20-11:40 Alcohol Dependence and Liver Transplantation: The Importance of Mental Health Care
Kye-Seong Lee (Incheon Chamsarang Hospital)
- 11:40-12:00 Liver Transplantation for Alcohol-Associated Liver Disease: A Surgical Perspective and Prognosis
Hae Won Lee (Seoul National Univ.)
- 12:00-12:20 Coordination of the Liver Transplant Process and Patient Management for Alcoholic Liver Disease: Evolving Roles of Transplant Coordinators in Korea
Sunyoung Son (Gangnam Severance Hospital)
- 12:20-12:40 Social Support and Rehabilitation for Liver Transplant Patients with Alcoholic Liver Disease
Eunseon Suh (Hwaseong Community Addiction Management Center)

ROOM 1 (3F)

Plenary Presentation 1

11:40-12:40 *Sung Su Yun (Yeungnam Univ.), Mi-Sook Kim (Korea Cancer Center Hospital), Yong-Han Paik (Sungkyunkwan Univ.)*

11:40-11:55 [PP 1-1] CXCR4⁺ CD8⁺ T Cells in Alcoholic Liver Disease: Enhanced Cytotoxicity and Associations with Liver Function Markers
Pil Soo Sung (The Catholic Univ. of Korea)

11:55-12:10 [PP 1-2] Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Hepatocellular Carcinoma: 9-Year Extended Follow-Up of a Randomized Controlled Trial and Post-Treatment Immune Cell Profiling
Hyunjae Shin (Seoul National Univ.)

12:10-12:25 [PP 1-3] Surgical Quality Assessment with Artificial Intelligence-Based Video Analysis for Laparoscopic Donor Right Hemihepatectomy: Usefulness of Round Ligament Fixation in Hilar Structure Dissection
Dai Hoon Han (Yonsei Univ.)

12:25-12:40 [PP 1-4] Performance of Expanded Criteria for Liver Transplantation in Patients with Hepatocellular Carcinoma: A Network Meta-Analysis
Yeongseok Hwang (Univ. of Ulsan)

ROOM 2 (3F)

12:40-13:30 KLCA General Meeting  

ROOM 1 (3F)**KASL Symposium 2****13:30-14:50** *The Immunological Horizon Towards Curing Viral Hepatitis and Beyond**Chun-Jen Liu (National Taiwan Univ., Taiwan), Sang Hoon Ahn (Yonsei Univ.)*

13:30-13:50 Pipelines for Curing Hepatitis B Using Immunological Targets: Successes and Failures

Won-Mook Choi (Univ. of Ulsan)

13:50-14:10 Targeting Innate Immunity as a Promising Approaches for Curing Hepatitis B

Loey Lung-Yi Mak (The Univ. of Hong Kong, Hong Kong)

14:10-14:30 Targeting Adaptive Immunity as a Promising Approaches for Curing Hepatitis B

Markus Cornberg (Hannover Medical School, Germany)

14:30-14:50 Development of a Novel Immune Modulator SA-5 as a Therapeutic Option for Chronic Hepatitis B

*Tatsuya Kanto (Japan Institute for Health Security, Japan)***ROOM 2 (3F)****KLCA-JLCA Joint Symposium****13:30-14:50** *Optimizing Bridging Gaps in Pre- and Post-Liver Transplantation Management for Hepatocellular Carcinoma**June Sung Lee (Inje Univ.), Etsuro Hatano (Kyoto Univ., Japan)*

13:30-13:50 Pre-Transplant Hepatocellular Carcinoma Control: Surgical Resection and Bridging Strategies

Jongman Kim (Sungkyunkwan Univ.)

13:50-14:10 Innovative Bridging Therapies for Hepatocellular Carcinoma: From Transarterial Chemoembolization to Immune Checkpoint Inhibitors

Tomoharu Yamada (The Univ. of Tokyo, Japan)

14:10-14:30 Post-Transplant Hepatocellular Carcinoma Recurrence: Predictors, Surveillance, and Novel Interventions

Soon Sun Kim (Ajou Univ.)

14:30-14:50 Immunosuppression and Immunotherapy in Post-Liver Transplant Hepatocellular Carcinoma: Striking the Right Balance

Tomoharu Yoshizumi (Kyushu Univ., Japan)

ROOM 3 (2F)

KAHBPS Symposium 3

13:30-14:50 *Recent Updates in Cholangiocarcinoma*

In Seok Choi (Konyang Univ.), Jin-Young Jang (Seoul National Univ.)

13:30-13:50 Minimal Invasive Surgery for Intrahepatic Cholangiocarcinoma
Kyeong Deok Kim (Inha Univ.)

13:50-14:10 Extent of Lymph Node Dissection in Intrahepatic Cholangiocarcinoma
Poowanai Sarkhampee (Sunpasitthiprasong Hospital, Thailand)

14:10-14:30 Surgical Approach to Hilar Cholangiocarcinoma
Sang Hwa Song (Chonnam National Univ.)

14:30-14:50 Role of Liver Transplantation in the Treatment of Intrahepatic Cholangiocarcinoma
Amit Singal (UT Southwestern Medical Center, USA)

ROOM 4 (2F)

Data Science Camp 1

13:30-14:50 *Statistics in Hepatology*

Jin-Wook Kim (Seoul National Univ.), Chang Wook Kim (The Catholic Univ. of Korea)

13:30-14:10 Advanced Survival Analysis
Woojoo Lee (Seoul National Univ.)

14:10-14:50 Development and Evaluation of Clinical Prediction Models
Sehee Kim (Univ. of Ulsan)

ROOM 6 (1F)**Health Insurance and Policy Forum ****13:30-14:50***In Hee Kim (Jeonbuk National Univ.), Hyun Woong Lee (Yonsei Univ.)
Panelist: Yunsuk Kim (Korea Disease Control and Prevention Agency)*

- 13:30-13:50 Current Status and Unmet Need of Reimbursement of Systemic Chemotherapy for Hepatocellular Carcinoma
Eileen L. Yoon (Hanyang Univ.)
- 13:50-14:10 Procedural Standards for Health Insurance Coverage and Criteria for Oncology Drug Reimbursement
Mi Young Kang (Health Insurance Review & Assessment Service)
- 14:10-14:30 Introduction of National Hepatitis C Screening and Post-Screening Management Plan
Young Joon Park (Korea Disease Control and Prevention Agency)
- 14:30-14:50 Disease Burden of MASLD and Management of High-Risk Groups in Korea
Won-Ho Kim (Korea National Institute of Health)

ROOM 7 (1F)**TLW Special Interest Group****13:30-14:50***Integrating Multi-Omics for Precision Oncology**Chien-Hung Chen (National Taiwan Univ., Taiwan), Jaeyoun Cheong (Ajou Univ.)*

- 13:30-13:50 Integration of Clinical, Computational and Genomic Resources for Early Hepatocellular Carcinoma Detection
Augusto Villanueva (NYU Langone, USA)
- 13:50-14:10 Molecular Insights into Hepatocellular Carcinoma Recurrence from Minimal Residual Disease after Therapy
Renumathy Dhanasekaran (Stanford Univ., USA)
- 14:10-14:30 Immune Microenvironment and Therapeutic Discovery in Hepatocellular Carcinoma Using Single-Cell Omics Analysis
Valerie Chew (Duke-NUS Medical School, Singapore)
- 14:30-14:50 Genomic Characteristics of RB1-Deficient Hepatocellular Carcinoma and Its Therapeutic Candidates
Ju Hyun Shim (Univ. of Ulsan)

ROOM 1 (3F)

KASL-KAHBPS-KLCA-KLTS Joint Symposium

15:10-16:30 *Multidisciplinary Practices to Prevent Hepatocellular Carcinoma Occurrence and Recurrence*

Tae Hun Kim (Ewha Womans Univ.), Dong-Hwan Jung (Univ. of Ulsan)

15:10-15:30 Etiology-Based Primary Prevention Strategies for Hepatocellular Carcinoma
Jeong Han Kim (Konkuk Univ.)

15:30-15:50 Post-Resection Monitoring and Predictors for Hepatocellular Carcinoma Recurrence
Min-Su Park (Kyung Hee Univ.)

15:50-16:10 Diagnosis and Multidisciplinary Management of Recurrent Hepatocellular Carcinoma after Hepatectomy
Hye Won Lee (Yonsei Univ.)

16:10-16:30 Criteria and Workups for Liver Transplant Eligibility in Recipients Focus on Hepatocellular Carcinoma Patients
Seok-Hwan Kim (Chungnam National Univ.)

ROOM 4 (2F)

Hepatology Associates 2 

15:10-16:30 *Essential Elements for a Successful Clinical Trial*

Young Seok Kim (Soonchunhyang Univ.), Byung-Cheol Song (Jeju National Univ.)

15:10-15:30 Differences between Sponsor-Initiated Trials and Investigator-Initiated Trials
Minjong Lee (Ewha Womans Univ.)

15:30-15:50 Human Subjects Protection and Data Review Board
Seungwon Jeung (Korea Health Information Service)

15:50-16:10 Collection and Management of Patient-Derived Samples in Clinical Trials
Dae Won Jun (Hanyang Univ.)

16:10-16:30 Keywords for Investigator-Initiated Trials (IIT): What Academia Needs to Know
Elisabet Kim (Asan Medical Center)

SEOUL INTERNATIONAL LIVER SYMPOSIUM
14th February 1982



Moments from Our 30-Year Scientific Journey

The first international academic conference, "The Seoul International Liver Symposium (SILS)", was held in 1982.




The SILS was last held in 2009. In 2014, a new chapter began with the launch of The Liver Week in Jeju.



Four leading academic societies—KASL, the Korean Liver Cancer Association, the Korean Association of Hepato-Biliary-Pancreatic Surgery, and the Korean Society for Liver Transplantation—came together in close collaboration to establish The Liver Week as a highly successful and truly multidisciplinary conference.

PROGRAM
Saturday, May 31, 2025





DAY 3

Saturday, May 31, 2025


Program at a Glance

	ROOM 1 3F	ROOM 2 3F	ROOM 3 2F	ROOM 4 2F	ROOM 5 2F
07:00					
08:00	KASL SIG 4 <i>The KASL Viral Hepatitis Study Group</i> 07:30-08:50 (B)	KLCA Symposium 3 <i>New Paradigms of HCC Treatment</i> 07:30-08:50 (B)	KLTS Symposium 1 <i>Pre-LDLT Approaches</i> 07:30-08:50 (B)	KASL SIG 5 <i>The KASL Study Group of Portal Hypertension</i> 07:30-08:50 (B)	
09:00	Coffee Break 08:50-09:10				
10:00	KASL-AASLD Joint Symposium 2 <i>Future Hepatology</i> 09:10-10:30	KLCA-TLCA Joint Symposium <i>Strategies in the I-O Era</i> 09:10-10:30	KLTS Symposium 2 <i>Techniques in LDLT</i> 09:10-10:30	Data Science Camp 2 <i>AI in Hepatology</i> 09:10-10:30	
	Coffee Break 10:30-10:50				
11:00	President's Choice Lecture 10:50-11:20				
12:00	Plenary Presentation 2 11:20-12:20				
13:00	Luncheon Symposium 10 (L) [Celltrion] 12:20-13:10	Luncheon Symposium 11 (L) [AstraZeneca] 12:20-13:10	Luncheon Symposium 12 (L) [IPSEN] 12:20-13:10	Luncheon Symposium 13 (K, L) [Dong-A ST] 12:20-13:10	
14:00	KASL Symposium 3 <i>Metabolic Dysfunction-Associated Steatotic Liver Disease</i> 13:10-14:30		KLTS Symposium 3 <i>Pre-DDLT Approaches</i> 13:10-14:30	KASL Symposium 4 <i>Alcohol-Associated Liver Disease</i> 13:10-14:50	Free Paper 8 <i>Liver Cancer, Clinical 2</i> 13:10-14:30
15:00	KASL Leading Research Achievement Award (K)				
15:00	The Liver Week 2025 Debrief 14:50-15:50				
16:00	Closing & Award 15:50-16:10				
17:00					

Program at a Glance

DAY 3

Saturday, May 31, 2025



ROOM 1 (3F)

KASL Special Interest Group 4 

The KASL Viral Hepatitis Study Group

07:30-08:50 *Advancing Insights into Hepatitis B Virus Pathogenesis and Therapy*

Hyung Joon Yim (Korea Univ.), Takehisa Watanabe (Kumamoto Univ., Japan)

07:30-08:00 **Maternal Chronic Hepatitis B Virus Infection and Its Potential Impact on Fetal Development and Congenital Anomalies**
Yewan Park (Kyung Hee Univ.)

08:00-08:25 **A Novel Anti-HBV Compound Reduces HBsAg and HBV-DNA by Destabilizing HBV-RNA**
Takehisa Watanabe (Kumamoto Univ., Japan)

08:25-08:50 **AI-Based Hepatocellular Carcinoma Risk Prediction in Chronic Hepatitis B Virus Patients**
Yeonjung Ha (CHA Univ.)

ROOM 2 (3F)

KLCA Symposium 3 

07:30-08:50 *Revisiting and Expanding Hepatocellular Carcinoma Treatment Paradigms: From Standard to Innovative Therapies*

Jong Young Choi (Chung-Ang Univ.), Augusto Villanueva (NYU Langone, USA)

07:30-07:50 **Systemic Therapy and Transarterial Chemoembolization in BCLC Intermediate Stage: A Survival Boost?**
Yi-Hsiang Huang (National Yang Ming Chiao Tung Univ., Taiwan)

07:50-08:10 **TACE/TARE in Advanced Hepatocellular Carcinoma: Can They Coexist with Systemic Therapy?**
Hyo-Cheol Kim (Seoul National Univ.)

08:10-08:30 **The Emerging Role of Immuno-Oncology Therapy in Neo- and Adjuvant Treatment for Hepatocellular Carcinoma**
Jacob George (The Univ. of Sydney, Australia)

08:30-08:50 **Cancer Vaccines in Hepatocellular Carcinoma: Current Status and Future Directions**
Jeong Heo (Pusan National Univ.)

ROOM 3 [2F]**KLTS Symposium 1** **07:30-08:50**

Living Donor Liver Transplantation-Based Protocol for Hepatocellular Carcinoma: Intention-to-Treat Approach with Pre-Transplant Therapy

Myoung Soo Kim (Yonsei Univ.), Il Han Song (Dankook Univ.)

07:30-07:50

Definition and Current Status of Bridging, Neoadjuvant, Downstaging, and Conversion Therapies

Moon Haeng Hur (Seoul National Univ.)

07:50-08:10

Pros and Cons of Repetitive Transarterial Chemoembolization or Other Locoregional Therapies Prior to Liver Transplantation

Dongho Hyun (Sungkyunkwan Univ.)

08:10-08:30

Practical Factors Considered in Immunotherapy Prior to Liver Transplantation

Dong Hyun Sinn (Sungkyunkwan Univ.)

08:30-08:50

Lessons for Developing Protocols Based on Real-World Data

Dong-Hwan Jung (Univ. of Ulsan)

ROOM 4 [2F]**KASL Special Interest Group 5** **The KASL Study Group of Portal Hypertension****07:30-08:50**

Advancing the Frontiers of Cirrhosis Care: Diagnostic and Therapeutic Insights

Young Seok Kim (Soonchunhyang Univ.), Won Hyeok Choe (Konkuk Univ.)

07:30-07:50

Optimal Management Strategies for Non-Selective Beta-Blockers in Cirrhosis

Jae Yoon Jeong (Ewha Womans Univ.)

07:50-08:10

Advances in Non-Invasive Methods for Detecting Clinically Significant Portal Hypertension

Hyunwoo Oh (Sungkyunkwan Univ.)

08:10-08:30

Updates in the Management of Acute Kidney Injury in Patients with Cirrhosis

Sung Hwan Yoo (Yonsei Univ.)

08:30-08:50

Optimizing Nutrition in Cirrhosis: Recent Advances and Clinical Implications

Masahito Shimizu (Gifu Univ., Japan)

ROOM 6 (1F)

KASL Special Interest Group 6 
The KASL Alcohol-Related Problem Study Group

07:30-08:50 *KASL-BATL Joint Session: Alcohol and Environmental Cues in Liver Disease*

Yoon Mee Yang (Kangwon National Univ.), Wonhyo Seo (Ewha Womans Univ.)

07:30-07:50 Hepatic Glutamate Signaling Pathway in Alcohol-Associated Liver Disease

Won-Il Jeong (KAIST)

07:50-08:10 IRONing Out MASLD: Hepatocyte Messages to Adipose Tissue

Chang Yeob Han (Jeonbuk National Univ.)

08:10-08:30 Calibration of Gut-Liver Axis via Bile Acid and Neutrophils

Yong-Hyun Han (Kangwon National Univ.)

08:30-08:50 Diagnosis and Treatment of Liver Disease Using Extracellular Vesicles

Shuji Terai (Niigata Univ., Japan)

ROOM 1 (3F)

KASL-AASLD Joint Symposium 2

09:10-10:30 *Looking into the Future of Hepatology*

Silvia Sookoian (Maimonides Univ., Argentina),

Sook-Hyang Jeong (Seoul National Univ.)

09:10-09:30 Anti-Fibrotic and Anti-Cirrhotic Approaches in Chronic Liver Disease

Seung Up Kim (Yonsei Univ.)

09:30-09:50 Future Directions in Liver Transplant Allocation Policies: Beyond MELD

W. Ray Kim (Mayo Clinic, USA)

09:50-10:10 Gut Microbiome-Targeted Therapies to Enhance Treatment Outcomes of Liver Diseases

Ki Tae Suk (Hallym Univ.)

10:10-10:30 Molecular and Immunological Biomarkers for Hepatocellular Carcinoma to Guide Personalized Treatment Decisions

Renumathy Dhanasekaran (Stanford Univ., USA)

ROOM 2 (3F)**KLCA-TLCA Joint Symposium**

09:10-10:30 *Innovating and Expanding Surgical Horizons for Hepatocellular Carcinoma in the Immunotherapy Era*

*Kyung Sik Kim (Yonsei Univ.),
Yi-Hsiang Huang (National Yang Ming Chiao Tung Univ., Taiwan)*

09:10-09:30 Surgical Innovations for Advanced Hepatocellular Carcinoma in the Immunotherapy Era

Gi Hong Choi (Yonsei Univ.)

09:30-09:50 Advancing Liver Surgery in the Immunotherapy Era: The Taiwanese Experience

Ming-Chin Yu (Chang Gung Medical Foundation, Taiwan)

09:50-10:10 Combining Immunotherapy with Local Treatments: New Directions for Hepatocellular Carcinoma Management in Korea

Yun Bin Lee (Seoul National Univ.)

10:10-10:30 Immune Checkpoint Inhibitors and Biomarker Discovery: Tailoring Treatment for Hepatocellular Carcinoma

Chien-Hung Chen (National Taiwan Univ., Taiwan)

ROOM 3 (2F)**KLTS Symposium 2**

09:10-10:30 *Technical Hurdles in Living Donor Liver Transplantation*

Dong-Sik Kim (Korea Univ.), Unenbat Gurbadam (National Cancer Center, Mongolia)

09:10-09:30 Outflow Reconstruction Tips in Liver Transplant for Budd-Chiari Syndrome

Gyu-seong Choi (Sungkyunkwan Univ.)

09:30-09:50 Portal Vein Reconstruction in a Recipient with Atretic Portal Vein

Kwang-Woong Lee (Seoul National Univ.)

09:50-10:10 Difficult Arterial Reconstruction: Multiple Arteries or Size-Mismatched Situations

Chul Soo Ahn (Univ. of Ulsan)

10:10-10:30 Various Bile Duct Anastomosis Methods for Multiple Duct Bile Situations

Tae-Seok Kim (Keimyung Univ.)

ROOM 4 [2F]

Data Science Camp 2

09:10-10:30 *Artificial Intelligence in Hepatology*
Jin-Woo Lee (Inha Univ.), Kang Mo Kim (Univ. of Ulsan)

09:10-09:35 *Hepatic Applications of Artificial Intelligence*
Seung Soo Lee (Univ. of Ulsan)

09:35-10:00 *Artificial Intelligence for Clinical Prediction*
Beom Kyung Kim (Yonsei Univ.)

10:00-10:30 *Imaging Reconstruction for Artificial Intelligence Models*
Jong Chul Ye (KAIST)

ROOM 1 [3F]

10:50-11:20 **President's Choice Lecture**

Yoon Jun Kim (Seoul National Univ.)

 **Real-Time Lecture**

10:50-11:20 *Management of Portal Hypertension in Advanced Cirrhosis*
Shiv Kumar Sarin (Institute of Liver and Biliary Sciences, India)

ROOM 1 [3F]

Plenary Presentation 2

11:20-12:20 *June Sung Lee (Inje Univ.), Si Hyun Bae (The Catholic Univ. of Korea), Kwang-Woong Lee (Seoul National Univ.)*

11:20-11:35 [PP 2-1] *Efficacy and Safety of Time-Restricted Eating in Metabolic Dysfunction-Associated Steatotic Liver Disease*
Joo Hyun Oh (CHA Univ.)

11:35-11:50 [PP 2-2] *Development of Glypican-3-Targeting CAR-NK Cells with IL-15 Secretion for Hepatocellular Carcinoma Treatment*
Wonseok Kang (Sungkyunkwan Univ.)

11:50-12:05 [PP 2-3] *A Novel Risk Prediction Model for Survival in Patients with Autoimmune Hepatitis: A Multicenter Cohort Study*
Soon Kyu Lee (The Catholic Univ. of Korea)

12:05-12:20 [PP 2-4] *Outcomes and Key Determinants in Living Donor Liver Transplants from Older Donors: A Multicenter Cohort Analysis*
Eun-Ki Min (Yonsei Univ.)

ROOM 1 (3F)**KASL Symposium 3**

13:10-14:30 *Emerging Concepts, Challenges, and Therapeutic Frontiers of Metabolic Dysfunction–Associated Steatotic Liver Disease*

*Tatsuya Kanto (Japan Institute for Health Security, Japan),
Won Kim (Seoul National Univ.)*

13:10-13:30 Identification of Genes Conferring Individual-Level Variation Responsible for MASLD Using Single-Cell eQTL Analysis
Murim Choi (Seoul National Univ.)

13:30-13:50 GLP-1 Receptor Agonists in MASLD: Current Clinical Status and Future Directions
Sang Bong Ahn (Eulji Univ.)

13:50-14:10 Resmetirom's Promise and the Challenges Ahead
Kris V. Kowdley (Washington State Univ., USA)

14:10-14:30 New Drug Discovery in MASLD Based on Multi-Omics
Silvia Sookoian (Maimonides Univ., Argentina)

ROOM 3 (2F)**KLTS Symposium 3**

13:10-14:30 *Frontline Approaches in Deceased Donor Liver Transplantation: Optimizing Outcomes with Limited Liver Grafts*

Yang Won Nah (Univ. of Ulsan), Young Kyoung You (The Catholic Univ. of Korea)

13:10-13:30 Current Status and Challenges of the Liver Allocation System for Deceased Donors in Korea
Young-In Yoon (Univ. of Ulsan)

13:30-13:50 Patient Selection and Timing of Referral for Liver Transplantation in Acute Alcoholic Hepatitis
Do Seon Song (The Catholic Univ. of Korea)

13:50-14:10 Perioperative Challenges and Solutions for Patients with Chronic Liver Disease Undergoing Deceased Donor Liver Transplantation
Young Chul Yoon (The Catholic Univ. of Korea)

14:10-14:30 Predicting Futile Outcomes in Deceased Donor Liver Transplantation: Focus on Acute-on-Chronic Liver Failure
YoungRok Choi (Seoul National Univ.)

ROOM 4 (2F)

KASL Symposium 4

13:10-14:50 *Integrative Approaches to Alcohol-Related Hepatic Disorders*
Dominique Damais-Thabut (Sorbonne Univ., France),
Sang Gyune Kim (Soonchunhyang Univ.)

- 13:10-13:30 Sex and Gender Differences in Alcohol-Associated Liver Disease
Young Chang (Soonchunhyang Univ.)
- 13:30-13:50 Altered Mental Status in Alcoholic Cirrhosis: Etiologies other than Hepatic Encephalopathy
Barjesh Chander Sharma (Govind Ballabh Pant Hospital, India)
- 13:50-14:10 Emerging Regimens Competing with Glucocorticoids for Severe Alcoholic Hepatitis
Sumeet Asrani (Baylor Univ., USA)
- 14:10-14:30 Multidisciplinary Approaches to Treat Alcohol-Associated Liver Disease
Seong Hee Kang (Korea Univ.)
- 14:30-14:50 Specific Management of Portal Hypertension before and after Liver Transplantation
Shashwat Sarin (Max Hospital, India)

ROOM 1 (3F)

14:30-14:50 KASL Leading Research Achievement Award 

- 14:30-14:50 Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease
Seung Up Kim (Yonsei Univ.)

The Liver Week 2025 Debrief Session

14:50-15:50 *Ju Hyun Shim (KASL), Su Jong Yu (KLCA), Jongman Kim (KAHBPS),*
Hae Won Lee (KLTS)

- 14:50-15:05  KASL *Eun Sun Jang (Seoul National Univ.)*
- 15:05-15:20  KLCA *Yuri Cho (National Cancer Center)*
- 15:20-15:35  KAHBPS *Min-Su Park (Kyung Hee Univ.)*
- 15:35-15:50  KLTS *Su Young Hong (Seoul National Univ.)*

15:50-16:10 Closing & Award Ceremony


Moments from Our 30-Year Scientific Journey



- APASL STC 2011 in Jeju
- APASL STC 2016 in Busan
- APASL STC 2023 in Busan



ABSTRACT
PRESENTATION



믿음도 효능도 계속 커 가고 있습니다

한국인의 간을 지키는 우루사! 끊임없는 연구개발로
효능에 대한 더 큰 믿음을 키워가고 있습니다

- Displacement of toxic bile acid
- Immunomodulatory effects
- Cytoprotective effects
- Stimulation of bile secretion

성분·함량

■ 1정중 - Ursodeoxycholic acid(KP) 100mg, 200mg, 300mg

효능·효과 / 용법·용량

- 100mg정**
 - 다음 질환의 보조 치료 - 담즙분비 부전으로 오는 간질환, 담도(단관, 담낭)계 질환
 - 만성 간질환의 간기능 개선
 - 소장 절제 후유증 및 염증성 소장 질환의 소화불량
 - ※ 1회 100mg, 1일 3회 복용
- 200mg정**
 - 담석증: 1회 200 ~ 250mg, 1일 3회 복용
 - 만성 C형간염: 1회 200mg, 1일 3회 복용
 - 담낭 쓸개관 간경화증(PBC): 1회 200 ~ 300mg, 1일 3회 복용
- 300mg정**
 - 비만형자 급격한 체중감소시 담석예방: 1회 300mg, 1일 2회 복용
 - 영남 쓸개관 간경화증(PBC): 1회 300mg, 1일3회복용
 - 위 절제술을 시행한 위암 환자에서의 담석예방: 1회 300mg, 1일 1회 복용

※제품에 대한 의문 사항이 있으시면 대웅제약 080-550-8308~9로 문의 바랍니다.



우루사®

FREE PAPER PRESENTATION

Friday, May 30, 2025

1. Hepato-Biliary and Pancreas Surgery

15:10-16:20

Yang-Seok Koh (Chonnam National Univ.), Sae Byeol Choi (Korea Univ.)

FP-1

15:10-15:20

Development and External Validation of an Online Risk Calculator for Early Mortality after Hepatic Resection in HCC

Han Liu (First Hospital of Jilin Univ., China)

FP-2

15:20-15:30

Role of Hepatobiliary Scintigraphy in Predicting Post-Hepatectomy Liver Failure: A Single-Center Cohort Study

Jeong-Moo Lee (Seoul National Univ.)

FP-3

15:30-15:40

Preoperative Risk Stratification in Hilar Cholangiocarcinoma Using a Novel Decision Tree Model

Han Liu (First Hospital of Jilin Univ., China)

FP-4

15:40-15:50

Medical Conflicts and Their Effect on Korean Liver-Related Publications: A 2019–2024 Analysis

Namkee Oh (Sungkyunkwan Univ.)

FP-5

15:50-16:00

The Role of Neoadjuvant Chemotherapy (nCT) in the Treatment of Patients with Resectable Pancreatic Cancer

Vervekin Ilya (Pavlov First Saint Petersburg State Medical Univ., Russia)

FP-6

16:00-16:10

Innovative Artificial Intelligence and Machine Learning Based Spatial Computing AR Navigation for Open, Lap, and Robotic Hepatectomy

Takuya Sueyoshi (Teikyo Univ., Japan)

FP-7

16:10-16:20

An Evaluation of Long-Term Fasting Effects on Preoperative and Postoperative Outcomes in Liver Surgery

Rosinta Hotmaida Pebrianti Purba (The Pranala Institute, Indonesia)

2. Liver Cancer, Clinical 1

15:10-16:30

Do Young Kim (Yonsei Univ.), In Hye Song (Univ. of Ulsan)

FP-8

15:10-15:20

Prognostic Impact of Tumor-Associated Endothelial B7-H3 Expression in HCC

Yunmi Ko (Seoul National Univ.)

FP-9

15:20-15:30

Non-Contrast Magnetic Resonance Imaging versus Ultrasonography for HCC Surveillance: A Randomized, Single-Center Trial

Hyungjin Rhee (Yonsei Univ.)

2. Liver Cancer, Clinical 1

<p>FP-10 15:30-15:40</p>	<p>Outcomes by Transarterial Chemoembolization (TACE) Modality from Participants (pts) with Embolization-Eligible Hepatocellular Carcinoma (HCC) Treated with Durvalumab (D) + Bevacizumab (B) + TACE and Placebos (PBO) + TACE: EMERALD-1 Subgroup Analysis</p> <p><i>Jeong Heo (Pusan National Univ.)</i></p>
<p>FP-11 15:40-15:50</p>	<p>Clinical Utility of Circulating Tumor DNA in Early-Stage Biliary Tract Cancer Following Curative Resection</p> <p><i>James Yu (H. Lee Moffitt Cancer Center, USA)</i></p>
<p>FP-12 15:50-16:00</p>	<p>Early Changes in Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Tumor Response to Atezolizumab and Bevacizumab in HCC: A Multicenter Retrospective Study</p> <p><i>Young Mi Hong (Pusan National Univ.)</i></p>
<p>FP-13 16:00-16:10</p>	<p>Comparative Efficacy of Lenvatinib versus Sorafenib as Sequential Therapies Following Atezolizumab and Bevacizumab Treatment in Advanced HCC: A Multicenter Retrospective Study</p> <p><i>Jun Sik Yoon (Pusan National Univ.)</i></p>
<p>FP-14 16:10-16:20</p>	<p>Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for HCC</p> <p><i>Won-Mook Choi (Univ. of Ulsan)</i></p>
<p>FP-15 16:20-16:30</p>	<p>Indeterminate Nodule-Like Arterial Phase Hyperenhancement in the Liver on CT: Differentiation of HCCs from Vascular Pseudolesions Using a CT Radiomics Approach</p> <p><i>Ijin Joo (Seoul National Univ.)</i></p>

3. MASLD, Clinical

<p>15:10-16:20 <i>Byung Ik Kim (Sungkyunkwan Univ.), Won-Choong Choi (Eulji Univ.)</i></p>	
<p>FP-16 15:10-15:20</p>	<p>Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score and the Risk of Liver-Related Events in the General Population</p> <p><i>Byeong Geun Song (Sungkyunkwan Univ.)</i></p>
<p>FP-17 15:20-15:30</p>	<p>Cost-Effectiveness Analysis of Masld Screening Using FIB-4 Based Two-Step Algorithm in the Medical Check-Up</p> <p><i>Hye-Lin Kim (Sahmyook Univ.)</i></p>

3. MASLD, Clinical

FP-18 15:30-15:40	The Prognostic Impact of Statin Exposure in Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Keungmo Yang (The Catholic Univ. of Korea)</i>
FP-19 15:40-15:50	Influence of Skeletal Muscle Loss on CKD Development in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients <i>Aryoung Kim (Inje Univ.)</i>
FP-20 15:50-16:00	Risk of Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease: Impact of Cardiometabolic Risk Factor Count and Its Longitudinal Changes <i>Han Ah Lee (Chung-Ang Univ.)</i>
FP-21 16:00-16:10	Impact of Steatotic Liver Disease and Metabolic Risk Factors on Post-Surgical Outcomes in HBV-Related HCC <i>Younghyeon Ahn (Univ. of Ulsan)</i>
FP-22 16:10-16:20	Allyl Nonanoate: A Bile Metabolite and Potential Biomarker for Hepatic Fibrosis in MASLD <i>Soo Hyeon Lee (Hanyang Univ.)</i>

4. HBV Basic and ALD

15:10-16:30		<i>Chul Ju Han (Korea Cancer Center Hospital), Soon Woo Nam (The Catholic Univ. of Korea)</i>
FP-23 15:10-15:20	Misclassification of Alcohol Use Disorder in MASLD and MetALD: Prevalence, Clinical Characteristics, and Outcomes <i>Hyo Young Lee (Hanyang Univ.)</i>	
FP-24 15:20-15:30	Circulating Fungal Mycobiome and Lipid Dysregulation Induces Mitochondrial Dysfunction Mediated Shock in Severe Alcoholic Hepatitis <i>Gaurav Tripathi (Institute of Liver and Biliary Sciences, India)</i>	
FP-25 15:30-15:40	Impact of Gastrectomy on the Risk of Alcohol-Related Liver Disease: A Nationwide Population-Based Cohort Study in Korea <i>Sang Yi Moon (Dong-A Univ.)</i>	
FP-26 15:40-15:50	Intrahepatic IgA Accumulation Activates Macrophages and Exacerbates Hepatic Inflammation in Alcoholic Liver Disease <i>Min Gu Kim (The Catholic Univ. of Korea)</i>	

4. HBV Basic and ALD

FP-27 15:50-16:00	Circulating HBcrAg Levels Reflect Transcriptionally Active cccDNA and Predict Advanced Fibrosis in HBeAg-Negative Inactive Carriers <i>Hye Seon Kim (The Catholic Univ. of Korea)</i>
FP-28 16:00-16:10	HBV Core Antigen and Impaired Placental Immunity: A Key Driver of HBV Entry Receptor Expression <i>Ashish Kumar Vyas (Amrita Research Center Delhi NCR, India)</i>
FP-29 16:10-16:20	Chronic Hepatitis B Genotype C Mouse Model with Persistent Covalently Closed Circular DNA <i>Deok Hwa Seo (The Catholic Univ. of Korea)</i>
FP-30 16:20-16:30	Thiazole-Coumarin-Azomethine Derivatives as Dual TLR7/STING Agonists for Innate Immune Activation in Chronic Hepatitis B: Computational Design and Pharmacokinetic Profiling <i>Rizki Rachmad Saputra (Universitas Palangka Raya, Indonesia)</i>

5. Acute Liver Failure and DILI

15:10-16:30		<i>Suk Bae Kim (Dankook Univ.), Seung Kak Shin (Gachon Univ.)</i>	
FP-31 15:10-15:20	TRAIP Alleviates DDC-Induced Cholestatic Liver Injury through Modulating PI3K/Akt/mTOR Signaling <i>Gangping Feng (Guangxi Medical Univ., China)</i>		
FP-32 15:20-15:30	NOX2 Is a Promising Target against Acute Liver Injury by Reversing Oxidative Stress, Mitochondrial Dysfunction and cGAS-STING Pathway-Dictated Inflammatory Response <i>Chao Sun (Tianjin Medical Univ., China)</i>		
FP-33 15:30-15:40	Plasma Derived Exosomes Multi-Omics Analysis Classifies Bacterial Peptide and Metabolomic Cargo as Predictor of Early Mortality in Acute Liver Failure <i>Neha Sharma (Institute of Liver and Biliary Sciences, India)</i>		
FP-34 15:40-15:50	Genetic Polymorphism Analysis That Associated with Metabolism and Idiopathic Pathway of Antituberculosis Drug Induced Liver Injury <i>Putrya Hawa (Indonesian Defense Univ., Indonesia)</i>		

5. Acute Liver Failure and DILI

FP-35 15:50-16:00	N-Acetylcysteine Reduces Mortality and Length of Stay in Adult with Non-Acetaminophen-Induced Acute Liver Failure: Evidence from a Meta-Analysis <i>Agil Noviar Alvirosa (Muhammadiyah Lamongan Hospital, Indonesia)</i>
FP-36 16:00-16:10	Elevated Plasma Chenodeoxycholic Acid as a Prognostic Marker and Therapeutic Target in Acute Liver Failure: Role of Bacteroides Intestinalis AM1 Intervention in Bile Acid Modulation and Mitigation of Liver Injury <i>Sushmita Pandey (Institute of Liver and Biliary Sciences, India)</i>
FP-37 16:10-16:20	Gallic Acid-Loaded Gold Nanoparticles Prevent High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease via Modulating Endoplasmic Reticulum, ATF6/AMPK/PPAR α /p-eIF2 α Levels, and the NF- κ B/SMAD-4 Protein Expression <i>Deepika Singh (SIHAS, SHUATS, India)</i>
FP-38 16:20-16:30	Quantum Chemical Features Meet Clinical Data for DILI Prediction: Integrating Electronic Density Distribution of Antibiotics with Patient EMR Data <i>Seongbin Kim (Handong Global Univ.)</i>

6. HBV 1

15:10-16:30		<i>Yun Soo Kim (Gachon Univ.), Sung Jae Park (Inje Univ.)</i>
FP-39 15:10-15:20	Inverted U-Shaped Association between Hepatitis B Core-Related Antigen and HCC Incidence in Patients with Chronic Hepatitis B <i>Ji Eun Han (Ajou Univ.)</i>	
FP-40 15:20-15:30	Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients with Chronic Hepatitis B: A Propensity Scores Matching Analysis <i>Seong Hee Kang (Korea Univ.)</i>	
FP-41 15:30-15:40	HCC Risk in Treatment-Naïve Chronic Hepatitis B Patients Treated with Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate: A Korean Nationwide Study <i>Jiwon Yang (Univ. of Ulsan)</i>	
FP-42 15:40-15:50	Superior Efficacy of Besifovir in Reducing HCC Risk Compared to Tenofovir in CHB Patients: A Nationwide Cohort Study <i>Yoon E Shin (Soonchunhyang Univ.)</i>	

6. HBV 1

FP-43 15:50-16:00	E-Cigarette Use and HCC Risk in Patients with Chronic Hepatitis B <i>Byeong Geun Song (Sungkyunkwan Univ.)</i>
FP-44 16:00-16:10	Prediction of Long-Term HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients <i>Hae Lim Lee (The Catholic Univ. of Korea)</i>
FP-45 16:10-16:20	Kinetics of Hepatitis B Surface Antigen Loss Following 8 Years of Tenofovir-Based Treatment with Chronic Hepatitis B <i>Jeong Heo (Pusan National Univ.)</i>
FP-46 16:20-16:30	Incidence and Risk of Controlled Attenuated Parameter-Based Non-Alcoholic Hepatosteatosis Development in Korean Patients with Chronic Hepatitis B <i>Ye-Rin Chae (Yonsei Univ.)</i>

7. Liver Cancer, Basic

15:10-16:30		<i>Ji Hoon Kim (Korea Univ.), Haeryoung Kim (Seoul National Univ.)</i>
FP-47 15:10-15:20	Aggressiveness-Promoting, Fibroblast Activation Protein-STAT3 Positive Feedback Loop Is Activated by IL-6 in Cancer Associated Fibroblasts of HCC <i>Deok Hwa Seo (The Catholic Univ. of Korea)</i>	
FP-48 15:20-15:30	Significance of Shelterin Component TPP1 Upregulation and Telomerase Activation in the Clinico-Pathological Features of HCC <i>Jung Eun Jang (The Catholic Univ. of Korea)</i>	
FP-49 15:30-15:40	AK7 Drives HCC Progression by Enhancing Stemness, EMT, and Hypoxia Adaptation <i>Geum Ok Baek (Ajou Univ.)</i>	
FP-50 15:40-15:50	NADPH Oxidase 2 Regulates Epithelial-Mesenchymal Transition Signaling via Sterol Regulatory Element-Binding Protein 2 and Promotes HCC Survival <i>Hei-Gwon Choi (Chungnam National Univ.)</i>	
FP-51 15:50-16:00	Diagnostic and Prognostic Impact of Circulating Exosome microRNA for the Early Stage of HBV Induced HCC <i>HyoJu Kim (Soonchunhyang Univ.)</i>	

7. Liver Cancer, Basic

FP-52 16:00-16:10	Investigation for Prognostic Value of Circulating Tumor DNA by Serum KMT2B Gene and Fragmentation Analysis for the HBV-Derived HCC after Curative Resection <hr/> <i>Sung Hwan Yoo (Yonsei Univ.)</i>
FP-53 16:10-16:20	Identification of Novel Links between Cirrhosis and HCC through Mechanisms of Immune Microenvironment <hr/> <i>Eunjeong Kim (Kyungpook National Univ.)</i>
FP-54 16:20-16:30	Association between Gut Microbial Dynamics and Clinical Outcomes in Patients with HCC Receiving Chemoembolization: A Prospective Study <hr/> <i>Jiwon Yang (Univ. of Ulsan)</i>

FREE PAPER PRESENTATION

Saturday, May 31, 2025

8. Liver Cancer, Clinical 2

13:10-14:30

Jin-Young Choi (Yonsei Univ.), Sang Min Yoon (Univ. of Ulsan)

FP-55

13:10-13:20

A Machine Learning Model to Predict the Treatment Response of Atezolizumab plus Bevacizumab in Patients with HCC Incorporating Computed Tomogram-Derived Imaging Biomarkers

Moon Haeng Hur (Seoul National Univ.)

FP-56

13:20-13:30

Association of Survival with Discordance between Preoperative Radiology and Postoperative Pathology in Patients with HCC

Woo Sun Rou (Chungnam National Univ.)

FP-57

13:30-13:40

Differential Therapeutic Effectiveness of Atezolizumab plus Bevacizumab in Unresectable HCC Based on Chronic Hepatitis B Viral Activity and Etiology: A Multicenter Cohort Study

Yunmi Ko (Seoul National Univ.)

FP-58

13:40-13:50

Identification of Plasma Protein Biomarkers for Predicting Response to Atezolizumab-Bevacizumab in Unresectable HCC

Myung Ji Goh (Sungkyunkwan Univ.)

FP-59

13:50-14:00

Efficacy and Safety of Sorafenib as a Later-Line Treatment in Advanced HCC: A Phase 2 Study

Yongsu Park (National Cancer Center)

FP-60

14:00-14:10

Can An AI Predictive Model Be Integrated into Clinical Decision-Making for Predicting Open Conversion in Minimally Invasive Liver Resection?

Boram Lee (Seoul National Univ.)

FP-61

14:10-14:20

Comparison of Treatment Efficacy and Safety Profile of Atezolizumab plus Bevacizumab in BCLC B and C Patients with HCC

Sun Young Chun (Chonnam National Univ.)

FP-62

14:20-14:30

Radiofrequency Ablation versus Minimally Invasive Liver Resection for Small Solitary HCC (3 cm) with MRI Features for Predicting Microvascular Invasion

Na Reum Kim (Yonsei Univ.)

9. HBV 2

13:10-14:30

Hyung Joon Kim (Chung-Ang Univ.), Jung Il Lee (Yonsei Univ.)

FP-63

13:10-13:20

X/Precore Mutational Complexity and Its Impact on HBV Replicative Activity and Histological Progression in HBeAg-Positive Chronic Hepatitis B

Jae Mo Han (The Catholic Univ. of Korea)

FP-64

13:20-13:30

Prevalence of Viral Hepatitis B, D, and C among Adolescent and Adult Mongolian Migrants in Seoul, Korea: Implications for Early Screening and Intervention

Wonseok Kang (Sungkyunkwan Univ.)

FP-65

13:30-13:40

Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent

Hyuk Kim (Soonchunhyang Univ.)

FP-66

13:40-13:50

Efficacy and Safety of Switching Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients with Multidrug Resistance

Jaehong Jeong (Yonsei Univ.)

FP-67

13:50-14:00

Comparing Liver Disease Severity and Comorbidity in Patients with HBV Mono-Infection and HBV/HDV Co-Infection: A Korean Nationwide Population-Based Study

Heejoon Jang (Seoul National Univ.)

FP-68

14:00-14:10

The Clinical Characteristics among HBV and HDV Co-Infected Mongolian Patients

Oyungerel Lkhagva-Ochir (Liver Center, Mongolia)

FP-69

14:10-14:20

An Artificial Intelligence Model Utilizing Imaging Biomarkers on Computed Tomogram to Predict HCC in Patients with Chronic Hepatitis B

Hyunjae Shin (Seoul National Univ.)

FP-70

14:20-14:30

Seroprevalence and Clinical Characteristics of Hepatitis D Virus Infection in Korean Patients with Chronic Hepatitis B, Liver Cirrhosis, and HCC

Eun Sun Jang (Seoul National Univ.)

10. HCV

13:10-14:30

Won Hyeok Choe (Konkuk Univ.), Geum-Youn Gwak (Sungkyunkwan Univ.)

FP-71 13:10-13:20	Changes in Healthcare Costs of Hepatitis C Patients after Introduction of Direct-Acting Antivirals (DAAs) in Korea <i>Hwa Young Choi (National Cancer Center)</i>
FP-72 13:20-13:30	Cost-Effectiveness of Direct Acting-Antivirals for Chronic Hepatitis C in South Korea <i>Won Sohn (Sungkyunkwan Univ.)</i>
FP-73 13:30-13:40	Advanced Fibrosis and Cardiometabolic Risk Burden Increase Atherosclerotic Cardiovascular Events in Chronic Hepatitis C Patients with Steatotic Liver Disease after Viral Eradication <i>Ming-Lung Yu (Kaohsiung Medical Univ., Taiwan)</i>
FP-74 13:40-13:50	Association between Hepatitis C Virus Infection and Cardiovascular Disease: A Nationwide, Population-Based Cohort Study in South Korea <i>Min Kyung Park (Seoul National Univ.)</i>
FP-75 13:50-14:00	Long-Term HCC Development Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Direct Acting Antivirals <i>Eunho Choi (Korea Univ.)</i>
FP-76 14:00-14:10	Real-World Outcomes of Sofosbuvir/Velpatasvir in a Variety of Hepatitis C Patient Populations: A Retrospective Cohort Study <i>Young Joo Park (Pusan National Univ.)</i>
FP-77 14:10-14:20	Chrono-Optimal Treatments for HIV/HCV Co-Infection Yield Comparable Survival Outcomes with HCV Mono-Infection <i>Jeayeon Park (Seoul National Univ.)</i>
FP-78 14:20-14:30	Study of Safety and Efficacy of Ledipasvir + Sofosbuvir in HCV Infection in Pregnancy: A Real-Life Experience <i>Jatinkumar Veljibhai Dhanani (GMERS Medical College, India)</i>

11. MASLD, LC, and Others, Basic

13:10-14:30		Youngmi Jung (Pusan National Univ.), Eun Young Cho (Wonkwang Univ.)
FP-79 13:10-13:20	Identification of Prognostic Factors and Regulatory Pathways in Porto-Sinusoidal Vascular Disorder	Won-Mook Choi (Univ. of Ulsan)
FP-80 13:20-13:30	A Novel 11 β -HSD1 Inhibitor Ameliorates Liver Fibrosis by Inhibiting the Notch Signaling Pathway and Increasing NK Cell Population	Ji Eun Kim (Hanyang Univ.)
FP-81 13:30-13:40	FiNi-Seq: A Quasi-Spatial Single-Cell Transcriptome Based on Physical Properties Defines Early Damage Niche of the Liver	Kwon Yong Tak (KAIST)
FP-82 13:40-13:50	Spatial Transcriptomics Reveals TAZ Signalling-Mediated Regulation of Liver Fibrosis in MASH	Young-Sun Lee (Korea Univ.)
FP-83 13:50-14:00	Nintedanib Alleviates Metabolic Dysfunction-Associated Steatohepatitis by Suppressing THBS1 Expression in Activated Fibroblasts	Sung Woo Cho (The Catholic Univ. of Korea)
FP-84 14:00-14:10	Targeting CD47 by Engineered Stem Cell-Derived SIRP α -Extracellular Vesicles Ameliorates Liver Fibrosis via Macrophage Reprogramming	Yoon Kyoung Kim (SHIFTBIO)
FP-85 14:10-14:20	PNPLA3 I148M GG Variant Driven Immune Cell Infiltration Associates with Metabolic Dysfunction-Associated Steatotic Liver Disease Progression	Jung Hoon Cha (The Catholic Univ. of Korea)
FP-86 14:20-14:30	Investigating the Induction Mechanism of the Initial Aging Microenvironment in the Liver through Single-Cell Multi-Omics Analysis	Seoyeong Lee (KAIST)

12. Liver Transplantation 1

13:10-14:30

Young Seok Han (Daegu Catholic Univ.), Bo-Hyun Jung (Inje Univ.)

FP-87 13:10-13:20	An Increase in Regulatory B Cells Plays a Crucial Role in Achieving Tolerance in Liver Transplantation Patients <i>Soon Kyu Lee (The Catholic Univ. of Korea)</i>
FP-88 13:20-13:30	Ferulic Acid-Loaded Liposomes Mitigate Hepatic Ischemia-Reperfusion Injury in a Rat Model Associated with Liver Transplantation via Altering Apoptosis, Mitochondrial Function and TLR-4/NF-B/NLRP3 Inflammatory Pathway <i>Deepika Singh (SIHAS, SHUATS, India)</i>
FP-89 13:30-13:40	Feasibility of Simultaneous Splenectomy in ABO Incompatible Living Donor Liver Transplantation with Small-for-Size Graft <i>JaRyung Han (Daegu Catholic Univ.)</i>
FP-90 13:40-13:50	The Impact of Everolimus Use on Incisional Hernia in Liver Transplant Patients <i>Eunjin Lee (Sungkyunkwan Univ.)</i>
FP-91 13:50-14:00	Transcriptomic Profiling of Personalized Immunosuppressant Modelling to Prevent Acute Cellular Rejection (ACR) in Pediatric Liver Transplant Recipients <i>Anindya Amanda Damayanti (Islamic Indonesia Univ., Indonesia)</i>
FP-92 14:00-14:10	Safety of Living Right Liver Donors Aged 45 and Older: Risks and Outcomes for Donors and Recipients <i>Sang-Hoon Kim (Univ. of Ulsan)</i>
FP-93 14:10-14:20	Adult-to-Adult Right Lobe Graft Living Donor Liver Transplantation for Acute-on-Chronic Liver Failure: A Single-Centre Retrospective Study in Vietnam <i>The Duy Nguyen (Vin Univ., Vietnam)</i>
FP-94 14:20-14:30	Quality Score: Development of Integrative Prognostic Index for Living Donor Liver Using Multicentric Registry Data <i>Mun Chae Choi (Armed Forces Capital Hospital)</i>

13. Liver Transplantation 2

13:10-14:30		Doojin Kim (Gachon Univ.), Sangho Bae (Soonchunhyang Univ.)
FP-95 13:10-13:20	Severity and Pattern of Bile Duct Complications after Donor Right Hepatectomy: Open versus Minimally Invasive Approaches	<i>Na Reum Kim (Yonsei Univ.)</i>
FP-96 13:20-13:30	Prognostic Concordance between LI-RADS Imaging and Pathology for Liver Transplant Eligibility in HCC: Results from 1,059 Patients	<i>Yeongseok Hwang (Univ. of Ulsan)</i>
FP-97 13:30-13:40	Aging in Place for Elderly Undergo Liver Transplantation: How Informal Care Could Help Maintaining Higher Quality of Life?	<i>Hepri Ardianson (The Pranala Institute, Indonesia)</i>
FP-98 13:40-13:50	Development and Optimization of Transplant Surgeon-Innovated Evmp: Validation in a Porcine DCD Liver Transplant Model	<i>Mun Chae Choi (Armed Forces Capital Hospital)</i>
FP-99 13:50-14:00	Prediction of Early Risk of Patient Survival Following Liver Transplant Based on Lifestyle Factors via Machine Learning Models	<i>Manvendra Singh (HMFA MIET, India)</i>
FP-100 14:00-14:10	Development of Immune-Evasive Meta-Soft Organ Modules through Advanced Cell Engineering and Assembly Technology	<i>Hee Ju Kim (Hanyang Univ.)</i>
FP-101 14:10-14:20	Rehabilitation for Fatigue after Liver Transplantation: Effects of Exercise and Physical Activity Counseling	<i>Ganesh Kumar Singh (Army Forced Hospital, Nepal)</i>
FP-102 14:20-14:30	Clinical Outcomes of 90 Cases of Post-Transplant Lymphoproliferative Disorder (PTLD) after Liver Transplantation: A 24-Year Single-Center Experience	<i>Young-In Yoon (Univ. of Ulsan)</i>

ORAL POSTER PRESENTATION

Friday, May 30, 2025

1. Autoimmune Disease

16:40-17:40		Su Cheol Park (Korea Cancer Center Hospital), Ja Kyung Kim (Yonsei Univ.)
OP-1 16:40-16:50	Constructing a Protein Interaction Network for Autoimmune Liver Diseases Using Protein-Protein Ratio Exposures: Insights from a Mendelian Randomization Study	<i>Dianzhe Tian (Peking Union Medical College Hospital, China)</i>
OP-2 16:50-17:00	Epidemiology, Treatment Response, and Genetic Characteristics of Autoimmune Liver Diseases: A Retrospective and Prospective Cohort Study	<i>Young Chang (Soonchunhyang Univ.)</i>
OP-3 17:00-17:10	Risk Factors for Predicting Incomplete Treatment Response in Patients with Primary Biliary Cholangitis: A Korean Multicenter Cohort Study	<i>Soon Kyu Lee (The Catholic Univ. of Korea)</i>
OP-4 17:10-17:20	Clinical Statement for the Diagnosis and Management of PBC-AIH Overlap 2024: Japanese Experience	<i>Atsumasa Komori (NHO Nagasaki Medical Center, Japan)</i>
OP-5 17:20-17:30	Intrahepatic Infiltration of Activated Regulatory T Cells Is Associated with the Degree of Inflammation in Autoimmune Hepatitis	<i>Mi Hyun Kwon (The Catholic Univ. of Korea)</i>
OP-6 17:30-17:40	Prevalence, Incidence, and Risk Factors of Hepatic Cysts	<i>Kang Seo (Seoul National Univ.)</i>

2. MASLD and ALD, Basic

16:40-17:40		Yoon Mee Yang (Kangwon National Univ.), Wonhyo Seo (Ewha Womans Univ.)
OP-7 16:40-16:50	Liver Kinome Profiling Identifies PS1145-IKK Inhibition as a Potential Therapeutic Strategy for Systemic Inflammation in Alcohol-Associated Liver Diseases	<i>Manisha Yadav (Institute of Liver and Biliary Sciences, India)</i>
OP-8 16:50-17:00	Adenosine Triphosphate-Binding Pocket Inhibitor for Mixed Lineage Kinase Domain-Like Protein Attenuated Alcoholic Liver Disease via Necroptosis-Independent Pathway	<i>Seung Min Lee (Hanyang Univ.)</i>

2. MASLD and ALD, Basic

OP-9 17:00-17:10	Polyethylene Glycol Relieves Hangover Symptoms and Protects Liver and Gut by Preventing Intestinal Absorption of Alcohol <i>Keungmo Yang (The Catholic Univ. of Korea)</i>
OP-10 17:10-17:20	GIN52 Accelerated Non-Alcoholic Fatty Liver Disease via Regulating TFEB Mediated Lipophagy <i>Zhaohong Mo (Guangxi Medical Univ., China)</i>
OP-11 17:20-17:30	Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis <i>Hye Young Kim (Hanyang Univ.)</i>
OP-12 17:30-17:40	Treatment with IL-18 Binding Protein Biologics Inhibits Fibrotic Progression in Metabolic Dysfunction-Associated Steatohepatitis <i>Dong-Hyun Kim (Kangwon National Univ.)</i>

3. MASLD, Clinical 1

16:40-17:40	<i>Sung Bum Cho (Chonnam National Univ.), Danbi Lee (Univ. of Ulsan)</i>
OP-13 16:40-16:50	Improvement of Hepatic Steatosis and Reduction in Cardiovascular Event in Patients with Diabetes Mellitus: A Prospective Study <i>Yoon Seok Lee (Gachon Univ.)</i>
OP-14 16:50-17:00	Sugar-Sweetened Beverage Consumption and Metabolic Dysfunction Associated Steatotic Liver Disease: Exploring Different Types of Beverages <i>Hong Jae Jeon (Chungnam National Univ.)</i>
OP-15 17:00-17:10	Higher Age-Adjusted Skeletal Muscle Index Associated with Severe Hepatic Steatosis and Fibrosis in Male MASLD Patients <i>Jang Han Jung (Hallym Univ.)</i>
OP-16 17:10-17:20	Effect of Vitamin E on Liver Stiffness in Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Seung Teak Lee (Seoul National Univ.)</i>
OP-17 17:20-17:30	Changing Prevalence and Risks Factors of Metabolic Dysfunction Associated Steatotic Liver Disease during Three Decades in Taiwan <i>Ming-Lun Yeh (National Sun Yat-sen Univ., Taiwan)</i>

3. MASLD, Clinical 1

OP-18 17:30-17:40	Association between Smoking and Clinical Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Tom Ryu (Soonchunhyang Univ.)</i>
-----------------------------	---

4. LC, Clinical and Liver Failure

16:40-17:30 <i>Woo Jin Chung (Keimyung Univ.), Myeong Jun Song (The Catholic Univ. of Korea)</i>	
OP-19 16:40-16:50	Impact of Cardiometabolic Risk Factors on Hepatic Fibrosis and Clinical Outcomes in MASLD: A Population-Based Multi-Cohort Study <i>Eileen L. Yoon (Hanyang Univ.)</i>
OP-20 16:50-17:00	Spleen Stiffness Measurement Using New Spleen-Dedicated Fibroscan: Intra/Interobserver Repeatability <i>Heon-Ju Kwon (Sungkyunkwan Univ.)</i>
OP-21 17:00-17:10	Validation and Comparative Performance of Postoperative Risk Scores in Cirrhotic Patients: A Korean Cohort Study <i>Hee Sun Cho (The Catholic Univ. of Korea)</i>
OP-22 17:10-17:20	Transplantation of Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Decompensated Liver Cirrhosis: A Real-World Evidence Study in a Population-Based Cohort <i>Seul Ki Han (Yonsei Univ. Wonju)</i>
OP-23 17:20-17:30	Impact of Hepatic Encephalopathy on Prognosis in Cirrhotic Patients with Acute Decompensation: The Crucial Role of Underlying Liver Function and Coagulation Failure <i>Junghee Kim (Hallym Univ.)</i>

5. Liver Transplantation 1

16:40-17:40 <i>Jeong-Ik Park (Univ. of Ulsan), Tae-Seok Kim (Keimyung Univ.)</i>	
OP-24 16:40-16:50	Renal Recovery Benefit of Living Donor Compared to Deceased Donor Liver Transplantation in High-MELD Recipients: A Propensity Score-Matched Study <i>Min-Ha Choi (Univ. of Ulsan)</i>

5. Liver Transplantation 1

OP-25 16:50-17:00	Impact of Radiation Therapy on Biliary Complications in Liver Transplant HCC Recipients Withoma: A Propensity Score-Matched Analysis <i>Min-Ha Choi (Univ. of Ulsan)</i>
OP-26 17:00-17:10	ABO Incompatible Dual Graft Living Donor Liver Transplantation Using Modified Extended Left Lateral Graft: Case Report <i>Min-Ha Choi (Univ. of Ulsan)</i>
OP-27 17:10-17:20	Liver Transplantation Can Be a Treatment Option for Patients with Cholangiocarcinoma: A Single-Center Experience <i>Youngju Ryu (Sungkyunkwan Univ.)</i>
OP-28 17:20-17:30	Bile Duct Complication and Impact on Outcomes after Living-Donor Liver Transplant: A Machine Learning Approach <i>Derizal Derizal (Ip Trisakti, Indonesia)</i>
OP-29 17:30-17:40	Outcomes and Risk Factors for De Novo Major Depressive Disorder after Liver Transplantation: Nested Case-Control Study <i>Young Jin Yoo (Yonsei Univ.)</i>

6. Liver Cancer, Basic 1

16:40-17:40	<i>Hyun Phil Shin (Kyung Hee Univ.), Pyoung Jae Park (Korea Univ.)</i>
OP-30 16:40-16:50	Identification of IKBKB as a Novel Regulator of Macrophage Phagocytosis That Enhances Antitumor Immunity in HCC <i>Sze Man Chan (The Hong Kong Polytechnic Univ., Hong Kong)</i>
OP-31 16:50-17:00	Identifying the Key Factors Contributing to the Progress of Liver Fibrosis to Cancer and the Tumor Microenvironment Immunosuppression <i>Hongping Xia (Southeast Univ., China)</i>
OP-32 17:00-17:10	Inhibition of PLD1 Increases Apoptosis in HCC Cells <i>Ha Neul Kim (Chungnam National Univ.)</i>
OP-33 17:10-17:20	Genomic Analysis of Combined Hepatocellular-Cholangiocarcinoma Reveals Common Lineage of Tumor Components with Unique Gene Expression Profile <i>Hyelim Joo (Seoul National Univ.)</i>

6. Liver Cancer, Basic 1

OP-34 17:20-17:30	CRY2 Is an Actionable Target to Modulate Tumor Growth and Stemness in HCC <i>Regina Lo (The Univ. of Hong Kong, Hong Kong)</i>
OP-35 17:30-17:40	PNPLA3 I148M GG Variant Correlates with Poor Tumor Differentiation but Not HCC Risk in MASLD Patients <i>Jaeeun Lee (The Catholic Univ. of Korea)</i>

7. Liver Cancer, Clinical 1

16:40-17:40	<i>Bo Hyun Kim (National Cancer Center), Won Sohn (Sungkyunkwan Univ.)</i>
OP-36 16:40-16:50	A New Prognostic Index for Patients with Advanced Biliary Tract Cancer Treated with Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index <i>Mara Persano (IRCCS San Raffaele, Italy)</i>
OP-37 16:50-17:00	Mass Spectrometry-Based Proteomics Analysis to Discover Biomarkers in Atezolizumab and Bevacizumab Therapy for Patients with Advanced HCC <i>Eunho Choi (Korea Univ.)</i>
OP-38 17:00-17:10	Development and Validation of a Risk Prediction Model for Patients with HCC Receiving Atezolizumab-Bevacizumab <i>Heechul Nam (The Catholic Univ. of Korea)</i>
OP-39 17:10-17:20	Prognostic Impact of Diabetes and Hypertension on HCC Survival: A 15-Year Registry-Based Analysis <i>Hyeyeon Hong (Univ. of Ulsan)</i>
OP-40 17:20-17:30	Machine Learning-Based Prediction of Clinically Significant Portal Hypertension and Future Hepatic Decompensation in Patients with BCLC-C HCC <i>Ji Won Han (The Catholic Univ. of Korea)</i>
OP-41 17:30-17:40	Bleeding Complications and Survival Outcomes in HCC Patients Treated with Atezolizumab/Bevacizumab: Multicenter Real-World Study <i>Yu Rim Lee (Kyungpook National Univ.)</i>

8. Liver Cancer, Clinical 2

16:40-17:40		<i>Do Seon Song (The Catholic Univ. of Korea), Eun Sun Jang (Seoul National Univ.)</i>
OP-42 16:40-16:50	The State of Pediatric Malignant Neoplasm of Liver in Korea: Nationwide Cohort Study	<i>Jihye Lim (The Catholic Univ. of Korea)</i>
OP-43 16:50-17:00	The Role of Transarterial Chemoembolization for Advanced HCC in the Era of Immune Checkpoint Inhibitor	<i>Kyungdeok Bae (Univ. of Ulsan)</i>
OP-44 17:00-17:10	15-Year Trends in HCC: Epidemiology, Treatment, and Outcomes from a Hospital-Based Registry	<i>Songgyung Kim (Univ. of Ulsan)</i>
OP-45 17:10-17:20	Impact of Endoscopic Retrograde Cholangiopancreatography and Radiation Therapy in HCC Patients with Bile Duct Invasion Receiving Atezolizumab plus Bevacizumab	<i>Kiyoun Yi (Pusan National Univ.)</i>
OP-46 17:20-17:30	RT Combination in Atezolizumab and Bevacizumab Benefits HCC with HBV Etiology	<i>Kwon Yong Tak (The Catholic Univ. of Korea)</i>
OP-47 17:30-17:40	Decision Tree Modeling of Exosomal miR-30a-5p for Predicting Response to Atezolizumab and Bevacizumab in Advanced HCC	<i>Ha Seok Lee (Korea Univ.)</i>

9. Liver Surgery

16:40-17:40		<i>Nam Kyu Choi (Chosun Univ.), Jai Young Cho (Seoul National Univ.)</i>
OP-48 16:40-16:50	Caregiver Perception, Knowledge, and Attitude toward Postoperative Recovery among Patients with Liver Disease	<i>Lintong Hottua Simbolon (The Pranala Institute, Indonesia)</i>
OP-49 16:50-17:00	Divergent Impact of Preoperative Platelet Count Abnormalities on Long-Term Outcomes after Curative Hepatic Resection for HCC: A Multi-Institutional Analysis of 3,116 Patients	<i>Han Liu (First Hospital of Jilin Univ., China)</i>

9. Liver Surgery

OP-50 17:00-17:10	Superior Prognostic Performance of the AFP Model Over Milan Criteria Following Hepatic Resection for HCC: A Multi-Institutional Analysis <i>Han Liu (First Hospital of Jilin Univ., China)</i>
OP-51 17:10-17:20	Development and Validation of a Laboratory Risk Score (APASL Score) to Predict Long-Term Survival after Hepatectomy for HCC: A Multicenter Analysis <i>Han Liu (First Hospital of Jilin Univ., China)</i>
OP-52 17:20-17:30	Laparoscopic Hepatectomy for Giant Hepatic Hemangioma: A Vietnamese Center Experience <i>Hieu Le Trung (108 Military Central Hospital, Vietnam)</i>
OP-53 17:30-17:40	Surgical Approach to Supradiaphragmatic IVC Tumor Thrombosis of HCC through Abdominal Cavity by Cutting Diaphragm Vertically without Opening the Pericardium <i>Nyamsuren Ganbileg (National Cancer Center of Mongolia, Mongolia)</i>

10. Liver Cancer, Basic 2

16:40-17:40		<i>Jooho Lee (CHA Univ.), Sung-Eun Kim (Hallym Univ.)</i>
OP-54 16:40-16:50	Focal Amplification of EGFR Drives Acquired Resistance to Lenvatinib in HCC <i>Ji Young Kim (Sungkyunkwan Univ.)</i>	
OP-55 16:50-17:00	A Study on the Development of a Traditional Liver Cancer Mouse Model Using Hydrodynamic Injection <i>HyeonJi Kim (Kyungpook National Univ.)</i>	
OP-56 17:00-17:10	Prolonged Lenvatinib Treatment Affects Tumor-Neutrophil Interaction and Contributes to Compromised Immune Checkpoint Blockade Treatment in HCC <i>Yunong Xie (The Chinese Univ. of Hong Kong, Hong Kong)</i>	
OP-57 17:10-17:20	IGF2BP1 Promotes Proliferation and Metastasis of HCC via m6A-Modified PEG10 mRNA <i>Qiongguang Huang (Guangxi Medical Univ., China)</i>	
OP-58 17:20-17:30	Finding the Role of a Novel Oncogene in Liver Cancer through Hydrodynamic Gene Delivery <i>Ha Gyun Kim (Kyungpook National Univ.)</i>	

10. Liver Cancer, Basic 2

OP-59

17:30-17:40

Long Non-Coding RNA TUG1 Regulates Multiple Glycolytic Enzymes in HCC Cells via Sponging microRNA-122-5p

Chaiyaboot Ariyachet (Chulalongkorn Univ., Thailand)

ORAL POSTER PRESENTATION

Saturday, May 31, 2025

11. HBV

09:30-10:30		Hyun Woong Lee (Yonsei Univ.), Sung-Eun Kim (Hallym Univ.)
OP-60 09:30-09:40	Comparative Renal Safety of Besifovir Dipivoxil Maleate and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: Insights from Nationwide Cohort Study	Hyun Bin Choi (Soonchunhyang Univ.)
OP-61 09:40-09:50	VELMIA®(DA-2803) versus VELMIDY® for the Treatment of Patients with Chronic Hepatitis B: A Multi-Center, Randomized, Double-Blind, Active-Controlled, Non-Inferiority Study	Jeayeon Park (Seoul National Univ.)
OP-62 09:50-10:00	Comparative Risk of Osteoporosis and Fractures in Chronic Hepatitis B Patients: Tenofovir Disoproxil Fumarate versus Entecavir in a Korean Nationwide Cohort	Jisoo Lee (Soonchunhyang Univ.)
OP-63 10:00-10:10	Turning LLMs into Clinical Decision Supporters: Optimizing Prompt Structures for Drug Side Effect Prediction in Chronic Hepatitis B Patients	Jihyun Moon (Handong Global Univ.)
OP-64 10:10-10:20	Longitudinal Renal Function Trajectories in Chronic Hepatitis B Patients on Entecavir or Tenofovir Alafenamide: A Nationwide Population-Based Study in Korea	Jae Hyun Yoon (Chonnam National Univ.)
OP-65 10:20-10:30	Efficacy of Prophylactic Antiviral Therapy in Preventing Hepatitis B Reactivation in Patients with Anti-HBc Antibody Undergoing Daratumumab Treatment	Jaejun Lee (The Catholic Univ. of Korea)

12. MASLD, Clinical 2

09:30-10:30		Tae-Hee Lee (Konyang Univ.), Yong Jin Jung (Seoul National Univ.)
OP-66 09:30-09:40	MEFV Dysfunction Promotes HCC Progression via Inflammasome Activation	Hyunjae Shin (Seoul National Univ.)
OP-67 09:40-09:50	A Randomized Controlled Trial to Explore the Effect of Modulation of Gut Microbiota on Liver Fibrosis in Patients with Non-Alcoholic Steatohepatitis	Aashal Bhavesh Shah (GMERS Medical College and Civil Hospital, India)

12. MASLD, Clinical 2

OP-68 09:50-10:00	Impaired Sensitivity to Thyroid Hormones Is Associated with Cardiovascular Outcomes in Euthyroid Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Yeonjung Ha (CHA Univ.)</i>
OP-69 10:00-10:10	Cancer Risk and Its Non-Invasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis <i>Hana Park (Univ. of Ulsan)</i>
OP-70 10:10-10:20	Aspirin and HCC Risk in MASLD: Nationwide Cohort Study with Genetic Risk Analysis <i>Min Kyung Park (Seoul National Univ.)</i>
OP-71 10:20-10:30	PNPLA3 p.I148M Polymorphism Increases Risk of Liver Fibrosis in Breast Cancer Patients Receiving Tamoxifen Therapy <i>Sangdeok Shin (Sungkyunkwan Univ.)</i>

13. Liver Cancer, Clinical 3

09:30-10:30	<i>Sang Youn Hwang (Dongnam Institute of Radiological & Medical Sciences), Bo Hyun Kim (National Cancer Center)</i>
OP-72 09:30-09:40	Impact of Metformin Administration on Clinical Outcomes in Patients with HCC Treated with Atezolizumab plus Bevacizumab <i>Yoonseok Lee (Gachon Univ.)</i>
OP-73 09:40-09:50	Comparative Analysis of Therapeutic Strategies in Combined Hepatocellular-Cholangiocarcinoma <i>Keungmo Yang (The Catholic Univ. of Korea)</i>
OP-74 09:50-10:00	Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage HCC <i>Eun Min Kim (Yonsei Univ.)</i>
OP-75 10:00-10:10	Effect of Combining Serum Alpha-Fetoprotein with LI-RADS v2018 on Gadobutate-Enhanced MRI in the Diagnosis and Prognostication of HCC <i>Dong Hwan Kim (Univ. of Ulsan)</i>

13. Liver Cancer, Clinical 3

OP-76 10:10-10:20	Association between Young Age and Prognosis of HCC: A Large Single-Center Matched Study <i>Sang-Hoon Kim (Univ. of Ulsan)</i>
OP-77 10:20-10:30	Real-World Incidence and Predictive Factors of Variceal Bleeding in HCC Patients Treated with Atezolizumab-Bevacizumab <i>Jeong Eun Song (Daegu Catholic Univ.)</i>

14. HBV and LC, Basic

09:30-10:30	<i>Ryu Soo Hyung (SSOK Internal Medicine Clinic), Byung Seok Kim (Daegu Catholic Univ.)</i>
OP-78 09:30-09:40	Liver on the Mend: CRISPR-Based Gene Therapy as a Game-Changer for Genetic Hepatic Diseases <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>
OP-79 09:40-09:50	In Silico Design and Evaluation of siRNA Targeting HBV S and C Genes for Hepatitis B Treatment <i>Reny Rosalina (Universitas Palangka Raya, Indonesia)</i>
OP-80 09:50-10:00	cccDNA as a Therapeutic Target in Hepatitis B Virus Infection: Mechanisms and Drug Development - A Systematic Review <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>
OP-81 10:00-10:10	In Patients with HCC, Autologous NK Cell Immunotherapy after Transarterial-Chemoembolization (TACE) Increased Disease-Free Survival and Improved Liver Fibrosis: Proof of Concept Study <i>Sooyeon Oh (CHA Univ.)</i>
OP-82 10:10-10:20	Intrahepatic B Cells Aggravate Liver Fibrosis by Producing Pro-fibrotic Mediators through CD40-mediated NKT Interaction <i>Jihyo Byun (KAIST)</i>
OP-83 10:20-10:30	Verification of Liver Sinusoid Endothelial Cell Normalization and Hepatic Progenitor Cell Activation Efficacy of Bone Marrow- Mesenchymal Stem Cell Derived Extracellular Vesicles <i>Mi Ra Lee (Yonsei Univ. Wonju)</i>

15. Others

09:30-10:30		Woo Jin Chung (Keimyung Univ.), In Hee Kim (Jeonbuk National Univ.)
OP-84 09:30-09:40	ROS Mediated HMGB1-RIPK1 Upregulation Mediates Hepatocellular Injury, Inflammation Promotes Endothelial Dysfunction and Ductal Proliferation in Drug Induced Liver Injury	<i>Himanshi Himanshi (Institute of Liver and Biliary Sciences, India)</i>
OP-85 09:40-09:50	STRAP Promotes Drug-Induced Acute Liver Injury via mTOR-Mediated Autophagy	<i>Mingbei Zhong (Guangxi Medical Univ., China)</i>
OP-86 09:50-10:00	3D Bioprinted Tubular Hepatobiliary Model Enabling Bile Acid Transport and Drainage	<i>Seon-Jin Kim (Pohang Univ. of Science and Technology)</i>
OP-87 10:00-10:10	Targeting Hepatic Stem Cell Niche with Epigenetic Modulators for Accelerated Liver Regeneration in Advanced Hepatic Fibrosis	<i>Venkatakrishnan Karunanithi (ACS Medical College and Hospital, India)</i>
OP-88 10:10-10:20	A Prospective Cohort Study of Hepatic and Biliary Complications in Pediatric Patients with Sickle Cell Disease in India	<i>Ashishkumar Chaudhari (GMERS Medical College, India)</i>
OP-89 10:20-10:30	The Effectiveness of Abdominal Doppler Ultrasound, Measurement of Abdominal Fat, and the Value of Swm/Att in the Assessment of Liver Disease	<i>Soung Won Jeong (Soonchunhyang Univ.)</i>

16. Liver Cancer, Clinical 4

09:30-10:30		Seung Ha Park (Inje Univ.), Hyun Young Woo (Pusan National Univ.)
OP-90 09:30-09:40	Comparative Effectiveness of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in HCC Recurrence and Mortality after Curative Treatment	<i>Ji Eun Han (Ajou Univ.)</i>
OP-91 09:40-09:50	The Role of TARE for Bridging and Downstaging of HCC before Resection or Liver Transplant: A Retrospective Analysis	<i>Abdullah Alshamrani (Sungkyunkwan Univ.)</i>

16. Liver Cancer, Clinical 4

OP-92 09:50-10:00	Proteinuria and Its Clinical Implications in HCC Patients Treated with Atezolizumab/Bevacizumab: A Multicenter Real-World Study <i>Yu Rim Lee (Kyungpook National Univ.)</i>
OP-93 10:00-10:10	Role of ALBI Score as a Predictive Factor for Mortality in Patients with HCC Undergoing Transarterial Chemoembolization <i>Kyoung A Ko (Sungkyunkwan Univ.)</i>
OP-94 10:10-10:20	The Real Change in Cholangiocarcinoma? A Real-World Experience <i>Stefano Mariani (A.O.U. Cagliari, Italy)</i>
OP-95 10:20-10:30	Efficacy of Lymphadenectomy in Intrahepatic Cholangiocarcinoma <i>In Soo Cho (Keimyung Univ.)</i>

17. Liver Transplantation 2

09:30-10:30 Kwangho Yang (Pusan National Univ.), Hyeyoung Kim (Soonchunhyang Univ.)	
OP-96 09:30-09:40	Clinical Significance of De Novo Malignancy after Liver Transplant: Update on a Single-Center Study <i>Jae-Yoon Kim (Seoul National Univ.)</i>
OP-97 09:40-09:50	Investigating Key Factors of Fatty Liver Disease in Liver Donors <i>E. Ben George (Univ. of Technology and Applied Sciences - Muscat, Oman)</i>
OP-98 09:50-10:00	Xenotransplantation of Pancreatic Islet Cells: A Promising Approach for Type 1 Diabetes Treatment <i>Nodirjon Ruzimurodov (IIHG AS RU, Uzbekistan)</i>
OP-99 10:00-10:10	Ameliorating Effect of Curcumin Loaded Silver Nanoparticles against Liver Transplantation Associated Ischemia-Reperfusion Injury by Downregulating Inflammation and TLR-4/NF-κB/NLRP3 Signalling Pathway <i>Ekta Yadav (SHUATS, India)</i>
OP-100 10:10-10:20	Machine Perfusion in Marginal Liver Grafts: A Systematic Review of Clinical Impact on Liver Transplantation <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>

17. Liver Transplantation 2

OP-101
10:20-10:30

Comparison of Effectiveness of Mycophenolate Mofetil Associated with Standard Dosage or Reduced-Dose Tacrolimus for Liver Transplantation Immunosuppression

Ulil Albab Habibah (Islamic Univ., Indonesia)

18. Liver Cancer, Basic 3

09:30-10:30

Hyun Phil Shin (Kyung Hee Univ.), Young-Sun Lee (Korea Univ.)

OP-102
09:30-09:40

Characterization of Diverse Extracellular Nanoparticles and Tumorigenic Relevance in HCC

Charlotte Jiaqi Lai (Univ. of Hong Kong, Hong Kong)

OP-103
09:40-09:50

Spatial Transcriptomics Uncovers Intratumoral Molecular Heterogeneity in Hepatoblastoma

In Hye Song (Univ. of Ulsan)

OP-104
09:50-10:00

Differential Infiltration of T-Cell Populations in Tumor and Liver Tissue Predicts Recurrence-Free Survival in Surgically Resected HCC

Eun Ji Jang (The Catholic Univ. of Korea)

OP-105
10:00-10:10

Visceral Adipose Tissue from Morbid Obesity Patients Promotes the Proliferation of HCC Cells

Ji Yeon Park (Keimyung Univ.)

OP-106
10:10-10:20

CTC-537E7.3 as a Liver-Specific Biomarker for HCC: Diagnostic and Prognostic Implications

Se Ha Jang (Ajou Univ.)

OP-107
10:20-10:30

RBPP7 Promotes HCC Progression via Enhancing Small Extracellular Vesicle Secretions

Wing Lam Tam (The Univ. of Hong Kong, Hong Kong)

19. Liver Cancer, Clinical 5

09:30-10:20		Sung Won Lee (The Catholic Univ. of Korea), Hye Won Lee (Yonsei Univ.)
OP-108 09:30-09:40	Clinical Outcomes of Atezolizumab plus Bevacizumab in Viral and Non-Viral Advanced HCC Patients: A Real-World, Multicenter Study	Yeo Wool Kang (Dong-A Univ.)
OP-109 09:40-09:50	Hepatic Perivascular Epithelioid Cell Tumor (PEComa) Mimicking HCC	Sukbae Kim (Dankook Univ.)
OP-110 09:50-10:00	Machine Learning-Based Risk Stratification to Optimize Treatment Selection between Surgical Resection and Liver Transplantation	Hyun Uk Kim (The Catholic Univ. of Korea)
OP-111 10:00-10:10	Clinical Outcomes of 2,000 HCC Patients Treated with Proton Beam Therapy at Single Center: Toward Further Optimized Treatment Strategies	Jeong Ha Lee (Sungkyunkwan Univ.)
OP-112 10:10-10:20	Liver Resection in Stage 0-A HCC in Segments 7/8: A Propensity-Matched Analysis Comparing Open, Laparoscopic, and Robotic Approach	Yunchuan Wang (Guangxi Medical Univ., China)

20. Biliary and Pancreatic Surgery

09:30-10:30		Jong Hoon Park (Daegu Fatima Hospital), Cheon Soo Park (The Catholic Univ. of Korea)
OP-113 09:30-09:40	Robotic-Assisted Surgery for Complex Biliary Strictures: A Prospective Study	Nandha Kumar (ACS Medical College and Hospital, India)
OP-114 09:40-09:50	Effect of Head Coring with Lateral Pancreaticojejunostomy on Pancreatic Exocrine Function in Patients with Idiopathic Chronic Pancreatitis – A Prospective Observational Study	Kislal Kant (All India Institute of Medical Sciences, India)
OP-115 09:50-10:00	Terminal Complement Cascade Contributes to the Pathogenesis of Severe Acute Pancreatitis by Intracellular Calcium Overload Induced Pyroptosis	Guandou Yuan (The First Affiliated Hospital of Guangxi Medical Univ., China)

20. Biliary and Pancreatic Surgery

OP-116 10:00-10:10	Immediate Results of Laparoscopic Spleen-Preserving Distal Pancreatectomy: Kimura vs. Warshaw Operation <i>Ilya Vervekin (Pavlov First Saint Petersburg State Medical Univ., Russia)</i>
OP-117 10:10-10:20	Preoperative UGI Scopy: Reducing Post-Cholecystectomy Syndrome and Pain Severity <i>John Thomas Arul J S (ACS Medical College and Hospital, India)</i>
OP-118 10:20-10:30	Comparison of Rectal Indomethacin with Placebo in Reducing the Clinical Progression of Mild and Moderate Acute Pancreatitis to Severe Acute Pancreatitis- A Double Blinded Randomized Controlled Trial <i>Raj Kumar Nagarajan (JIPMER, India)</i>

POSTER EXHIBITION

Acute Liver Failure and Drug-Induced Liver Injury

PE-01	Risk Factors Leading to Acute Liver Failure in Cirrhosis Patients Treated at Thai Nguyen Central Hospital and Control Results <i>Hien LTT (Thai Nguyen Univ. of Medicine and Pharmacy, Vietnam)</i>
PE-02	Hepatotoxicity of Statins: A Real-World Study Based on the US Food and Drug Administration Adverse Event Reporting System Database <i>Bojing Wang (The Affiliated Hospital of Southwest Medical Univ., China)</i>
PE-03	Prevalence and Prognostic Significance of Cachexia Diagnosed by Novel Definition for Asian Population among Chinese Cirrhotic Patients <i>Chao Sun (Tianjin Medical Univ. General Hospital, China)</i>
PE-04	Characteristics of the Patient with Drug-Induced Liver Injury at the Gastroenterology and Hepatology Center, Bach Mai Hospital, Vietnam <i>Nguyen Thi Phuong Nga (Thai Nguyen National Hospital, Vietnam)</i>
PE-05	Oxidative Catastrophe: The Ferroptotic Paradigm in Hepatic Necroinflammation <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>
PE-06	Adeno Associated Virus Vector Gene Therapy Related Acute Liver Failure-Challenges Faced by Pediatric Hepatologist <i>Arjun Maria (Sir Ganga Ram Hospital, India)</i>
PE-07	Toxic Hepatitis and Dilated Cardiomyopathy Induced by Creosote Oil Toxicity: A Rare Case Report <i>Nyam Biziyi (Dornod Medical Center, Mongolia)</i>
PE-08	Liver Injury Induced by Stannous Oxide Nanoparticles (SnO ₂ NPs) by COX-2 and αSMA Modulation in the Liver of Wistar Rats <i>Hadiya Husain (Univ. of Lucknow, India)</i>
PE-09	Exploration of Hepatoprotective Plants in Indonesia as Green Future Drug Candidates: A Network Pharmacology Approach <i>Andi Nursanti (Univ. of Wallacea, Indonesia)</i>
PE-10	Artificial Liver Support Systems in Acute Liver Failure: A Systematic Review of Efficacy and Limitations <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>
PE-11	Biomarkers for Early Diagnosis and Prognosis of Drug-Induced Liver Injury: A Systematic Review <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>

Alcohol-Related Liver Disease, Basic

PE-01	Complement Deficiency and Inflammatory Markers in Acute Pancreatitis: A Comparative Analysis of Alcoholic vs. Non-Alcoholic Types <i>Nazokat Rustamova (Institut of Immunology and Genimics Human, Uzbekistan)</i>
PE-02	The MTHFR C677T Polymorphism: A Double-Trouble in Metabolic Health and Alcohol Use Disorder <i>Rajendra Dev Bhatt (Dhulikhel Hospital-Kathmandu Univ. Hospital, Nepal)</i>
PE-03	Comprehensive Profiling of Infiltrated Circulating Immune Cell Types and Their Subset Responsible for Alcoholic Steatohepatitis by Scrnaseq Analysis <i>Hye Won Jang (Hanyang Univ.)</i>
PE-04	Bile Acid Signaling Induces Retinol Metabolism in Hepatic Stellate Cells to Protect against Alcohol-Induced Liver Injury <i>Sung Eun Choi (KAIST)</i>
PE-05	Identification and Validation of Severe Alcoholic Hepatitis Therapeutic Targets Based on Meta-Analysis through Animal Model <i>Seul Ki Han (Yonsei Univ. Wonju)</i>
PE-06	Deep Multi-Omics Fusion Predicts Alcohol-Induced Hepatic Ferroptosis and Identifies Targetable Lipid Peroxidation Regulators in Alcohol-Related Liver Disease <i>Sahnaz Vivinda Putri (International Univ. Semen Indonesia, Indonesia)</i>
PE-07	SCL1 Protein of Streptococcus Pyogenes Induces Fibrosis by Activating TGF β R1 Kinase in Alcohol-Related Liver Disease <i>Manisha Yadav (Institute of Liver and Biliary Sciences, India)</i>
PE-08	Elucidation of Leptosidin Loaded Mesoporous Silica Nanoparticles on Acute Alcoholic Liver Injury (ALI) in a Mouse Model via Alteration of Apoptosis, Autophagy, and Ferroptosis (GPX4/SLC7A11/Beclin-1/ATG5/LC3II/I/FTL/P62) Cascade <i>Manvendra Singh (HMFA-MIET, India)</i>

Alcohol-Related Liver Disease, Clinical

PE-01	Early Hepatic Changes and Biomarkers in Alcohol-Related Liver Disease: A Cross-Sectional Study of Short-Term Consumption <i>Nandha Kumar (ACS Medical College and Hospital, India)</i>
-------	---

POSTER EXHIBITION

Alcohol-Related Liver Disease, Clinical

PE-02

The Impact of Alcohol Consumption on the Risk of Liver-Related Mortality in People with Metabolic Risk Factors

Young Eun Chon (CHA Univ.)

PE-03

Early Liver Transplantation for Severe Alcoholic Hepatitis: A Systematic Review of Outcomes and Ethical Considerations

Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)

Autoimmune Liver Disease

PE-01

Azomethine-Clubbed Thiazoles as Dual-Target Therapeutics for Autoimmune Liver Disease: Anti-Ferroptotic and Bile Acid Regulatory Potential via Nrf2-Keap1 and FXR Modulation

Rizki Rachmad Saputra (Universitas Palangka Raya, Indonesia)

PE-02

Deep Learning-Driven Single-Cell Epigenetic Memory Mapping Identifies Regulatory T-Cell Exhaustion as a Predictor of Fulminant Autoimmune Hepatitis Progression

Prihantini Prihantini (The Integrated Mathematical, Computational, and Data Science for BioMedicine Research Community Foundation, Indonesia)

PE-03

Epidemiological Trends of Autoimmune Hepatitis in South Korea: A Population-Based Study from 2010 to 2023

Kyung-Ah Kim (Inje Univ.)

PE-04

Heterogenous MUCIN1 Positive Population of Cholangiocytes Contributes to Liver Fibrosis in Cholestatic Models

Aishwarya Bhatnagar (Institute of Liver and Biliary Sciences, India)

Biliary and Pancreatic Surgery

PE-01

Long-Term Efficacy and Safety Outcomes of Folfirinox versus Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Ulil Albab Habibah (Islamic Univ. of Indonesia, Indonesia)

PE-02

Report of Two Cases Video-Assisted Retroperitoneal Debridement: New Approach in Management of Necrotizing Pancreatitis

Trieu Hai Pham (Binh Dan Hospital, Vietnam)

Biliary and Pancreatic Surgery

PE-03	<p>Efficacy of Biliary Stent Placement in Malignant Biliary Tract Obstruction: A Prospective Study in India</p> <p><i>Ashishkumar Chaudhari (GMERS Medical College, India)</i></p>
PE-04	<p>Ectopic Liver Tissue in the Gall Bladder: A Rare Entity</p> <p><i>Suman Baral (Mediplus Hospital and Trauma Center Ltd., Nepal)</i></p>
PE-05	<p>Biliary Adenoma with Reactive Lymphoid Hyperplasia in a 68-Year-Old Man with Chronic Hepatitis B Patient: A Case Report</p> <p><i>Min Ji kim (Pusan National Univ.)</i></p>
PE-06	<p>Effectiveness of Giving Probiotics and Sinbiotik on the Survival of Post-Pancreatectomy Patients</p> <p><i>Putri Ayu (Andalas Univ., Indonesia)</i></p>
PE-07	<p>Sociodemographic Conditions, Behavior Risk, and Metabolic Risk Factors on the Quality of Life and Death for Pancreatic Cancer Patients in Indonesia Using the Global Burden of Disease</p> <p><i>Derizal Derizal (IP Trisakti, Indonesia)</i></p>
PE-08	<p>Identification of Sensitivity between EUS and MRCP for Malignancy-Induced Obstructive Jaundice Diagnosis: A Systematic Review</p> <p><i>Derizal Derizal (IP Trisakti, Indonesia)</i></p>
PE-09	<p>Recent Developments in Diagnosis, Risk Factors, and Therapy of Pancreatic Cancer: A Review of the Literature</p> <p><i>Devi Yulia Rahmi (Universitas Andalas, Indonesia)</i></p>
PE-10	<p>Percutaneous Transhepatic Cholangioscopy Applying Bernoulli Effect with the Amplatz Sheath for Hepatolithiasis Treatment</p> <p><i>Minh Nhat Nguyen (Binh Dan Hospital, Vietnam)</i></p>
PE-11	<p>Understanding the Lived Experiences of Patients with Pancreatic Cancer: A Systematic Literature Review on Emotional, Social, and Healthcare Challenges</p> <p><i>Muhammad Irzaq (Alumnus of Padang State Univ., Indonesia)</i></p>
PE-12	<p>Gastric Partitioning Compared to Conventional Gastrojejunostomy as Palliative Surgeries in Patients with Gastric Outlet Obstruction Due to Unresectable Gastric or Pancreatic Cancers: A Pair-Wise and Individual Patient Data Meta-Analysis</p> <p><i>Mohamed Hamouda Elkasaby (Al-Azhar Univ., Egypt)</i></p>

POSTER EXHIBITION

Biliary and Pancreatic Surgery

PE-13	Near-Infrared Fluorescence Cholangiography Using Indocyanine Green in Laparoscopic Cholecystectomy: A Meta-Analysis of Visualization Rates and Complications <i>Mohamed Hamouda Elkasaby (Al-Azhar Univ., Egypt)</i>
PE-14	Mini-incision Cystogastrostomy for Management of Giant Pancreatic Pseudocysts: Preliminary Results on a Case Series <i>Hieu Le Trung (108 Military Central Hospital, Vietnam)</i>
PE-15	Modified Laparoscopic Left Lateral Segmentectomy for the Management of Left-Sided Hepatolithiasis <i>Hieu Le Trung (108 Military Central Hospital, Vietnam)</i>
PE-16	Percutaneous Gelfoam Slurry Injection in the Management of Hemobilia Following Percutaneous Biliary Intervention: A Case Series and Review of Literature <i>Ho Chi Linh (Binh Dan Hospital, Vietnam)</i>
PE-17	Comparative Analysis on the Efficacy and Accuracy of EUS, ERCP, MRI, and CT Scans in the Management of Pancreatic Disease <i>Lintong Hottua Simbolon (The Pranala Institute, Indonesia)</i>
PE-18	Magnet-Assisted Biliary Reconstruction: A Paradigm Shift in Minimally Invasive Hepatobiliary Surgery <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>
PE-19	Integration of Multiple Preoperative Serum Biomarkers Using Decision Tree Analysis Enhances Outcome Prediction in Resectable Gallbladder Cancer <i>Han Liu (First Hospital of Jilin Univ., China)</i>
PE-20	Single Port Robotic Assisted Cholecystectomy and Common Bile Duct Exploration: Initial Experience <i>Choi Nim (CHCSJ, Macau)</i>
PE-21	Uncommon Presentation: Case Report of Pancreatic Tumor in a Young Patient <i>Salwa Bilao (Cotabato Regional and Medical Center, Philippines)</i>
PE-22	Clinical Pattern & Postoperative Outcome of Whipples Patient for Solid Pseudopapillary Tumour of Pancreas in Tertiary Care Hospital In Bangladesh: A Retrospective Observational Study <i>Anharur Rahman (Central Hospital Ltd., Bangladesh)</i>

POSTER EXHIBITION

Biliary and Pancreatic Surgery

PE-23	Evaluated the Effectiveness of Rutin in Treating Diabetes Mellitus Using an Experimental Rat Model <i>Shiv Kumar Yadav (Govt LBS PG College Sironj, India)</i>
PE-24	The Role of Microrna in Biliary Atresia Pathogenesis <i>Pavithran Damodaran (ACS Medical College and Hospital, India)</i>
PE-25	3D-Printed Pancreatic Scaffolds for Diabetes Treatment <i>Pavithran Damodaran (ACS Medical College and Hospital, India)</i>
PE-26	Pancreatic Tuberculosis Masquerading as Pancreatic Cancer: A Rare Case Report <i>Wei Min Chee (National Univ. of Malaysia, Malaysia)</i>
PE-27	Totally Laparoscopic Pancreaticoduodenectomy: First Case Reported in Mongolia <i>Munkhchuluun Bayanjargal (First Central Hospital of Mongolia, Mongolia)</i>
PE-28	Economic Analysis of Cost-Benefit in Pancreatic Cancer Treatment, Therapeutic Efficacy, and Socioeconomic Outcomes <i>Yesika Simbolon (Atmajaya Univ., Indonesia)</i>
PE-29	Optimizing Biliary Drainage Success in Malignant Biliary Obstruction: A Machine Learning-Driven Approach Integrated with Endoscopic Ultrasound <i>Roland Helmizar (Baiturrahmah Univ., Indonesia)</i>
PE-30	A Rare Case of Gallbladder Hypoplasia: Diagnostic Challenges and Surgical Management <i>Jose Mari Rafael Montero (Southern Philippines Medical Center, Philippines)</i>
PE-31	Distal Pancreatospelenectomy with Metastasectomy and Perioperative Chemotherapy in a 59-Year-Old Male with Pancreatic Tail Adenocarcinoma and Liver Oligometastasis <i>Ianchross Vacaro (Southern Philippines Medical Center, Philippines)</i>
PE-32	Features of Relaparoscopy in Case of Bile Leakage after Surgery on the Liver and Bile Ducts <i>Farukh Mahmudzoda (Avicenna Tajik State Medical Univ., Tajikistan)</i>

POSTER EXHIBITION

HBV, Basic

PE-01	Mitigating Hepatitis B Mother-to-Child Transmission through Early Detection and Prophylaxis: A Prospective Study at a Tertiary Care Center <i>Sumit Rawat (Bundelkhand Medical College, India)</i>
PE-02	Suppression of HBV Transcription and Replication by Host RNA-Binding Protein #RB11 <i>Gahee Kim (National Institute of Health)</i>
PE-03	Prevalence and Co-Infection of Hepatitis-B, Hepatitis-C, HIV, and Syphilis among Individuals in a Tertiary Care Hospital of Nepal <i>Bindu Sen (Kist Medical College & Teaching Hospital, Nepal)</i>
PE-04	Next Generation Sequencing Analysis of HBV Mutations in Liver Biopsy Samples from HBeAg-Negative Chronic Hepatitis B Patients <i>Hee Sun Cho (The Catholic Univ. of Korea)</i>
PE-05	Epigenetic Modifications in HBV-Associated Hepatocarcinogenesis: A Systematic Review <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>

HBV, Clinical

PE-01	Atherosclerotic Cardiovascular Risk in Patients with Chronic Hepatitis B: Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide: A Korean Nationwide Study <i>Jiwon Yang (Univ. of Ulsan)</i>
PE-02	Trends, Inequalities, and Projections of Acute Viral Hepatitis in the Elderly: Results from the Global Burden of Disease Study 2021 <i>Qi Chen (The Affiliated Hospital of Southwest Medical Univ., China)</i>
PE-03	Evaluation of Tenofovir Disoproxil Fumarate Treatment in Patients with Chronic Hepatitis B at Clinic 103 Cam Khe <i>Ha Tien Khiem (Cam Khe 103 Clinic, Vietnam)</i>
PE-04	Comparison of the Effects of Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) on Liver Function in Patients with Hepatitis B <i>Phuong L. H. (Cam Khe 103 Clinic, Vietnam)</i>

POSTER EXHIBITION

HBV, Clinical

PE-05	Risk Factors for Relapse after Discontinuation of Tenofovir in HBeAg-Negative Patients <i>Hien LTT (Thai Nguyen Univ. of Medicine and Pharmacy, Vietnam)</i>
PE-06	Analysis of the Relationship Between HBcrAg Levels and the Natural History of Chronic Hepatitis B Virus Infection <i>Kwon Yong Tak (The Catholic Univ. of Korea)</i>
PE-07	Protective Effect of Nucleos(t)ide Analogue Therapy on the Incidence of Alzheimer's Disease in Patients with Chronic Hepatitis B Virus Infection <i>Ha Il Kim (Hanyang Univ.)</i>
PE-08	Time Varying Effect of Nucleos(t)ide Analogue Therapy with Parkinson Disease in Chronic Hepatitis B Patients <i>Ha Il Kim (Hanyang Univ.)</i>
PE-09	Nationwide Analysis of Renal Outcomes in Chronic Hepatitis B Patients Treated with Tenofovir Alafenamide vs. Entecavir <i>Jae-Young Kim (Soonchunhyang Univ.)</i>
PE-10	Hepatitis B Prevalence and Its Impact on Liver Cancer Risk <i>Doljinsuren Enkhbayar (Molor Clinic, Mongolia)</i>
PE-11	Characterization of Changes in Noninvasive Fibrosis Markers Over 8 Years of Tenofovir-Based Treatment in Patients with Chronic Hepatitis B <i>Hoyoung Na (Gilead Sciences Korea)</i>
PE-12	Predictors of Liver Fibrosis Improvement in Patients with HBV-Induced Cirrhosis Treated with Tenofovir Alafenamide <i>Ha Tien Khiem (Cam Khe 103 Clinic, Vietnam)</i>
PE-13	Metabolic Dysfunction-Associated Steatotic Liver Disease Increases HCC Risk in Chronic Hepatitis B: A Systematic Review and Meta-Analysis <i>Han Ah Lee (Chung-Ang Univ.)</i>

HCV, Basic

PE-01	Burden of Viral Hepatitis and Syphilis Coinfections and Their Association with Virological Status of People Living with HIV in Nepal <i>Saroj Kumar Gupta (Tribhuvan Univ. Teaching Hospital, Nepal)</i>
-------	---

POSTER EXHIBITION

HCV, Basic

PE-02	Comparison of Hepatitis C Virus Infection Risk between Spouses of HCV Patients and Control Group <i>Hwa Young Choi (National Cancer Center)</i>
PE-03	Design and Evaluation of siRNA Candidates for Silencing NS3 and NS4 Genes of Hepatitis C Virus: A Bioinformatics Approach <i>Rian Ka Praja (Universitas Palangka Raya, Indonesia)</i>
PE-04	Exploring Antiviral Peptides as Potential Inhibitors of NS3 in Hepatitis C Virus: A Computational Study <i>Rian Ka Praja (Universitas Palangka Raya, Indonesia)</i>
PE-05	Analysis of Demographics and Risk Factors for Liver Disease Mortality in West Asia <i>Andi Makkasau (STIKAP Center, Indonesia)</i>
PE-06	Molecular Mechanisms of Direct-Acting Antiviral Resistance in Hepatitis C Virus: A Systematic Review <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>

HCV, Clinical

PE-01	The Characteristics of HCV Related HCC among Mongolian Patients <i>Ganbolor Jargalsaikhan (The Liver Center, Mongolia)</i>
PE-02	Risk Factors for HCC in Chronic Hepatitis C Patients after Sustained Virologic Response Following Glecaprevir/Pibrentasvir Treatment <i>Jae Hyun Yoon (Chonnam National Univ.)</i>
PE-03	Awareness and Knowledge of Hepatitis C among People Who Use Drugs (PWUDs) in Korea <i>Gwang Hyeon Choi (Seoul National Univ.)</i>
PE-04	Adverse Events Associated with Vosevi Based on Real-World Data: A Pharmacovigilance Study of the Faers Database <i>Shiqi Li (Southwest Medical Univ., China)</i>
PE-05	The Association between Hepatitis C Virus Infection and Estimated Glomerular Rate after Direct Acting Antiviral Treatment in Mongolia <i>Gantogtokh Dashjamts (Institute of Medical Sciences, Mongolia)</i>

POSTER EXHIBITION

HCV, Clinical

PE-06	<p>Stereotactic Body Radiotherapy for HCC in a Quaternary Care Centre : A Clinical Experience with an Intention-to-Treat Approach</p> <p><i>Radhika Venugopal (Dr. Rela Institute & Medical Centre, India)</i></p>
PE-07	<p>Clinical Significance of Low HCV RNA Levels in Korean Patients with Chronic Hepatitis C Infection: A Multicenter Prospective Cohort Study</p> <p><i>Juneyoung Lim (Seoul National Univ.)</i></p>
PE-08	<p>Hepatitis C Virus Genotypes and Their Clinical Outcomes in South Korea: A Prospective Multicenter Cohort from 2007 to 2024</p> <p><i>Seungteak Lee (Seoul National Univ.)</i></p>

Liver Cancer, Basic

PE-01	<p>AI-Driven Hepatic Splicing Dysregulation Mapping Using a Deep Quantum Graph Learning Model to Predict Cryptic Exon Activation in Non-Alcoholic Steatohepatitis Driven Fibrosis and HCC Progression</p> <p><i>Rifaldy Fajar (The Integrated Mathematical, Computational, and Data Science for BioMedicine Research Community Foundation, Indonesia)</i></p>
PE-02	<p>Differential Gene Expression between Early and Advanced Stages of HCC as Potential Biomarkers for Early Detection and Therapeutic Targeting</p> <p><i>Nadyatul Husna (Dr. Reksodiwiry Military Hospital Padang, Indonesia)</i></p>
PE-03	<p>Identification and Functional Analysis of Differentially Expressed Genes in HCC</p> <p><i>Nadyatul Husna (Dr. Reksodiwiry Military Hospital Padang, Indonesia)</i></p>
PE-04	<p>Association between Family History of Cancer and Liver Cancer: Statistical Analysis of Viral and Non-Viral Etiologies</p> <p><i>Anujin Batkholboo (The Liver Center, Mongolia)</i></p>
PE-05	<p>A Novel Flavonoid Galangin Modulates Hepatic Ischemia-Reperfusion Injury and Regulates TLR-4/NF-κB/NLRP3 Inflammatory Pathway Following Orthotopic Liver Transplants in Rat Models</p> <p><i>Deepika Singh (SIHAS, SHUATS, India)</i></p>
PE-06	<p>A Study on Factors Related to the Efficacy of Triple Therapy in Patients with Advanced HCC</p> <p><i>Batkhuu Batdorj (Mongolian National Univ. of Medical Science, Mongolia)</i></p>

POSTER EXHIBITION

Liver Cancer, Basic

PE-07	Unraveling HCC Immunotherapy Outcomes: A Radiomics-Enabled Framework for Precision Medicine <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>
PE-08	Impact Evaluation of Policy Interventions on Liver Disease Prevalence: Assessing the Smoking and Alcohol Regulation <i>Rosinta Hotmaida Pebrianti Purba (The Pranala Institute, Indonesia)</i>
PE-09	Biomarkers Identification to Predict Inflammatory and Immune Outcomes in Liver Cancer Surgery Patients <i>Yesika Simbolon (Atmajaya University, Indonesia)</i>
PE-10	The Role of Radiogenomics in Early-Stage Liver Cancer Screening <i>Ester Marnita Purba (The Pranala Institute, Indonesia)</i>

Liver Cancer, Clinical

PE-01	Values of AFP-L3% and PIVKA-II in Diagnosing in HCC <i>Phuong L. H. (Cam Khe 103 Clinic, Vietnam)</i>
PE-02	Understanding the Differences in Acute Kidney Injury in Acute-on-Chronic Liver Failure and Decompensated Cirrhosis <i>Ashok Kumar Sah (A' Sharqiyah Univ., India)</i>
PE-03	Diagnostic Performance of Tumor Marker DCP and AFP with HCC in Mongolia <i>Purevjargal Bat-Ulzii (The Liver Center, Mongolia)</i>
PE-04	Prognostic Effect and Potential Therapeutic Implication of Mitotic Index in Very Early HCC <i>Sangjoon Choi (Shinwon Medical Foundation)</i>
PE-05	S100A14 as a Diagnostic Marker for HCC among Sudanese Patients at Ibn Sina Hospital <i>Ramah Hassan (Wits Univ., Sudan)</i>
PE-06	Resurrecting Oncogenic Relics: Endogenous Retrovirus Reactivation as an Impetus for HCC - A Trailblazing for Precision Therapeutics <i>Surendar Arulalan (ACS Medical College and Hospital, India)</i>

Liver Cancer, Clinical

PE-07	Advanced HCC Was Treated Radically with Multimodality Treatment: A Case Report <i>Hoa Nguyen (K National Cancer Hospital, Vietnam)</i>
PE-08	Ion Channel Genes as Predictive Biomarkers: Implications for Personalized Prognosis in HCC <i>Yizhou Wang (Southwest Medical Univ., China)</i>
PE-09	Disparities and Trends in Hepato-Biliary-Pancreatic Cancer Incidence and Mortality in the United States <i>Jia Xu (The Affiliated Hospital of Southwest Medical Univ., China)</i>
PE-10	Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in HCC Patients Treated with Atezolizumab and Bevacizumab <i>Jaejun Lee (The Catholic Univ. of Korea)</i>
PE-11	MRI with Gadoxetate Disodisum Using Conventional Portal Venous Phase and Late Portal Venous Phase for the Noninvasive Diagnosis of HCC: Intraindividual Comparison of MRI with Extracellular Agent <i>Sunyoung Lee (Yonsei Univ.)</i>
PE-12	Liver Stiffness by VCTE Predicts Hepatic Decompensation and Differential Efficacy of Atezolizumab-Bevacizumab versus TKIs in Advanced HCC <i>Jaejun Lee (The Catholic Univ. of Korea)</i>
PE-13	Prognostic Impact of Cytokeratin 19 Expression in Advanced HCC Treated with Hepatic Arterial Infusion Chemotherapy <i>Keungmo Yang (The Catholic Univ. of Korea)</i>
PE-14	Metastatic Patterns and Their Clinical Implications in HCC: Analysis of a Nationwide Korean Cancer Registry <i>Ha Il Kim (Hanyang Univ.)</i>
PE-15	Adjuvant CIK Cell Therapy Following Curative Treatment of HCC Prolongs Recurrence-Free Survival in the Real-World Setting: A Large Two-Center Cohort Study <i>Hyunjae Shin (Seoul National Univ.)</i>
PE-16	Assessment of Focal Liver Observations Using the Ultrasound LI-RADS Algorithm: Experience from the Detect-HCC Study in Mongolia <i>Sharavdorj Gur (The Liver Center, Mongolia)</i>

POSTER EXHIBITION

Liver Cancer, Clinical

PE-17	Validation for the Efficacy of AI Platforms on Liver Cancer Treatment Strategies <i>Keungmo Yang (The Catholic Univ. of Korea)</i>
PE-18	Comparison of the Pathological Features among HBV, HCV, and Fatty Liver Disease-Related HCC on the Post Liver Resection Patients <i>Enkhtsatsral Batmunkh (National Cancer Center of Mongolia, Mongolia)</i>
PE-19	Role of Erastin in Intestinal Injury Following Perioperative Liver Transplantation via Ferroptosis in Animals <i>Deepika Singh (SIHAS, SHUATS, India)</i>
PE-20	Single-Cell Omics in HCC: Dissecting the Immune Microenvironment to Unlock Novel Therapeutic Paradigms <i>Roland Helmizar (Baiturrahmah Univ., Indonesia)</i>
PE-21	HCC in Korea: An Analysis of the 2016–2018 Korean Nationwide Cancer Registry <i>Jihyun An (Hanyang Univ.)</i>
PE-22	Association between Early Changes in Tumor Markers and Treatment Efficacy in Combination Therapy of Durvalumab and Tremelimumab for Unresectable HCC <i>Akihiro Deguchi (Kagawa Rpsai Hospital, Indonesia)</i>
PE-23	Impact of Routine Screening on Early Detection and Clinical Outcomes of Primary Liver Cancer: A Randomized Controlled Study in a High-Risk Population <i>Sahil Arora (NIIMS Univ., India)</i>
PE-24	A Comparative Analysis of Prognosis through Propensity Score Matching Following Surgical Resection of Combined HCC and Cholangiocarcinoma in Patients with BCLC 0 or a Stage versus Those with HCC <i>Yeongseok Hwang (Univ. of Ulsan)</i>
PE-25	Success Story: Introducing Stereotactic Body Radiation Therapy for Patients with Liver Cancer at the National Cancer Center of Mongolia <i>Byambasuren Magsar (National Cancer Center of Mongolia, Mongolia)</i>
PE-26	AI-Driven Multi-Omics Integration for Early HCC Detection: A Breakthrough in Precision Oncology <i>John Thomas Arul J S (ACS Medical College and Hospital, India)</i>

Liver Cancer, Clinical

PE-27	CRISPR-Based Gene Editing in Liver Cancer <i>John Thomas Arul J S (ACS Medical College and Hospital, India)</i>
PE-28	The Declining Trend of HCC-Related Mortality during the COVID-19 Pandemic <i>Young Eun Chon (CHA Univ.)</i>
PE-29	Mongolian Experience in HCC Assessment Using the CT/MRI LI-RADS: Preliminary Results <i>Orkhon Gombosuren (UB Songdo Hospital, Mongolia)</i>
PE-30	Preoperative ASAP Score for Prognostic Prediction among Patients Undergoing Hepatectomy for HBV-Associated HCC: A Multicenter Analysis <i>Han Liu (First Hospital of Jilin Univ., China)</i>
PE-31	Statistical Cure Analysis Following Hepatic Resection in HBV-Associated HCC: A Novel Risk-Stratified Approach <i>Han Liu (First Hospital of Jilin Univ., China)</i>
PE-32	The Application of Contrast-Enhanced Ultrasound with Sonazoid in the Diagnosis of Small Liver Cancer <i>Jiajie Lu (Medical School of Nantong Univ., China)</i>

Liver Cirrhosis, Portal Hypertension with Cx. Basic

PE-01	From Injury to Recovery: Single-Cell RNA Sequencing Sheds Light on Liver Fibrosis and Regeneration Pathways <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>
PE-02	Assessing the Diagnostic Accuracy of APRI and FIB-4 Scores for Liver Fibrosis in Patients with Chronic Liver Disease <i>Baigal Narantuya (The Liver Center, Mongolia)</i>
PE-03	Hydoxycholeic Acid Ameliorates Cholestatic Liver Fibrosis by Facilitating m6A-Regulated Expression of a Novel Anti-Fibrotic Target <i>Xiaoyong Xue (Beijing Univ. of Chinese Medicine, China)</i>
PE-04	Deep Learning-Driven Integration of Spatial Transcriptomics and Circulating Epitranscriptomics Identifies Endothelial RNA Modifications as Predictors of Hepatic Decompensation in Cirrhotic Portal Hypertension <i>Elfiany Syafruddin (BLK Muhammadiyah Univ., Indonesia)</i>

POSTER EXHIBITION

Liver Cirrhosis, Portal Hypertension with Cx. Basic

PE-05	Target Validation of CYP8B1 and Establishment of Small Molecule Screening in Non-Alcoholic Fatty Liver Disease <i>Jae Eun Ryu (Hanyang Univ.)</i>
PE-06	Low Shear Stress Activates Hepatic Kallikrein-Kinin Signaling, Enhancing Vascular Adhesion and Thrombosis in the Liver <i>Rajni Yadav (Institute of Liver and Biliary Sciences, India)</i>

Liver Cirrhosis, Portal Hypertension with Cx. Clinical

PE-01	Do Systemic Inflammation, Severity and Treatment Modalities of Hepatic Encephalopathy Determine Prognosis in Patients with Acute Overt HE in Liver Cirrhosis? <i>Venkatesh V S (GIPMER, India)</i>
PE-02	Growth Differentiation Factor-15 Is Associated with Adverse Outcome, Malnutrition Risk, and Health Deficit in Decompensated Cirrhosis <i>Chao Sun (Tianjin Medical Univ. General Hospital, China)</i>
PE-03	Efficacy of Terlipressin in Cirrhosis with Acute Kidney Injury HRS AKI at Gastroenterology: Hepatology Center, Bach Mai Hospital, Viet Nam <i>Lon Dang (Bach Mai Hospital, Vietnam)</i>
PE-04	The Etiology of Chronic Liver Disease Is an Independent Prognostic Factor in Patients with Acutely Deteriorated Chronic Liver Disease <i>Do Seon Song (The Catholic Univ. of Korea)</i>
PE-05	Reduced COVID-19 Vaccination Effectiveness and Clinical Outcomes for Decompensated Cirrhosis: A Nationwide Population-Based Study <i>Won Sohn (Sungkyunkwan Univ.)</i>
PE-06	Prevalence of Zinc Deficiency in Patients with Liver Cirrhosis and Its Clinical Correlation <i>Lkhagvasuren Batbaatar (Molor Clininc, Mongolia)</i>
PE-07	Comparative Efficacy and Safety of Lactulose versus Polyethylene Glycol in the Management of Overt Hepatic Encephalopathy: A Comprehensive Meta-Analysis of Randomized Controlled Trials <i>Roland Helmizar (Baiturrahmah Univ., Indonesia)</i>

POSTER EXHIBITION

Liver Cirrhosis, Portal Hypertension with Cx. Clinical

PE-08	Task-Adaptive Transfer Learning for Non-Invasive HVPG Classification with Induced Spatially-Aware Feature Localization <i>Seul Ki Han (Yonsei Univ. Wonju)</i>
PE-09	Evaluating the Prognostic Value of the MELD 3.0 Score in Predicting Mortality in Cirrhosis Patients with Acute Variceal Bleeding <i>Tram Que Nguyen Pham (Univ. Medical Center HCMC, Vietnam)</i>
PE-10	Sarcopenia in Cirrhosis: A Systematic Review of Diagnostic Tools and Interventions <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>
PE-11	A Prospective Multicenter Study for Comparison of Standard Dose Repeated Bolus Injection vs. Low Dose Continuous Intravenous Infusion of Terlipressin for Acute Esophageal Variceal Bleeding in Patients with Liver Cirrhosis <i>Hyung Joon Yim (Korea Univ.)</i>

Liver Surgery

PE-01	Results of Surgical Treatment of Hepatic Alveolar Echinococcosis in Non-Endemic Region <i>Andrii Andreichuk (National Scientific Center, Ukraine)</i>
PE-02	C3aR Deficiency Attenuates Liver Ischemia-Reperfusion Injury by Suppressing Glycolysis-Dependent Macrophage M1 Polarization via STAT3 Signaling <i>Xianxiang Chen (Guangxi Medical Univ., China)</i>
PE-03	Initial Steps of Implementing Liver Cancer Treatment at the National Hospital of Tropical Diseases: Experiences of a New Center <i>Truong Giang Nguyen (National Hospital of Tropical Diseases, Vietnam)</i>
PE-04	Early Outcomes of Anatomical Liver Resection at a Nascent Hepatobiliary Center in Vietnam <i>Nguyen Kieu Hung (National Hospital of Tropical Diseases, Vietnam)</i>
PE-05	A Decade of Global Bibliometric Analysis on Research Trends in Minimally Invasive Liver Surgery <i>Nadyatul Husna (Dr. Reksodiwiry Military Hospital Padang, Indonesia)</i>

POSTER EXHIBITION

Liver Surgery

PE-06	<p>The Transplant Technologies in the Treatment of So-Called “Inoperable Patients” with Liver Alveococcosis</p> <p><i>Edir Surov (Kyrgyz-Russian Slavic Univ., Kyrgyzstan)</i></p>
PE-07	<p>Does Digital Aging, Social Capital, and Macroeconomic Factors Matter on Recovery Advancement among Elderly with Liver Disease?</p> <p><i>Ester Marnita Purba (The Pranala Institute, Indonesia)</i></p>
PE-08	<p>Posthepatectomy Bile Leakage: A Single-Center Experience in Kazakhstan</p> <p><i>Adina Kulanbayeva (National Research Oncology Center, Indonesia)</i></p>
PE-09	<p>Intraductal Papillary Neoplasm of the Bile Duct (Ipnb) with Invasion to the Stomach and Left Lobe Atrophy: Case Presentation</p> <p><i>Bekkozha Yeskendirov (National Research Oncology Center, Kazakhstan)</i></p>
PE-10	<p>Enhanced Recovery after Surgery in Liver Resection: A Systematic Review of Clinical Outcomes</p> <p><i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i></p>
PE-11	<p>Prognostic Value of an Integrated AFP-PIVKA-II Based Tumour Biology Characteristics Score Following Curative-Intent Resection of HCC: A Multicenter Cohort Study</p> <p><i>Han Liu (First Hospital of Jilin Univ., China)</i></p>
PE-12	<p>Development and Validation of a Risk Stratification Model for Post-Hepatectomy Distant Metastasis in HCC: A Multi-Center Study</p> <p><i>Han Liu (First Hospital of Jilin Univ., China)</i></p>
PE-13	<p>Development and Validation of an Individualized Prediction Calculator for Postoperative Late Recurrence of HCC (POLAR-HCC)</p> <p><i>Han Liu (First Hospital of Jilin Univ., China)</i></p>
PE-14	<p>Laparoscopic Glisson Pedicle Priority Hepatectomy Based on Cone Unit</p> <p><i>Yu Cheng (Binzhou Medical Univ., China)</i></p>
PE-15	<p>Modified Extra-Fascial Transfissural Approach- Revisiting Tung's Livers</p> <p><i>Aayush Vasavada (NHL Medical College, India)</i></p>

Liver Surgery

PE-16	Results of Laparoscopic versus Open Major Hepatectomy for the Management of HCC in a Vietnamese Tertiary Hospital: A Five-Year Retrospective Comparative Study <i>Thi Ha Quach (108 Military Central Hospital, Vietnam)</i>
PE-17	Modified ALPPS Procedure to Treat HCC with Macrovascular Invasion <i>Giang Nguyen (National Hospital of Tropical Diseases, Vietnam)</i>
PE-18	Breaking Barriers: The Role of Liver Resection in Giant HCC <i>Citra Aryanti (Hasanuddin Univ., Indonesia)</i>
PE-19	Early Experience with Robotic Single-Port Liver Resections Using the Da Vinci SP System in a Small Center <i>Eun Jeong Jang (Dong-A Univ.)</i>
PE-20	Report of Two Cases of Aberrant Hepatic Duct Entering Cystic Duct: Identifying and Preventing Bile Duct Injury <i>Dieu Tran Thi (Binh Dan Hospital, Vietnam)</i>
PE-21	Evaluating the Effectiveness of Surgical Approaches for Hepatolithiasis: Insights from a Bangladeshi Tertiary Care Institution <i>Anharur Rahman (Central Hospital Ltd., Bangladesh)</i>
PE-22	Rare Case of Hepatic Epithelioid Hemangioendothelioma Managed with Minimally Invasive Surgery: A Case Report and Literature Review <i>Sang Hoon Shin (Chonnam National Univ.)</i>
PE-23	Single Center Experience of ABO-Incompatible Adult-to-Adult Living Donor Liver Transplantation: A Case Report <i>Geunhyeok Yang (Kyung Hee Univ.)</i>
PE-24	Analysis of the Results of Surgical Treatment of Benign Liver Tumors <i>Farukh Mahmudzoda (Avicenna Tajik State Medical Univ., Tajikistan)</i>

Liver Transplantation

PE-01	Two Cases of Living Donor Liver Transplantation for Colorectal Liver Metastases in Korea <i>Abdullah Alshamrani (Sungkyunkwan Univ.)</i>
-------	---

POSTER EXHIBITION

Liver Transplantation

PE-02	Application of Machine Learning Algorithm in Diagnosing Post-Operative Complications in Hepatitis C Patients after Liver Transplantation <i>Putri Ayu (Andalas Univ., Indonesia)</i>
PE-03	MALS (Median Arcuate Ligament Syndrome) Associated HAT after LDLT: Successful Treatment by Interventional Balloon Dilatation of Anastomosis and Stent Placement at Celiac Artery <i>Yang Won Nah (Univ. of Ulsan)</i>
PE-04	Significance of Clinical Laboratory Evaluations in Post-Liver Transplant Recipients: The Impact on Management Strategies <i>Aryofri Afan (Institut Asia Malang, Indonesia)</i>
PE-05	Liver Regeneration and Organoid Technology: Engineering Functional Hepatocytes for Transplantation and Drug Discovery <i>John Thomas Arul J S (ACS Medical College and Hospital, India)</i>
PE-06	A Successful Case of Coordination of Brain-Dead Donor with The Highest Number of Organ and Tissue Transplantation in Vietnam: Case Report and Review of the Literature <i>Le Anh Van (108 Military Central Hospital, Vietnam)</i>
PE-07	Leveraging Machine Learning Algorithms for Prognosis Stratification in Salvage Liver Transplantation <i>Yusril Yusril (UIN Sjech M. Djamil Djambek Bukittinggi, Indonesia)</i>
PE-08	Outcomes and Complications of Living Donor Liver Transplantation in Pediatric Patients <i>Nadyatul Husna (Dr. Reksodiwiry Military Hospital Padang, Indonesia)</i>
PE-09	Global Research Trends in Pediatric Living Donor Liver Transplantation <i>Nadyatul Husna (Dr. Reksodiwiry Military Hospital Padang, Indonesia)</i>
PE-10	Blockchain-Enhanced Liver Transplantation: A Paradigm Shift in Ethical Allocation, Data Security, and Transplant Logistics <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>
PE-11	Post-Liver Transplantation Depression and Anxiety: Prevalence and Risk Factors <i>John Thomas Arul J S (ACS Medical College and Hospital, India)</i>

POSTER EXHIBITION

Liver Transplantation

PE-12	Extended Indications for Robotic Donor Right Hepatectomy: Risk Factor Analysis and Surgical Step-Based Recommendations <i>Na Reum Kim (Yonsei Univ.)</i>
PE-13	Identifying Risk Factors for Diffuse Intrahepatic Biliary Stricture in ABO-Incompatible Living Donor Liver Transplantation: An Analysis of 1,000 Cases <i>Young-In Yoon (Univ. of Ulsan)</i>
PE-14	Artificial Intelligence in Predicting Liver Transplant Graft Rejection <i>Pavithran Damodaran (ACS Medical College and Hospital, India)</i>
PE-15	Gut-Liver Axis: The Role of Probiotics in Accelerating Recovery after Liver Surgery <i>Pavithran Damodaran (ACS Medical College and Hospital, India)</i>
PE-16	Comprehensive Management and Liver Transplantation for Huge HCC with Main Portal Vein Tumor Thrombosis: A Five-Year Case Report <i>Cheon-Soo Park (The Catholic Univ. of Korea)</i>
PE-17	Feasibility of Pure Laparoscopic Donor Right Hepatectomy Compared to Open Donor Right Hepatectomy: A Large Single-Center Cohort Study <i>Sang-Hoon Kim (Univ. of Ulsan)</i>
PE-18	Liver Transplantation by a Single Surgeon <i>Chong Woo Chu (Changwon Hanmaum Hospital)</i>

MASLD, Basic

PE-01	Researching the Role of the Advanced Biomarker Kallistatin in MASLD <i>Rajiv Nehra (Rani Durgavati Medical College, India)</i>
PE-02	Thiazole-Naphthyl Derivatives as PPAR γ /NRF2/COX-2 Modulators for Fibrosis Prevention in Metabolic Dysfunction-Associated Steatohepatitis: Molecular Docking and ADMET Profiling <i>Rizki Rachmad Saputra (Universitas Palangka Raya, Indonesia)</i>
PE-03	B Cell Activation to Produce Autoantibodies Are Promoted in the Spleen of MASH-Induced Mice Model <i>Hong-Gyu Han (Kangwon National Univ.)</i>

POSTER EXHIBITION

MASLD, Basic

PE-04	Trends in Metabolic Dysfunction-Associated Steatotic Liver Disease by Household Income, 2007-2022: A National Representative Study in South Korea <i>Hyunjee Kim (Kyung Hee Univ.)</i>
PE-05	Palmitic Acid Reduces LDLR-Dependent Uptake of Macrophage-Derived Extracellular Vesicles by Hepatoma Cells <i>Bootsakorn Boonkaew (Chulalongkorn Univ., Thailand)</i>
PE-06	MASLD-Related Oral Microbes Were Associated with Obesogenic Metabolites and Clinical Parameters <i>In Young Kang (Hanyang Univ.)</i>
PE-07	11 β -HSD1 Inhibition on Non-alcoholic Fatty Liver Disease: Investigating Immune Cell Dynamics via Single-Cell Mass Cytometry <i>Sun Mi Park (Hanyang Univ.)</i>
PE-08	Microbiome Analysis in MASLD and Obesity: Identifying a Beneficial Strain and Its Hepatoprotective Effects in a Western Diet Mouse Model <i>Moon Gyeong Yoon (Ajou Univ.)</i>
PE-09	Lobeglitazone Alleviates Palmitic Acid-Induced Hepatic Steatosis by Enhancing Mitochondrial Function and Regulating Lipid Metabolism in HepG2 Cells <i>Jeayeon Park (Seoul National Univ.)</i>
PE-10	AI-Driven Single-Cell Spatiotemporal Metabolic Trajectory Mapping Identifies Hepatic Fibrosis Onset in MASLD: A Transformer-Based Multi-Scale Predictive Framework <i>Rini Winarti (Yogyakarta State Univ., Indonesia)</i>
PE-11	siRNA-Based Modulation of PCSK9 for the Treatment of Liver Metabolic Disorders: A Bioinformatics Study <i>Rian Ka Praja (Universitas Palangka Raya, Indonesia)</i>
PE-12	Targeting Lipid-Regulating Proteins with Bajakah-Derived Compounds, A Borneo-Native Plant: A Strategy for Managing Hyperlipidemia in MASLD <i>Reny Rosalina (Universitas Palangka Raya, Indonesia)</i>
PE-13	Lipid Droplets Beyond Storage: Orchestrators of Inter-Organ Crosstalk in Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>

POSTER EXHIBITION

MASLD, Basic

PE-14	Deep Learning-Driven Identification of Novel lncRNA-Regulated Mitochondrial RNA Editing Dysregulation as a Core Mechanism Driving Metabolic Failure and Fibrosis Progression in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) <i>Rifaldy Fajar (The Integrated Mathematical, Computational, and Data Science for BioMedicine Research Community Foundation, Indonesia)</i>
PE-15	Kahweol Attenuates Western Diet-Induced Hepatic Steatosis by Suppressing Fatty Acid Synthase <i>Hye-Young Seo (Keimyung Univ.)</i>
PE-16	Deep Learning-Driven Epitranscriptomic Profiling of N6-Methyladenosine (m6A) Modifications in Liver Regeneration among Transgender Individuals on Long-Term Gender-Affirming Hormone Therapy: A Multi-Omics AI Integration Approach <i>Prihantini Prihantini (The Integrated Mathematical, Computational, and Data Science for BioMedicine Research Community Foundation, Indonesia)</i>
PE-17	Maternal Obesity Induced Trained Immunity on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Offspring <i>Moonhyung Lee (Kyung Hee Univ.)</i>
PE-18	Establishment of Small Molecule Base Drug Screening System for Mixed Lineage Kinase Domain-Like Protein Inhibitor <i>Gye Ryeol Park (Hanyang Univ.)</i>
PE-19	MAAP Deficiency Prevents from Metabolic Dysfunction-Associated Fatty Liver Disease through Autophagy Regulation <i>Heeju Kim (Ewha Womans Univ.)</i>

MASLD, Clinical

PE-01	Impact of Sleep Duration on the Incidence of MASLD in Korean Adults: Mediating Effects of Sedentary Behavior Time <i>Soon Ok Kim (Chungnam National Univ.)</i>
PE-02	Assessing the Diagnostic Utility of Pro-Neurotensin in the Patient with Non-Alcoholic Fatty Liver Disease: A Meta-Analysis <i>Sunil Thatal (B.P Koirala Institute of Health Sciences, Nepal)</i>

POSTER EXHIBITION

MASLD, Clinical

PE-03	Designing an End-to-End Artificial Intelligence (AI) Deep Learning Pipeline for Hepatic Steatosis Quantification: Less Is More? <i>Leow Wei-Qiang (Singapore General Hospital, Singapore)</i>
PE-04	Effectiveness of Semaglutide in Non-Alcoholic Steatohepatitis Resolution: A Meta-Analysis and Systematic Review <i>Claudine G. Feliciano (Skyline Hospital and Medical Center, Philippines)</i>
PE-05	Microbiota Transplantation as a Novel Therapeutic Avenue for NAFLD: Bridging Gut Dysbiosis and Metabolic Health <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>
PE-06	Noninvasive Fibrosis Indices Are Less Effective in Predicting Significant Fibrosis in Younger Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Jaejun Lee (The Catholic Univ. of Korea)</i>
PE-07	Myricetin Alleviates Steatotic Liver Disease through Gut Microbiota Modulation and Wnt-Signaling Activation <i>Min Ju Kim (Hallym Univ.)</i>
PE-08	New-Onset Metabolic Dysfunction-Associated Steatotic Liver Disease and Cholecystectomy: A Risk-Stratified Analysis <i>Hong Jae Jeon (Chungnam National Univ.)</i>
PE-09	A Novel Steatosis Liver Disease (SLD) Index with Easy-to-Use Clinical Parameters in Primary Care Settings for Steatotic Liver Disease <i>Jin Kim (Hanyang Univ.)</i>
PE-10	Global Burden of Non-Alcoholic Fatty Liver Disease, 1990-2021, and Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021 <i>Soeun Kim (Kyung Hee Univ.)</i>
PE-11	The Characteristics of Metabolic Dysfunction Associated Steatotic Liver Disease in Young College Students in Taiwan <i>Jee-Fu Huang (Kaohsiung Medical Univ., Taiwan)</i>
PE-12	Efficacy and Safety of Statins for Nonalcoholic Fatty Liver Diseases and Metabolic Dysfunction-Associated Fatty Liver Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials <i>Xiaohui Fang (PLA Northern Theater Command General Hospital, China)</i>

POSTER EXHIBITION

MASLD, Clinical

PE-13	Exploring Significance of a Hypothetical Drug in View of Cost-Effectiveness Its Initial and Durable Efficacy in Metabolic-Associated Steatotic Liver Disease <i>Hye-Lin Kim (Sahmyook Univ.)</i>
PE-14	Impact of Breast Cancer and Hormone Therapy on Liver Disease Progression in Patients with MASLD <i>Na Ryung Choi (Ewha Womans Univ.)</i>
PE-15	Steatotic Liver Disease Predicts Lower Likelihood of LDLR Gene Mutations in Young Patients with Suspected Familial Hypercholesterolemia <i>Jaejun Lee (The Catholic Univ. of Korea)</i>
PE-16	A Randomized Controlled Trial to Evaluate the Effect of Vitamin D Supplementation on Nonalcoholic Fatty Liver Disease in Pediatric Patients <i>Aashal Bhavesh Shah (GMERS Medical College and Hospital, India)</i>
PE-17	Impact of Thyroid Hormone Replacement on MASLD Progression in Hypothyroid Patients: A Hospital-Based Cohort Study in Chennai, India <i>Aishwariya Devi Nadarajah (ACS Medical College and Hospital, India)</i>
PE-18	Unraveling Platelet Dynamics in MASLD: A Silent Catalyst in the March toward Cirrhosis <i>Surendar Arulalan (ACS Medical College and Hospital, India)</i>
PE-19	A Prospective Observational Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Patients with Advanced Liver Fibrosis Due to Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Aashal Bhavesh Shah (GMERS Medical College and Hospital, India)</i>
PE-20	Ultrasound Elastography in Fatty Liver vs. Normal Controls: A Retrospective Study <i>Min Seong Kim (Millenium Seoul IM Clinic)</i>
PE-21	Risk of Major Adverse Liver Outcomes in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Large Population-Based Retrospective Cohort Study <i>Youra Ko (Novo Nordisk Pharma Korea Ltd.)</i>
PE-22	Cardiovascular Disease Burden in Patients with and without Metabolic Dysfunction-Associated Steatohepatitis: Data from the unCoVer-MASH Longitudinal Cohort Study <i>Robert Morgan-Warren (Novo Nordisk Pharma Korea Ltd.)</i>

POSTER EXHIBITION

MASLD, Clinical

PE-23	Phase 3 ESSENCE Trial of Semaglutide 2.4 MG in Participants with Non-Cirrhotic Non-Alcoholic Steatohepatitis: Baseline Characteristics, Impact of New Metabolic Dysfunction-Associated Steatotic Liver Disease Criteria and Non-Invasive Tests <i>Won Kim (Seoul National Univ.)</i>
PE-24	Metabolic Dysfunction-Associated Steatotic Liver Disease and the Risk of Cardiovascular Disease: Results from Two Independent Nationwide Cohort Studies <i>Moon Haeng Hur (Seoul National Univ.)</i>
PE-25	Risk of Pyogenic Liver Abscess and Its Clinical Complications in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Cohort Study <i>Na Ryung Choi (Ewha Womans Univ.)</i>
PE-26	Prevalence and Trends of Metabolic Syndrome among Chronic Viral Hepatitis Patients in Korea: A KNHANES 2013-2022 Analysis <i>Eun Sun Jang (Seoul National Univ.)</i>
PE-27	Association of Metabolic Dysfunction-Associated Steatotic Liver Disease and Subclinical Coronary Atherosclerosis: Observation Cohort Study <i>Joonho Jeong (Univ. of Ulsan)</i>
PE-28	Improved Decision-Making in Advanced Fibrosis Assessment through the Incorporation of PNPLA3 and TM6SF2 Genetic Information into Existing Non-Invasive Test Scores <i>Dong Yun Kim (Yonsei Univ.)</i>
PE-29	Metabolic Dysfunction Associated Steatotic Liver Disease: Trivandrum Cohort 3 <i>Shenoy K T (Sree Gokulam Medical College and Research Foundation, India)</i>
PE-30	GLP-1 Receptor Agonists for the Treatment of MASLD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials <i>Lok Ranjan Rajmohan (ACS Medical College and Hospital, India)</i>
PE-31	Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Depression as a Risk Factor in a Population Cohort in S India (Cohort 1) <i>Mohanan Leena (Population Health and Research Institute, India)</i>

POSTER EXHIBITION

MASLD, Clinical

PE-32	Liver Histology and Non-Invasive Tests (NITs) for Hepatic Fibrosis in a Large Cohort of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Kerala, S India <i>Shenoy K T (Sree Gokulam Medical College and Research Foundation, India)</i>
PE-33	A Machine Learning Model for Predicting HCC in Patients with MASLD <i>Han Ah Lee (Chung-Ang Univ.)</i>
PE-34	Trajectory of Trivandrum Cohort of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) over Two Decades <i>Mohanan Leena (Population Health and Research Institute, India)</i>
PE-35	Impact of Menopause on Liver Fibrosis Progression in Metabolic Dysfunction-Associated Steatotic Liver Disease <i>Sae Kyung Joo (Seoul National Univ.)</i>
PE-36	Intermittent Calorie Restriction Modulates Gut Microbiota in Patients with MASLD without Diabetes <i>Han Ah Lee (Chung-Ang Univ.)</i>

Others, Medical

PE-01	Prevalence and Risk Factors Associated with Human Fascioliasis Infection at Cam Khe 103 Clinic <i>Ha Tien Khiem (Cam Khe 103 Clinic, Vietnam)</i>
PE-02	Senolytics in Liver Disease: Unlocking the Secret to Reversing Aging and Restoring Liver Vitality <i>Surendar Arulalan (ACS Medical College and Hospital, India)</i>
PE-03	Elevated Levels of IL-1 β , IL-2, and IL-6 Correlate with Disease Severity in Non-Alcoholic Acute Pancreatitis <i>Zukhra Azizova (IIHG AS RU, Uzbekistan)</i>
PE-04	Clinico-Immunological Features of Chronic Hepatitis in Children <i>Diloram Musakhodjaeva (IIHG AS RU, Uzbekistan)</i>
PE-05	Silent Invaders: Exploring Microplastic Accumulation and Toxicity in the Human Liver <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>

POSTER EXHIBITION

Others, Medical

PE-06	Validation of Metallothionein Immunohistochemistry for Diagnosis of Wilson Disease in Korean Patients <i>In Hye Song (Univ. of Ulsan)</i>
PE-07	Wilson Disease: Clinical Presentation and Management at Gastroenterology and Hepatology Center <i>Ngoc Nguyen (Bach Mai Hospital, Vietnam)</i>
PE-08	Effectiveness of the acNASH Index in Diagnosing Dyselectrolytemia in Subjects with Liver Disease: A Retrospective Study <i>S. Mounika Shri (ACS Medical College and Hospital, India)</i>
PE-09	Epidemiological Analysis of Hepatitis E Virus Infections in South Korea Using Serum Samples from the Korea National Health and Nutrition Examination Survey <i>Chang Hun Lee (Jeonbuk National Univ.)</i>
PE-10	A Retrospective Analysis of the Predictive Value of Serum Albumin-to-Creatinine Ratio in Assessing Hepatorenal Function <i>Pooja Sri (ACS Medical College and Hospital, India)</i>
PE-11	Epidemiological Analysis of Hepatitis E Virus Infections in South Korea Using Infectious Disease Reporting Data from the Korea Disease Control and Prevention Agency <i>Chang Hun Lee (Jeonbuk National Univ.)</i>
PE-12	Hepatic Whispers: Decoding GGT, ALP, and Genetic Clues in Ischemic Stroke Risk <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>
PE-13	Effect of High-Sensitivity C-Reactive Protein on Gallstones in Janata Pharmacy for Early Diagnosis Rather than Accidentally <i>Sarita Shrestha (Janata Pharmacy, Nepal)</i>
PE-14	Hepatoprotective Effect of ALD-1 (4',7-Dihydroxy-3'-methoxyflavone) Isolated from Albizzia lebbeck Benth in Experimental Liver Injury <i>Danish Ahmed (Sam Higginbottom Univ. of Agriculture, Technology and Sciences, India)</i>
PE-15	Precision Insights into Gender-Specific Liver Fibrosis: Evaluating FIB-4, AAPRI, and mFIB-4 as Predictive Markers of Disease Progression <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>

POSTER EXHIBITION

Others, Medical

PE-16	Impact of Diabetes on the Activity of the Chronic Viral Hepatitis in Mongolia: A Cross-Sectional Study <i>Zolzaya Doljoo (The Liver Center, Mongolia)</i>
PE-17	Revolutionizing Wilson's Disease Management: Gene Therapy and RNA-Based Interventions for Copper Homeostasis <i>Santiya Ramalingam (ACS Medical College and Hospital, India)</i>
PE-18	Clinical and Epidemiological Features of Acute Viral Hepatitis in South Korea: A Nationwide Prospective Multicenter Study <i>Chang Hun Lee (Jeonbuk National Univ.)</i>
PE-19	Dietary Diversity and Its Impact on Liver Disease Risk: A Population-Based Study in Indonesia <i>Nadyatul Husna (Dr. Reksodiwiry Military Hospital Padang, Indonesia)</i>
PE-20	Diagnostic Performance of FIB-4, APR, and APRI in Liver Fibrosis: A Study of 586 Patients <i>John Thomas Arul J S (ACS Medical College and Hospital, India)</i>
PE-21	"Hey SIRI, Tell Me About My Liver!" – A Reliable Inflammatory Marker Meets FIB-4 <i>Gayathri Saravanan (ACS Medical College and Hospital, India)</i>
PE-22	Unraveling Metabolic Interplay: Insights from TG/HDL Ratio and RBC-TLLRI Correlations across Thyroid, Liver, Lipid, and Renal Indices <i>Surendar Arulalan (ACS Medical College and Hospital, India)</i>
PE-23	Gut-Liver-Brain Axis in Hepatic Encephalopathy: Microbiome-Derived Neurotransmitters as Novel Therapeutic Targets <i>Santiya Ramalingam (ACS Medical College and Hospital, India)</i>
PE-24	Hepatic Glymphatic System: A Hidden Pathway for Detoxification and Liver-Brain Crosstalk <i>Surendar Arulalan (ACS Medical College and Hospital, India)</i>
PE-25	Impact of Klebsiella Pneumoniae Strain and Serotype on Mortality and Clinical Outcomes in Liver Abscess Patients <i>Young Chang (Soonchunhyang Univ.)</i>

POSTER EXHIBITION

Others, Medical

PE-26

Research about Biliary Stent's Cover Produced by Alternative Materials Compared to Conventional Materials

Hyung Tae Kim (S&G Biotech Inc.)

PE-27

Coexistence of Shock Liver, Tumor Lysis Syndrome, and Rasburicase Toxicity in Waldenström Macroglobulinemia: A Complex Case Study

Monika Jain (Interfaith Medical Center One Brooklyn Health, USA)

Others, Surgical

PE-01

Surgical Outcomes and Quality of Life between Laparoscopic and Open Approach for Giant Hepatic Hemangioma

Le Anh Van (108 Military Central Hospital, Vietnam)

PE-02

Quality of Life of Laparoscopic versus Open Left Hemihepatectomy for Left-Sided Hepatolithiasis

Le Anh Van (108 Military Central Hospital, Vietnam)


PE-03

Implementing Virtual Reality (VR) in Surgical Education for Pancreatic Procedures

Pavithran Damodaran (ACS Medical College and Hospital, India)

Woljeonggyo Bridge

The Bridge, built in the 8th century during the Silla Dynasty, has been restored as a wooden bridge and stands as a symbol of Gyeongju's heritage.




Gold Crowns of Silla

This artifact represents the ancient culture and artistic achievements of the Silla Dynasty, highlighting its highly advanced goldsmithing techniques.



Painting of Heavenly Horse on a Saddle Flap

Cheonmado (Painting of the Heavenly Horse), created during the 5th-6th century Silla period, reflects stylistic elements found in Goguryeo tomb murals, suggesting artistic influence. As one of the few surviving Silla paintings, it is of great historical and cultural value.





GENERAL INFORMATION

The Liver Week 2025

ABOUT THE LIVER WEEK 2025

Date	May 29-31, 2025			
Venue	HICO, Gyeongju, Korea			
Theme	A Big Welcome to the Liver Festival in Gyeongju, Korea!			
Official Language	English			
Official Website	www.theliverweek.org			
Hosted by	 The Korean Association for the Study of the Liver	 THE KOREAN ASSOCIATION OF HP-SURGERY	 THE KOREAN LIVER CANCER ASSOCIATION	 The Korean Liver Transplantation Society

REGISTRATION DESK

Location	Lobby (3F)		
Opening Hour	May 29 07:40-17:20	May 30 07:00-17:40	May 31 07:00-16:10

Name badges will be provided with meeting materials on site and must be worn during all events.






OPENING CEREMONY

Location	Room 1 (3F)
Date & Time	May 30 10:30-11:10

CLOSING & AWARD CEREMONY

Location	Room 1 (3F)
Date & Time	May 31 15:50-16:10

INDUSTRIAL EXHIBITION / COMPANY LOUNGE

Location	Exhibition Hall (1F) & Lobby (3F)		
Opening Hour	May 29 08:40-17:20	May 30 09:10-17:40	May 31 09:10-16:10
Company Lounge (2F) for	 YUHAN	 Roche	 AstraZeneca  DAEWOONG  GILEAD
Opening Hour	May 29 08:40-17:20	May 30 09:10-17:40	May 31 09:10-16:10

PREVIEW ROOM / FACULTY LOUNGE

for invited faculty and committee members

Preview Room	Lobby (1F)		
Opening Hour	May 29 07:40-17:20	May 30 06:30-16:30	May 31 06:30-16:10

All presenters are requested to come to the Preview Room at least 1 hour in advance of the presentations to verify if the data function properly on the equipment provided.

Faculty Lounge (4F)			
Opening Hour	May 29 08:40-17:20	May 30 07:30-17:40	May 31 07:30-16:10

ORAL POSTER PRESENTATION

Location	Exhibition Hall (1F)	
Presentation Time	May 30 16:40-17:40	May 31 09:30-10:30

POSTER EXHIBITION / BUSINESS CENTER / CAFÉ 

Location	Exhibition Hall (1F)		
Opening Hour	May 29 08:40-17:20	May 30 09:10-17:40	May 31 09:10-16:10

MEAL

Breakfast (All Participants)	Korean breakfast will be provided during the breakfast sessions on May 30 and 31. Please arrive early, as it may run out later in the session. Morning pastries, fresh fruit, coffee, and tea will also be available in the lobby area.
Lunch (All Participants)	Lunch boxes will be provided during the industry luncheon symposium. Please refer to the program book and join the session of your choice.
Welcome Reception (All Participants)	May 30, 2025, 18:00, Hwangnyongwon
Faculty Dinner (Invitation Only)	May 29, 2025, 18:00, Hilton Gyeongju Garden

평점안내

(★) 본 평점은 해당되는 강의실 앞에서 입실 및 퇴실시 스캔하여야 인정됩니다.

평점구분	29일(목)		30일(금)	31일(토)
	PG	TLW	TLW	TLW
대한의사협회	6점		6점	6점
대한내과학회 평생교육	6점	6점	6점	6점
대한내과학회 분과전문의	★ 6점	None		
대한내과학회 전공의 외부학술회의	2점			
대한간학회 복부초음파 세부전문의	★ 3점			
대한임상초음파학회	★ 3점			
대한내과학회 전공의 초음파교육	★ 17건			
대한내과학회 초음파 지도전문의 교육	★ 3점			

- * 대한의사협회 평점, 대한내과학회 평생교육 평점, 대한내과학회 분과전문의 평점은 시간당 부분 평점이 부여됩니다 (시간당 1점).
- * 본 학술대회는 분과전문의 자격갱신 시, 학회 참석확인서 및 대한의사협회 교육센터의 이수확인서 제출 시 1일 2점이 인정됩니다.
- * 대한내과학회 분과전문의 평점은 5월 29일(목) PG Course를 수강한 경우에만 인정됩니다.
- * 대한내과학회 전공의 외부학술회의 평점은 일일 총 6시간 이상 2일간 참석 시 2점이 인정됩니다.
- * 대한간학회 복부초음파 세부전문의, 대한임상초음파학회 평점은 5월 29일(목), Ultrasound Trainee Session & Hands-On Course 또는 Ultrasound Trainer Session 수강 시 인정됩니다.
- * 대한내과학회 전공의 초음파교육은 5월 29일(목), Ultrasound Trainee Session & Hands-On Course 수강 시 인정됩니다.
- * 대한내과학회 초음파 지도전문의 교육 평점은 5월 29일(목), Ultrasound Trainer Session 수강 시 인정됩니다.
- * QR Scanner: 평점이 필요한 등록자께서는 매일 최초 입실 및 최종 퇴실시 (2회 이상) 명찰을 스캔하시기 바랍니다.

MAY FESTIVAL



WELCOME RECEPTION

Friday, May 30, 2025, 18:00
Hwangnyongwon, Gyeongju, Korea

We are delighted to invite you
to the **Welcome Reception**
of **The Liver Week 2025!**


Join us for an evening filled with refreshing beer, lively performances, and exciting lucky draws. Your presence will truly enhance the spirit of the event, and we look forward to sharing this memorable occasion with you.

Feel free to bring your friends along—we hope to make it a night to remember! We look forward to seeing you there!



HICO → Hwangnyongwon

17:40



INDUSTRIAL EXHIBITION FLOOR PLAN


3F

★ QR Scanner



DIAMOND		
Roche	Yuhan	
PLATINUM		
AstraZeneca	Daewoong	Gilead

INDUSTRIAL EXHIBITION FLOOR PLAN



GOLD

1 Samil	2 Boryung	3 GC
4 AbbVie	5 Dong-A ST	6 Celltrion

SILVER-PLUS / SILVER

10 Eisai		
7 CKD	8 Pharma King	9 IPSEN

MAY 29-31

11 Bukwang	15 Novartis	19 Samjin
12 Astellas	16 Mitsubishi Tanabe	20 Novo Nordisk
13 Sysmex	17 Han Wha	
14 Hanmi	18 BMS	

MAY 30

21 GSK
22 GC Wellbeing
23 ACME MEDICAL
24 SAEHAN



VEMLIDY-for the flow of life with chronic hepatitis B

평생 관리해야 하는 만성 B형 간염¹,
환자의 생애주기를 고려한다면², Vemlidy® 로 시작해 주세요.^{1,3,4}



References 1. 2018 대한간학회 만성 B형 간염 진료 가이드라인 2. Oh H, et al. Aliment Pharmacol Ther 2020;52:371-81, 3. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection 4. Terrault NA, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018 Apr;67(4):1560-1599.

베를리디®정 (테노포비르알라페나미드헤미푸마르산염)

[수입자] 길리어드 사이언스 코리아(유), 서울특별시 중구 을지로5길 26 센터빌딩 서관 15층 (대표전화: 02-6030-3300, 제품관련문의: 0079-814-800-9172 (수신자 부담))

* 처방하시기 전에 반드시 허가사항 전문을 확인하여 주시기 바랍니다. 최신 허가사항은 아래 QR 코드를 통해 확인하실 수 있으며, 길리어드사이언스 코리아 홈페이지(www.gilead.co.kr) 또는 식품의약품안전처 의약품정보시스템 (<http://nedrug.mfds.go.kr>) 에서도 보실 수 있습니다.



QR 코드를 스캔하여
Vemlidy® P를 확인하십시오.



KR-VEM-0185_v1,0(29/August/2025)

Tour Date: Friday, May 30, 2025

Lucky Draw Time: 16:30 @ Room 1 (3F)

Absentees will be excluded from the event.

Please get stamps from all the participating exhibition booths and bring it to the registration desk.

LOBBY (3F)

Gilead

Daewoong

Roche

Yuhan

Astra
Zeneca

EXHIBITION HALL (1F)

Samil

Boryung

GC

AbbVie

Dong-A ST

Pharma
King

Celltrion

CKD

IPSEN

Eisai

Bukwang

Astellas

GC
Wellbeing

Novo
Nordisk

GSK

SAEHAN

ACME
MEDICAL

Hanmi

Systemex

Samjin

BMS

Han Wha

Mitsubishi
Tanabe

Novartis



Tour Date: Friday, May 30, 2025

Lucky Draw Time: 16:30 @ Room 1(3F)

Absentees will be excluded from the event.

Please get stamps from all the participating exhibition booths and bring it to the registration desk.

Name

Affiliation



Apple Watch Series 10



BOSE SoundLink Revolve+II (Bluetooth)



BALMUDA The Toaster Pro



SAMSUNG Gift Certificate (₩100,000)

(2EA)

Tour Date: Saturday, May 31, 2025

Lucky Draw Time: 15:50 @ Room 1(3F)

Absentees will be excluded from the event.

Please get stamps from all the participating exhibition booths and bring it to the registration desk.

LOBBY (3F)

Gilead

Daewoong

Roche

Yuhan

Astra
Zeneca

EXHIBITION HALL (1F)

Samil

Boryung

GC

AbbVie

Dong-A ST

Pharma
King

Celltrion

CKD

IPSEN

Eisai

Bukwang

Astellas

Novo
Nordisk

Hanmi

Sysmex

Samjin

BMS

Han Wha

Mitsubishi
Tanabe

Novartis



Tour Date: Saturday, May 31, 2025

Lucky Draw Time: 15:50 @ Room 1(3F)

Absentees will be excluded from the event.

Please get stamps from all the participating exhibition booths and bring it to the registration desk.

Name

Affiliation



Dyson Supersonic
Nural Hair Dryer



Samsung Inverter
Dehumidifier



BALMUDA
GreenFan S



AirPods 4
(Active Noise Cancelling)



SAMSUNG
Gift Certificate
(₩100,000)

THE LIVER WEEK 2025

Conference Bag

Lunch Coupon

Thursday, May 29, 2025



Breakfast Coupon

Friday, May 30, 2025



Lunch Coupon

Friday, May 30, 2025



Breakfast Coupon

Saturday, May 31, 2025



Lunch Coupon

Saturday, May 31, 2025



THE LIVER WEEK 2025

May 29 - 31, 2025 | HICO, Gyeongju, Korea



THE LIVER WEEK 2025 SUPPORTERS

DIAMOND



YUHAN



PLATINUM



DAEWOONG



GILEAD

GOLD

abbvie

BORYUNG



CELLTRION PHARM
CELLTRION



DONG-A ST



GC Biopharma
GC Cell

Samil

SILVER-PLUS



SILVER



CKD Pharm



IPSEN



BRONZE



astellas



BUKWANG PHARM. CO., LTD.



sysmex



ACME MEDICAL INC.



Bristol Myers Squibb



GC Wellbeing

GSK



Han Wha Pharma Co., Ltd.



Hanmi Pharm.



NOVARTIS



novo nordisk



SAEHAN Pharm.Co.,Ltd.



SAMJIN PHARM.



**KOREA
TOURISM
ORGANIZATION**

Gyeongju **CVB**
Heritage Conservation and Visitor Bureau



THE LIVER WEEK 2025

May 29 - 31, 2025 | HICO, Gyeongju, Korea



Program Book
Abstract Book
and View More

www.theliverweek.org

